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Chapter 1
General introduction
Barae Jomaa
Based on Thyroid toxicogenomics: A multi-organ paradigm. In J. Kleinjans [ed.], 
Toxicogenomics-Based Cellular Models: Alternatives to Animal Testing for Safety 
Assessment, 159–180 (2014). Academic Press.
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1.1 The thyroid scare
Disorders related to the thyroid have long been known to man owing to the visible 
enlargement of the gland known as goiter. This condition can be due to either an 
overactive or an underactive thyroid gland, with the former increasing and the latter 
decreasing the rate at which the body breaks down nutrients and produces cellular 
components necessary to sustain life (Terris and Gourin, 2008). The successful 
treatment of goiter with animal thyroid glands was reported in China as early as 643 CE 
(Temple and Needham, 2007). That environmental contaminants, particularly lead, are 
associated with goiter had already been proposed by Paracelsus in the sixteenth century. 
In the nineteenth century, the essential element iodine that is a basic constituent of 
thyroid hormones (THs) was discovered (Anon, 2013; Kelly, 1961). Thyroid hormones 
were characterized in the twentieth century, starting with tetraiodothyronine (T4) in 1915, 
and later triiodothyronine (T3) in 1952 (Figure 1.1) (Edward Calvin Kendall, 1915; Gross 
and Pitt-Rivers, 1952).
The twentieth century saw a chain of events that raised the level of public concern over 
compounds that affect the thyroid, and ultimately culminated in the inclusion of thyroid 
disruption endpoints by the Organisation for Economic Co-operation and Development 
(OECD) in guidelines for the testing of chemicals (Figure 1.2). The “cranberry scare” of 
1959 brought a herbicide, aminotriazole, and its effect on the thyroid into US politics, 
and toxicology to the forefront of public life. At the very core of the debate was a rat study 
that showed a high incidence of thyroid cancer upon exposure to high amounts of the 
pesticide. The idea that chemicals affecting rodents at high doses will affect humans at 
moderate doses, also known as the “mouse-as-little-man” principle, was so entrenched 
in people’s minds at the time that it formed part of an amendment to the Federal 
Food, Drug, and Cosmetic Act known as the Delaney clause. To ease the newly created 
“chemophobia,” the then-vice-president Richard Nixon ate cranberry sauce during 
his presidential election campaign (Lieberman, Adam J., 2004). A decade later, Nixon 
became president and proposed the establishment of the US Environmental Protection 
Agency (USEPA), which was approved by congress. Today, the jury is still out on the human 
relevance of the adverse effect of aminotriazole that was detected in the rat study, even 
after a retrospective cohort study of exposed Swedish railroad workers found it to be a 
“suspicious” carcinogen (Axelson et al., 1980). On the one hand, epidemiological data 
are often mired with confounders such as the presence of a mixture of active compounds 
in pesticides, and on the other hand, rodents have been shown to be overly sensitive 
to thyroid hormone disruption (Alison et al., 1994). These uncertainties have led the 
USEPA to consider aminotriazole as a “probable” human carcinogen (Group B) instead of 
a definitive human carcinogen (Group A) (USEPA, 1996b).
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The establishment of the European Chemicals Agency (ECHA) in 2007 came on the 
heels of another public concern, that of endocrine disruption. Again, as one of the three 
main classes of endocrine disruptors, thyroid disruptors are at the very heart of modern 
toxicology—the other two classes being estrogen disruptors and androgen disruptors. 
The main fear today is that a change to thyroid homeostasis could be caused by man-
made chemicals and affect the hormone system’s well-documented orchestration of 
sexual and mental development, and this at much smaller doses than predicted from 
the effects observed at high doses (Vandenberg et al., 2012).
1.2 The thyroid system
The thyroid system is highly responsive to a wide range of external stressors. The 
hypothalamus responds to conditions requiring increased energy expenditure, such as 
pregnancy or prolonged periods of cold, by secreting thyrotropin-releasing hormone (TRH), 
which stimulates the anterior pituitary to produce thyroid-stimulating hormone (TSH), 
which in turn stimulates the thyroid to secrete thyroid hormones. The hypothalamus also 
responds to changes in diet by setting off a similar downstream chain of events. A diet 
that is high in carbohydrates promotes energy expenditure and leads to increased T3 
levels, whereas fasting promotes energy conservation and therefore leads to a drop in 
T3 levels (Palmblad et al., 1977).
In order to keep the rise in T3 production and resulting increase in energy 
consumption and thermogenesis under control, the body has a negative feedback loop, 
whereby high levels of T3 downregulate TRH and TSH production. The resultant drop in 
these tropic hormones leads to decreased stimulation of thyroid hormone production 
and secretion, and ultimately a drop in serum thyroid hormone levels.
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Fig. 1: Chemical structures of T3 and T4, respectively.
General introduction   11
Ch
ap
te
r 
1
The circulating levels of the hormones T3, T4, and TSH are constantly reacting to 
environmental factors that include temperature, oxygen levels, light, diet, and physical 
and emotional stress, in addition to chemicals and drugs (Capen and Martin, 1989; Chan 
et al., 1978; Hackney et al., 1995; Roth et al., 2002; Singh and Turner, 1969; Tingley et 
al., 1965). TH levels are also influenced by age and sex (Franklyn et al., 1985). Moreover, 
an individual’s range is half the width of the population reference range, which means 
that TH levels that are normal for one individual can be abnormal for another (Andersen 
et al., 2002). This also means that there is a genetically determined set-point, whose 
heritability was estimated in a study on healthy twins to be around 65%, with the rest 
being attributed to environmental factors (Hansen et al., 2004).
1.3 Rodent toxicity tests with thyroid endpoints
The first laws requiring animal testing were passed in 1938 for marketed 
pharmaceuticals following the death of 105 users of Elixir Sulfanilamide, which 
consisted of sulfanilamide dissolved in the sweet but poisonous solvent diethylene 
glycol (Geiling EK and Cannon PR, 1938; United States Department of Agriculture, 
1937). More than half a century later, in 1996, the first legislations requiring the 
USEPA to address endocrine disruption were put in place (USEPA, 1996a; c). A decade 
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later, the European Union regulation on the Registration, Evaluation, Authorisation and 
Restriction of Chemicals (REACH) was passed, which also required an authorization 
for endocrine disrupting chemicals for which evidence of serious effects on humans or 
the environment exists (REACH, 2006). In 2009, the USEPA selected 67 chemicals for 
screening based on exposure potential and in 2013, an additional 109 were selected 
for endocrine disruptor screening (USEPA, 2009, 2013). Today, the establishment and 
standardization of animal tests with endocrine endpoints is a work in progress. Table 
1.1 presents an overview of rodent test guidelines with thyroid-related endpoints, 
which include serum thyroid hormone levels, thyrotropin levels, thyroid and pituitary 
weights as well as thyroid histopathology.
Standardized rodent tests for thyroid-active compounds are inherently unethical, 
low-throughput and do not always represent effects seen in humans. This means that 
large-scale chemical screening programs need to move away from animal testing. 
1.4 Mode-of-action-based alternative testing strategies for thyroid activity
The development of in vitro testing strategies for thyroid-active compounds must be 
directed at a variety of endpoints, taking into account all the physiological targets that 
are known to be sensitive to interference by exogenous thyroid-active chemicals with 
various modes of action (MOAs). Figure 1.3 illustrates a breakdown and simplification 
of the potential targets of thyroid-active compounds that are relevant to the thyroid 
system.
Table 1.2 gives an overview of the currently available in vitro assays that could 
serve as potential candidates for high-throughput screening. The MOAs that they 
represent are discussed hereafter, providing a basis for the future development of 
screens for thyroid-active compounds, including thyroid toxicogenomics-based screens. 
The number of studies using transcriptomics, let alone other ’omics, when studying 
thyroid hormone disruption is still very limited. Nonetheless, the aim is still the same—
to delineate modes/mechanisms of action, to identify signatures and biomarkers of 
exposure and effect, and to classify phenotypes of thyroid toxicity (Shirai and Asamoto, 
2003).
Primary effects on the thyroid system
Compounds with a primary effect target hormonogenesis at the level of the thyroid 
and might lead to primary hypothyroidism/hyperthyroidism. The main MOAs involved 
include inhibition of TSH receptor (TSHR) activation, iodide transport, iodination and 
coupling, proteolysis, and iodide scavenging (Figure 1.4). The following sections will 
present these targets for primary effects on the thyroid system in some more detail.
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Inhibition of TSHR activation
TSH, also known as thyrotropin, is a glycoprotein hormone that is produced by 
thyrotrophic cells in the anterior pituitary and secreted into the circulation where it 
eventually reaches the thyroid. Once at the basolateral side of thyroid follicular cells, 
it binds the thyrotropin receptor (TSHR), a G-protein coupled receptor (GPCR), and the 
ligand–receptor pair gets internalized, thereby initiating a signaling cascade that leads 
to thyroid hormone production as well as cell proliferation (Werthmann et al., 2012).
There are two pathways that are mostly initiated by TSH-regulated TSHR activation, 
likely owing to the presence of different active conformations of this receptor (Wonerow 
et al., 2000). The first involves the adenyl cyclase (AC) pathway. TSHR-mediated 
G-protein alpha s (Gαs) subtype activity leads to AC catalyzed conversion of ATP to 
cyclic AMP (cAMP), which then activates cAMP-dependent protein kinase (PKA) and 
exchange proteins directly activated by cAMP (EPACs), both of which are mediators 
of the mitogenic action of TSH (Hochbaum et al., 2008). The second involves the 
phospholipase C (PLC) pathway. TSHR-mediated G-protein alpha q (Gαq) subtype 
activity leads to PLC-catalyzed hydrolysis of phosphoinositol 4,5 biphosphate (PIP2) 
and production of diacylglycerol (DAG) and inositol triphosphate (IP3). DAG activates the 
calcium-dependent protein kinase C (PKC) cascade that results in mitogenic activity, 
while IP3 signaling leads to the release of the required calcium from the endoplasmic 
reticulum.
Tab. 1.1: Current standardized rodent toxicity tests with thyroid system endpoints
Screening Assay Thyroid weight Pituitary weight Thyroid Histopathology Serum TH levels 
OECD TG 407 + + + + (optional)
OECD TG 408 - - + -
OECD TG 416 + + - -
OECD TG 422 - - + -
OECD TG 441 - - - + (T3 and T4, 
optional)
OECD TG 443 + + + (optional) + (T4 and TSH)
OECD TG 451 +
OECD TG 452 + +
OECD TG 453 + +
EPA 15-day intact 
adult male rat assay 
+ - + +
EPA Pubertal male + + + + (T4 and TSH)
EPA Pubertal female + + + + (T4 and TSH)
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Inhibition of iodide transport
All dietary iodine is reduced to iodide prior to absorption in the small intestine (Hays, 
1984). Once in the circulation, iodide is absorbed by tissues through the sodium iodide 
symporter (NIS), also known as solute carrier family 5, member 5 (SLC5A5). NIS is a 
transmembrane glycoprotein that is mainly expressed on the basolateral side of thyroid 
follicles and which concentrates iodide to a level that is 20 to 50 times that in plasma 
(Caillou et al., 1998; Eskandari et al., 1997).
NIS is also functional in extrathyroidal tissues, including the small intestine where 
dietary iodide is taken up into the bloodstream, and lactating mammary glands, through 
which iodide is delivered to the newborn for proper development. Gastric mucosa, 
salivary glands, and rectal mucosa also express NIS but its function in these tissues is 
still unknown. In the thyroid, TSH up-regulates the expression of the NIS gene, whereas 
iodide inhibits it (Dohán et al., 2003). Anions such as thiocyanate (SCN−) compete with 
iodide for transport through NIS.
NIS activity is dependent on the sodium potassium pump (Na/K-ATPase) to provide 
a sodium gradient. It is through this sodium gradient that iodide is transported along 
with sodium into the cell through NIS. Accordingly, the Na/K-ATPase inhibitor ouabain 
inhibits NIS-mediated iodide transport (Josefsson et al., 2006). Na/K-ATPase ATP1A1 
and ATP1B1 expression levels are more than threefold and tenfold higher, respectively, 
in the brain, kidney, and thyroid than in other tissues (Su et al., 2004).
In 1997, a century after Vaughan Pendred described a genetic condition giving rise 
to hearing loss and goiter, mutations in the pendrin gene (SLC26A4) were associated 
with the disease (Everett et al., 1997). As can be seen from Figure 1.4, iodide does not 
only need to be transported in the blood and enter the basolateral side of the thyroid 
cell, it also needs to cross the apical side in order to reach the follicular lumen where 
the iodination of thyroglobulin (TG) and the coupling of monoiodotyrosine (MIT) and 
diiodotyrosine (DIT) take place as penultimate steps in thyroid hormone production. 
While research on the apical transport of iodide is ongoing, pendrin is, at the very least, 
one of the key transporters involved in TSH-mediated iodide efflux at the apical side of 
follicular cells, thus completing the transport into the follicular lumen that was started by 
NIS at the basolateral side (Pesce et al., 2012; Twyffels et al., 2011).
Inhibition of iodination and coupling
At the apical surface of the thyroid follicle, thyroglobulin is iodinated in the presence 
of H2O2 by thyroid peroxidase (TPO) (Schweizer et al., 2008). Iodinated tyrosyl residues 
on thyroglobulin form MIT and DIT — the building blocks for T3 and T4 (Figure 1.4). 
TPO inhibitors can be divided into three classes: drugs, environmental pollutants, and 
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Fig. 3: Overview of the thyroid hormone system from synthesis to clearance. Chemicals can 
exert their effects through MOAs relating to 1) thyroidal hormonogenesis 2) pituitary control 3) 
hypothalamic CNS control 4) thyroid activity at the target tissue 5) kinetics and 6) epigenetics, 
immune response and other mechanisms [Source: Barae Jomaa/Wikimedia Commons].
food products. Antithyroid drugs, which are given in cases of hyperthyroidism, act on 
TPO, and include methimazole and propylthiouracil. Psychotropic drugs such as tricyclic 
antidepressants deactivate TPO by binding to its heme (Bou Khalil and Richa, 2011). 
Environmental contaminants shown to inhibit TPO include benzophenone 2 (BP2) 
(Schmutzler et al., 2007). Flavonoids contained in food can also inhibit this enzyme both 
in vitro and in vivo (de Souza Dos Santos et al., 2011).
Since the reactive oxygen species H2O2, needed along with TPO for hormonogenesis, 
can induce oxidative damage, additional safety mechanisms are needed by the 
thyrocytes. H2O2-generating dual oxidases (DUOXs) are localized at the apical membrane 
bordering the follicular lumen (Senou et al., 2010). As will be detailed later in the text, 
TPO is capable of degrading T4. Hence, TPO and H2O2, needed in the production of T4, 
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could both antagonize hormonogenesis and must be constantly kept under control. The 
extracellular surface of the cell membrane, facing the TG-rich lumen, is covered with a 
thin film rich in H2O2, while the intracellular surface of the cell membrane is lined with 
regions that are high in TPO (Ekholm and Björkman, 1997; Masini-Repiso et al., 2004). 
The apical surface of the thyroid cell can be thought of as a toxic bioreactor. This functional 
morphology is critical and might help explain why thyroid hormone production has not 
yet been achieved in an in vitro model. In 2012, a step in the right direction was taken 
and involved the in vitro overexpression of transcription factors needed for thyroid cell 
differentiation followed by in vivo grafting onto mice to finally produce hormones (Antonica 
et al., 2012). Nonetheless, in vitro results of this breakthrough experiment only indicated 
the in vitro iodination of TG, suggesting that either the proteolysis of TG to produce thyroid 
hormones is not taking place or the hormones are being degraded before they can be 
measured. Follow-up research could soon lead to an in vitro model for thyroid toxicity that 
encompasses all the complex mechanisms involved in the synthesis of thyroid hormones.
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Fig. 4: Primary MOAs that take place at the level of the thyroid and affect thyroid hormone synthesis, 
including: I) TSH secreted from the pituitary reaches the thyroid and binds to its membrane 
receptor (TSHR) leading to upregulation of the expression of genes that encode both structural 
and functional proteins necessary for thyroid hormone production, II) iodide is transported through 
the cell and into the lumen, III) iodination and coupling reactions take place and form iodinated 
TG molecules, IV) iodinated thyroglobulin undergoes lysosomal proteolysis to release thyroid 
hormones as well as V) MIT and DIT whose iodide anions are scavenged [Source: Barae Jomaa/
Wikimedia Commons].
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Inhibition of proteolysis
Iodinated thyroglobulin is pinocytosed back into the cell from the thyroglobulin-rich 
follicular lumen and is subjected to proteolysis by lysosomal proteases, which releases 
active hormones (Selmi and Rousset, 1988). This process is inhibited by excess iodide 
either from the diet, the environment, or iodine-rich drugs such as amiodarone (Radvila 
et al., 1976).
Inhibition of iodide scavenging
In addition to the release of thyroid hormones, proteolysis of iodinated TG also results 
in the release of MIT and DIT. These molecules carry the valuable iodide anion, which 
is scavenged by iodotyrosine deiodinase (IYD) and recycled. The importance of this 
mechanism of intrathyroidal iodide conservation was further elucidated after the cloning 
and characterization of IYD in 2002, and the implication of its mutation in 2008 in 
various cases of hypothyroidism (Afink et al., 2008; Moreno et al., 2002, 2008).
Secondary effects on the thyroid system
Compounds with a secondary effect on the thyroid system exert their action at the 
level of the pituitary, affect the gland’s ability to regulate thyroid hormone secretion, 
and thereby have the potential to lead to secondary hypothyroidism/hyperthyroidism. 
TSH is secreted by the pituitary gland in response to hypothalamic TRH, which arrives 
directly through the hypophyseal portal system and is quickly degraded (half-life of 5 
minutes) in the systemic circulation by a TRH-degrading enzyme (Marangell et al., 1997; 
Schmitmeier et al., 2002).
Inhibition of TRHR activitation and TSH secretion
TRH binds to the TRH receptor (TRHR), a GPCR on the cell membrane of TSH-producing 
thyrotrophic cells of the anterior pituitary, and sets off a signaling cascade whose net 
effect is the production of more TSH. TRHR has been studied in detail in rodents, where 
two subtypes were identified and named TRHR1 and TRHR2. As with many GPCRs, the 
receptors are desensitized by internalization upon agonist binding in order to regulate 
the length of the signal (Jones and Hinkle, 2009). Signal transduction that leads to TSH 
production is mediated by the PLC pathway described earlier. It has been postulated 
that the anticonvulsant and mood stabilizer carbamazepine inhibits TRH-induced TSH 
secretion in humans (Joffe et al., 1984) and further studies revealed decreased binding 
of TRH to TRHR (Rosen et al., 1994).
The activation of signal transduction by TRH takes place when TRHR present on the 
surface of thyrotrophic cells is coupled to Gq proteins (Sun et al., 2003) and is mediated 
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by transcription factors including cAMP response-element-binding protein (CREB), AP-1 
and Elk-1 (Wang and Gershengorn, 1999). The three main genes of interest that are 
being expressed in response to this TRH-mediated signaling are TSH, DIO2, and THRB 
(the gene for TRβ).
Factors that suppress the eventual secretion of TSH include somatostatin, thyroid 
hormones, growth hormone, glucocorticoids, melatonin, and opioid peptides.
Calcium channel blockers have been found to significantly decrease serum levels of 
T3 and T4 and to elevate serum TSH in rabbits, which is thought to result from impaired 
thyroid hormone synthesis or release at the level of the thyroid (Mittal et al., 1993). In 
man, the pituitary is more affected by calcium channel blockers than the thyroid, as 
studies have revealed that there is a significant decrease in TRH-stimulated TSH release 
but no significant change in levels of either T3 or T4 (Teba et al., 1985; Yamada et al., 
1986).
Thyroid cancer in rats follows continuous secretion of TSH, which leads to the 
overstimulation of thyroid cells and results in hyperplasia that progresses to adenoma 
and later to carcinoma (Segev et al., 2003). Iodine-deficient and goiterous patients 
have elevated levels of TSH but not the thyroid cancer that is observed in rats. This 
implies that rat thyroids are more responsive to TSH than human thyroids and that the 
human relevance of TSH has more to do with its role in modulating the secretion of 
thyroid hormones. While this underlines species differences, excessive and prolonged 
TSH stimulation of the thyroid can lead to thyrotoxicosis in humans (Ahmed and Steve, 
2011). Excessive TSH secretion can be the result of increased TRH activity but can also 
be due to improper negative feedback, which involves the other two genes of interest 
that are expressed in the thyroid—DIO2 and THRB.
Tertiary effects on the thyroid system
Compounds with a tertiary effect exert their action at the level of the hypothalamus 
and compromise its role as a control center that is able to translate various stimuli into 
messages to the pituitary where the message is relayed to the thyroid. 
TRH is present throughout the central nervous system and is highly expressed in 
the paraventricular nucleus (PVN) region of the hypothalamus. The median eminence 
at the base of the brain contains both the hypothalamo-hypophyseal portal vessels 
and axons of a group of neurons that originate in the PVN. These neuroendocrine cells 
release TRH directly into the portal vessels that vascularize the pituitary. There, the 
hormone acts as a stimulant of TSH release by binding the TRH receptor (TRHR) on the 
membrane of thyrotrophic cells (Shibusawa et al., 2008).
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This function as a stimulant of TSH release seems to have evolved as animals 
moved to land, since in poikilotherms, including the zebrafish that is increasingly 
being used in thyroid research, TRH does not stimulate TSH release. The ancestral 
role of TRH as a neuroregulator is being increasingly recognized and an analog has 
been successfully used in vitro as a neuroprotective agent in the glutamate-induced 
toxicity that is associated with neurodegenerative diseases such as Alzheimer’s disease 
(Veronesi et al., 2007).
The secretion of TRH is down-regulated by T3 through local deiodination of 
T4 by deiodinase type 2 (DIO2). This action is thought to be TRβ mediated. A rapid 
fall in serum TSH, T4, and T3 is brought about by fasting and leads to a drop in the 
appetite suppressant leptin, which has been found to increase DIO2 activity (Coppola 
et al., 2005). Other regulators of TRH neurons include neuropeptide Y, melanocortin-
stimulating hormone, and agouti-related peptide. What is known about the regulation of 
the TRH neuron has been reviewed in detail by Eduardo Nillni (Nillni, 2010).
Interference by chemicals at the level TRH signalling might lead to tertiary 
hypothyroidism and tertiary hyperthyroidism; the latter condition, although theoretically 
possible, is very rare (Gavras and Thomson, 1972). 
Peripheral effects
Compounds with a peripheral effect exert their action at the level of the target organ and 
could result in either hypothyroidism or hyperthyroidism. The effects of thyroid hormones 
are mediated in a large part by their binding to thyroid hormone receptors (TRs), which 
act as transcription factors that mediate specific patterns of gene expression. There 
are four different isoforms: A1, A2, and B1 that are widely expressed, with B1 having 
its highest levels in the liver, and B2 that is expressed mainly in the hypothalamus and 
pituitary, where it regulates TH negative feedback, as well as in the inner ear and retina 
during development (Abel et al., 2001; Zandieh Doulabi et al., 2002). TRα2 does not 
bind thyroid hormones but as an apoprotein can still play a role in the regulation of TR-
mediated gene expression, especially in its dephosphorylated state (Katz et al., 1995).
Inhibition of TR activity
DNA-binding domains on TRs have a high affinity for certain sequences of DNA called 
thyroid hormone response elements (TREs) and the resulting binding of the receptors 
to the DNA dictates the expression of linked genes. TRs can be found as monomers, 
homodimers, and heterodimers with retinoid X receptor (RXR), with the last having the 
highest affinity for TREs. Positive regulation of gene activity by thyroid hormones involves 
three general states of expression of genes that are linked to TREs. First, there is basal 
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activity, which can be exemplified in experimental knockout models of TRs. Second, there 
is repression of gene expression when TRs are bound to DNA in the absence of T3, since 
this state favors the formation of a co-repressor complex with histone deacetylase (HDA) 
activity. Third and last, there is activation of gene expression when TRs are bound to DNA 
in the presence of T3, since this state favors the formation of a co-activator complex with 
histone acetyltransferase (HAT) activity (Yen, 2001). This is relevant when considering 
that acetylated histones pack DNA less tightly and allow for greater gene expression. 
Negative regulation of gene activity is exemplified by T3-dependent repression of TRH 
expression in the hypothalamus and repression of TSH expression in the pituitary, a 
process that involves TRβ2 binding to negative TREs (nTREs) and interaction of TRβ2 
with the co-activator SRC-1 (Abel et al., 2001; Carr and Wong, 1994; Weiss et al., 1999).
Co-regulator activity
Resistance to thyroid hormones is a condition in which the majority of tissues are not 
responsive even when the level of thyroid hormones is high. A mutation in the TRβ 
gene has been implicated and is thought to cause a disruption of the charge clusters 
(acidic, basic, or a mixture of both) in the tertiary structure of the protein that allows for 
co-activator binding (Lee et al., 2011). It is therefore evident that co-regulators play a 
physiologically significant role in the regulation of TR-mediated gene expression. As was 
mentioned above, thyroid-hormone-mediated transcriptional regulation involves either 
co-activator or co-repressor recruitment. While canonical steroid hormone receptors are 
inactive in the unliganded state, TR and retinoic acid receptor (RAR) form heterodimers 
with RXR that bind to DNA and recruit nuclear receptor co-repressor (NCoR) and silencing 
mediator for retinoid or thyroid-hormone receptors (SMRT), as well as Sin3 and HDAC 
that actively repress gene expression (Safi et al., 2009; Yen, 2001).
Hormone-kinetics-based effects
Thyroid hormone kinetics involves the distribution of T3 and T4 to the body’s tissues, 
their metabolism, and their eventual clearance. Though these are mainly peripheral 
effects, they are classified separately due to the different MOAs of chemical disruptors 
acting on this level and their potential for kinetic modeling.
Circulation
Due to the lipophilic nature of the thyroid hormones T3 and T4, their transport in the 
body’s circulatory system must be assisted by transport proteins. Thyroxine-binding 
globulin (TBG), transthyretin (TTR), and albumin (ALB) are, in order, the three proteins 
with the highest affinity for T4 and T3. While most of the thyroid hormones in humans 
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are transported by TBG, it is thought that albumin alone is sufficient for carrying these 
hormones (Schussler, 2000). “Free” T3 and T4 that are unbound to blood transport 
proteins are called fT3 and fT4 respectively. These free hormones are thought to be 
good indicators of the amount that is available at the cellular level.
Unlike humans, rodents only express thyroxine-binding globulin (TBG), which acts 
as a reservoir for thyroid hormones, when they need it the most—during development 
and again later on during senescence (Savu et al., 1991). TTR is the main T4 carrier in 
the circulation of rodents but TTR null mice did not respond any differently than wild-
type mice when challenged with exposure to cold, which is known to result in thyroid-
hormone-mediated thermogenesis. Additional experiments including thyroidectomy 
and gene-expression analysis led the authors to conclude that TTR has no role to play 
in thyroid hormone homeostasis (Sousa et al., 2005). In humans, decreased thyroid 
hormone binding to transport proteins raises the ratio of fT4 to T4, which results in 
greater clearance of T4 and a drop in total T4 (Schussler, 2000). Patients with 
undetectable levels of TBG in their serum due to a mutation in the gene had low total 
T4, which is associated with fatigue (Carvalho et al., 1998). Another study examined 
patients with sepsis and found a clear association between a drop in TBG, TTR, and ALB, 
a rise in fT4/T4, and a drop in total T4 (Afandi et al., 2000). It can be concluded that 
using rodents as models in animal experiments does not reflect the human situation 
and that in vitro experiments should take into consideration all of the main three thyroid-
hormone-binding proteins.
Transport into cells
While it was previously thought that the lipophilic nature of thyroid hormones is sufficient 
for them to passively diffuse across the cell membrane, it is now clear that their transport 
is facilitated by plasma membrane transporters, including monocarboxylate (MCT) MCT8, 
MCT10, and organic anion transporting polypeptide (OATP) OATP1C1 (Pizzagalli et al., 
2002; Friesema et al., 2003, 2008). A mutation in the MCT8 gene causes Allan–Herndon–
Dudley syndrome, which includes high serum T3 levels coupled with severe psychomotor 
retardation. This transporter has been found to be expressed in a variety of tissues, 
including the heart, brain, liver, kidney, intestine, and placenta, while MCT10 is expressed 
in the skeletal muscles, liver, kidney, intestine, and placenta (Nishimura and Naito, 2008). 
To date, there have been no clinical cases of thyroid disease linked to either MCT10 or 
OATP1C1. While MCT8 is a specific thyroid hormone transporter, OATPs are also known to 
transport xenobiotics (Deure et al., 2010). However, OATP1C1 is specific to the brain and 
has high affinity for T4, and its lack in an OATP1C1 knockout mouse has been shown to 
lead to central nervous system (CNS)-specific hypothyroidism (Mayerl et al., 2012).
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In addition to the previously mentioned role of calcium channels in thyroid hormone 
production, it appears that they are also involved in the transport of these hormones into 
peripheral organs.
Calcium channels have been found to be involved in T4 uptake into cardiomyocytes. 
In fact, the calcium channel blocker dilitazem reduced T4 uptake by 45%, whereas T3 
uptake was unaffected (Verhoeven et al., 2001). Moreover, calcium has been found to be 
a first messenger in thyroid-hormone-mediated increases in sugar uptake, and calcium 
blockers inhibited this physiologically relevant action of thyroid hormones (Segal, 1990).
Metabolism and clearance
The metabolism and clearance of thyroid hormones is an essential process in the 
regulation of thyroid hormone activity and serum levels (Figure 1.5) with deiodination 
being the main mechanism and accounting for 85% of T4 and around 50% of T3 
breakdown (Benedetti et al., 2005). The rest is accounted for by sulfonation and 
glucuronidation.
Thyroid-hormone-regulated transcriptional activity is largely dependent on DIO2 for 
the removal of an iodine atom from the outer ring of T4, turning it into T3, in order to 
boost the hormone’s affinity for the TRs. Deiodinase type 3 (DIO3) removes an iodine 
from the inner ring of T4, turning it into rT3, an inactive congener (Figure 1.5). Deiodinase 
type 1 (DIO1) is capable of both inner and outer ring deiodination. rT3, containing two 
outer ring iodine atoms, can now be deiodinated into T2 by DIO2, while T3, which has 
two inner ring iodine atoms, can be deiodinated by DIO3 to form T2.
DIO3 is highly expressed in the placenta and embryonic tissue but has only been 
detected in a few adult tissues. Nonetheless, DIO3 has been shown to be responsible for 
the degradation of up to 80% of thyroid hormone production, which might indicate that 
the anatomical location of the bulk of this enzyme has yet to be defined. This enzyme 
has been found to be re-expressed during neoplasia and critical illness, leading to the 
hypothesis that it is a contributing factor in the low T3 levels that are observed in these 
situations (Huang and Bianco, 2008).
In the liver and to a lesser extent the kidney, sulfotransferases (SULTs) add a sulfate 
or, alternatively, UDP-glucuronosyltransferases (UGTs) add a glucuronic acid moiety to 
the phenolic hydroxyl group of T4, T3, rT3, and T2, rendering them more water soluble 
thereby facilitating excretion. Among the studied SULTs, 1A1, which is also involved in 
the inactivation of estrogens, has the lowest Km value and thus the highest affinity for 
thyroid hormones; in order, T2 > > rT3 > T3 > T4 (Wu et al., 2005). Glucuronidation takes 
place mainly in the liver, with the result being an increase in the water solubility of thyroid 
hormones, which is followed by biliary excretion. While drug-metabolizing enzymes are 
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not very abundant under normal circumstances, they are up-regulated upon xenobiotic 
challenge (Xu et al., 2005). The importance of glucuronidation for the thyroid system 
became apparent when compounds such as anti-epileptic drugs (AEDs) were tested on 
rats and were found to cause thyroid hyperplasia and tumors. These drugs, by acting 
as microsomal enzyme inducers (MEIs), increase the breakdown of thyroid hormones, 
which in turn leads to compensatory TSH production and its associated thyroid cell 
hyperplasia and tumor formation in rats. The only problem with these results is that AEDs 
are well studied in man and do not result in an increase in TSH production, nor have 
they ever been correlated with thyroid cancer. This is an important species difference 
between humans and rodents with regards to thyroid-active compounds, both in terms 
of sensitivity and outcome.
Clearly, there are differences between humans and rodents in the way they 
metabolize thyroid hormones. Indeed, it was found that in humans, unlike rats, T3 is not 
significantly glucuronidated. Nonetheless, in both species, T4 and rT3 are conjugated by 
UGT1A1 and UGT1A9. What is missing in humans is UGT1A9-mediated glucuronidation 
of T3 (Findlay et al., 2000; Visser et al., 1993). This means that T3 is first converted 
to rT3 by deiodinases before being glucuronidated, and rT3 is by far the preferred 
iodothyronine substrate for both UGT1A1 and UGT1A9.
Phenobarbital, an anticonvulsant, has been shown to increase thyroid hormone 
clearance by inducing the expression of OATP and UGT genes (Wieneke et al., 2009). 
This increased expression of hepatic transport and conjugation genes is mediated by 
the constitutive androstane receptor (CAR), which in addition to OATP and UGT, has also 
been shown to regulate SULT, leading to a drop in circulating levels of thyroid hormone. 
The same is thought to happen with other anticonvulsants, including phenytoin and 
carbamazepine, as well as certain antibiotics such as rifampicin (Zavacki and Larsen, 
2005).
Minor degradation pathways for thyroid hormones are much less known and 
studied but are arousing interest simply because the resulting metabolites, while in 
small quantities, may have a significant biological role. Tetrac and triac, the deaminated 
forms of T4 and T3 respectively, are potent metabolites that act on the thyroid receptor 
in vitro and suppress TSH secretion in vivo (Everts et al., 1994; Juge-Aubry et al., 1995; 
Lameloise et al., 2001).
The deamination reactions are catalyzed by L-amino acid oxidase (LAO) and thyroid 
hormone aminotransferase (AT). Triac, which is present in human serum at a picomolar 
range, represents 14% of T3 degradation, and has a higher clearance rate than T3 
owing to its rapid conjugation in the liver (Gavin et al., 1980). T4, sold as Synthroid, has 
long been used illicitly for weight loss, and now triac is being sold under various names 
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as a dietary supplement for weight loss, leading the US Food and Drug Administration 
(FDA) to issue repeated safety alerts and go to court in the case United States v. Syntrax 
Innovations, Inc., et al. (FDA, 2004). According to the FDA, the health consequences of 
consuming products containing triac include heart attacks and strokes (FDA, 2009).
Decarboxylation of T4 and T3 by a still unknown decarboxylase can lead to the 
formation of 3,3,5,5-tetraiodothyronamine (tetram) and 3,3,5-triiodothyronamine (triam), 
respectively. Though these were not found in vivo, other decarboxylation metabolites of 
thyroid hormones were. A 2004 Nature Medicine article by Scanlan et al. surprised the 
thyroid community with results suggesting that the observed non-genomic effects of 
thyroid hormones are in fact mediated by even less recognized metabolites of thyroid 
hormones. The authors found that 3-iodothyronamine (T1AM) and thyronamine (T0AM) 
are in vitro agonists of G-protein-coupled trace amine receptor TAR1 and in vivo induce 
hypothermia and bradycardia within minutes (Scanlan et al., 2004). It is increasingly 
becoming evident that the action of these minor metabolites within new signaling 
pathways should be of major concern for toxicologists; however, in vitro models of the 
disruption of thyroid hormone metabolism and clearance still look solely at inhibition of 
SULTs, UGTs, and DIOs (Murk et al., 2013).
Ether link cleavage of T4 by peroxidases in the presence of H2O2 leads to DIT. It is 
not surprising then that, in the thyroid, TPO and its substrate H2O2 can also act on newly 
synthesized T4 and degrade it. This means that the thyroid follicles have mechanisms in 
place to safeguard T4 from TPO-mediated degradation. Glutathione peroxidase, which is 
found intracellularly, has been found to inhibit TPO activity by disposing of the substrate 
H2O2 (Ekholm and Björkman, 1997).
Other MOAs affecting the thyroid hormone system
Epigenetics
Abnormal thyroid gland development, also called thyroid dysgenesis (TD), accounts for 
80% of reported cases of congenital hypothyroidism (CH), with the remaining 20% of 
patients having a normal thyroid but a dysfunction in the synthesis of thyroid hormones 
(Gruters, 2004). A study on monozygotic twins led its authors to conclude that a classic 
genetic hypothesis for thyroid dysgenesis is unlikely (Kuehnen et al., 2009). In addition, 
mutations in genes commonly associated with thyroid development, such as PAX8, 
FOXE1, NKX2.1, and NKX2.5, were identified in only 3% of patients with congenital 
hypothyroidism from thyroid dysgenesis (Castanet et al., 2005). The sporadic nature 
of thyroid dysgenesis suggests that there could be epigenetic factors involved (Felice 
and Lauro, 2004; Vassart and Dumont, 2005). Xenobiotic exposure during critical time-
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windows of development could affect both biochemical and epigenetic mechanisms and 
help explain the lack of a clear genetic underpinning for this disease.
While it is a challenge to gather epidemiological data showing the contribution 
of xenobiotics to thyroid dysgenesis, it is well established that hyperthyroid mothers 
receiving treatment with antithyroid drugs such as methimazole and propylthiouracil 
or who have been given radioactive iodine (RAI) are at higher risk of having a child with 
hypothyroidism (Atkins et al., 2000; Gorman, 1999). CH is associated with an increased 
risk of other congenital malformations and of these, most are cardiac malformations 
(Olivieri et al., 2002).
A recent study correlating pituitary cell proliferation upon exposure to thyroid-active 
compounds to pituitary gland weight ended up finding high correlation with the weight 
of another organ—the heart (Jomaa et al., 2013). This underlines the strong interplay 
between the heart and the thyroid system and also emphasizes the potential of in vitro 
systems to unravel physiological effects.
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Fig. 5: Enzymes involved in the metabolism of T4, sulfotransferases (SULTs), UDP-
glucuronosyltransferases (UGTs), deiodinases (DIOs), L-amino acid oxidase (LAO), thyroid hormone 
aminotransferase (AT), peroxidases (PODs) and a yet to be discovered decarboxylase (?DC) [Source: 
Barae Jomaa/Wikimedia Commons].
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Autoimmunity
Autoimmune thyroid disease (AITD) can be divided into diseases that lead to 
hypothyroidism, such as Hashimoto’s (chronic autoimmune thyroditis) and postpartum 
thyroditis, and diseases that lead to hyperthyroidism, such as Grave’s disease. 
Autoimmune hypothyroidism results mainly from autoantibodies against TPO and TG, 
whereas autoimmune hyperthyroidism results from autoantibodies that bind the TSHR 
and activate it in a similar way to TSH. Even though the symptoms of autoimmune 
hypothyroidism and autoimmune hyperthyroidism are different, they both have a high 
degree of heritability and share susceptibility genes, including those for HLA-DR3, 
HLA-C*07, PTPN22, and CTLA4—all linked to the deregulation of T-cell activation 
(Panicker, 2011). Nonetheless, a Danish twin cohort revealed that 21% of Grave’s 
disease could not be explained by heredity alone and must be due to the environment 
(Brix et al., 2001). On the other hand, a steady increase in the incidence of autoimmune 
thyroditis could be due to increased diagnosis, but increasing evidence is linking iodine to 
this disease (McLeod and Cooper, 2012; Rose et al., 1999). Some have even suggested 
the involvement of soy isoflavones in the formation of TPO neoantigens during their 
covalent binding and inactivation of the enzyme (Doerge and Sheehan, 2002).
Novel pathways
Integrin alpha v beta 3 (ITG αvβ3) has been found to be a cell surface receptor for T4 
inducing a downstream signaling cascade that might help elucidate some of the in vivo 
effects that cannot be accounted for fully by other mechanisms (Bergh et al., 2005).
Multiple effects
The widespread use of lithium that followed its approval in the 1970s by the FDA for 
the treatment of bipolar disorder quickly led to its association with goiter (Bocchetta 
and Loviselli, 2006; Maletzky and Shore, 1978). However, a single MOA cannot explain 
this drug’s antithyroidal effects. The multiple effects of lithium include abnormal iodine 
kinetics, altered thyroglobulin structure, inhibition of iodotyrosine coupling and thyroid 
hormone secretion, DIO2 inhibition, immunostimulation, and altered TR gene expression 
(Chakrabarti, 2011). These effects may be exacerbated by other factors such as iodine 
exposure, dietary goitrogens, and immunogenic background (Lazarus, 1998).
1.5 Objective and outline of the thesis
The objective of the studies described in this thesis is to identify and develop in vitro and 
toxicogenomics-based alternatives to in vivo thyroid hormone disruption tests. Given that 
thyroid-active compounds could exert their effect through numerous MOAs occurring 
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across multiple organs, a battery of in vitro tests has to be developed, validated and 
implemented. The research work presented in the following chapters begins with one-
to-one replacements of in vivo endpoints with in vitro assays and proceeds in exploring 
additional tests and strategies that aim to tackle the pitfalls of these assays, such as the 
lack of the feedback mechanisms involved in thyroid homeostasis.
In the first part of Chapter 1, some of the key events that have led to the current 
interest in testing for thyroid active compounds have been outlined. These events 
have fuelled public interest and have led to regulations that have reverberated across 
continents. This was followed by a list of the available rodent in vivo test guidelines with 
thyroid endpoints. The latter part of this chapter presented known mechanisms of action 
that can serve as the basis for alternative in vitro tests.
The following two chapters address the current in vivo endpoints and explore 
potential alternatives as well as their relevance. While rodent tests for thyroid activity 
have three main parameters, namely, thyroid weight, serum thyroid hormone levels, and 
thyroid histopathology, the latter cannot be replaced with current in vitro tests. Hence, 
Chapter 2 compares chemically-induced in vivo changes in thyroid and pituitary organ 
weights with the in vitro proliferation of representative cell lines. Chapter 3 follows with 
a comparison between the effect of model compounds on serum thyroid hormone level 
changes in vivo and their effect on a potential in vitro counterpart. In this regard, the 
thyroid peroxidase enzyme, which is involved in the synthesis of thyroid hormones, is 
exposed to known inhibitors and known non-inhibitors and the results were compared to 
in vivo changes in thyroid hormone levels as reported in literature. Chapter 4 introduces 
the up and coming ‘omics technology of Microarray Assay for Real-time Coregulator-
Nuclear Receptor Interaction (MARCoNI) and details its implementation to the thyroid 
system in tests for thyroid hormone receptor-corregulator interaction upon exposure 
to known thyroid hormone disrupting compounds. In Chapter 5, zebrafish embryos are 
proposed as an in vitro test organism due to their intact thyroid system and potential 
for high throughput. The dose-dependent effect of model thyroid-active compounds 
on embryo development was assessed from 0 – 120 hours post fertilization and an 
adjusted developmental scoring system was developed. Chapter 6 provides an overview 
of the results obtained in this thesis and proposes an integrated testing strategy for the 
testing of thyroid active compounds. This includes the systematic and tiered integration 
of both highly sensitive and highly specific in vitro endpoints for thyroid activity.
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Summary
This study investigates the in vitro effect of eleven thyroid-active compounds known to 
affect pituitary and/or thyroid weights in vivo, using the proliferation of GH3 rat pituitary 
cells in the so-called “T-screen,” and of FRTL-5 rat thyroid cells in a newly developed 
test denoted “TSH-screen” to gain insight into the relative value of these in vitro 
proliferation tests for an integrated testing strategy (ITS) for thyroid activity. Pituitary cell 
proliferation in the T-screen was stimulated by three out of eleven tested compounds, 
namely thyrotropin releasing hormone (TRH), triiodothyronine (T3) and thyroxine (T4). 
Of these three compounds, only T4 causes an increase in relative pituitary weight, and 
thus T4 was the only compound for which the effect in the in vitro assay correlated 
with a reported in vivo effect. As to the newly developed TSH-screen, two compounds 
had an effect, namely, thyroid-stimulating hormone (TSH) induced and T4 antagonized 
FRTL-5 cell proliferation. These effects correlated with in vivo changes induced by 
these compounds on thyroid weight. Altogether, the results indicate that most of the 
selected compounds affect pituitary and thyroid weights by modes of action different 
from a direct thyroid hormone receptor (THR) or TSH receptor (TSHR)-mediated effect, 
and point to the need for additional in vitro tests for an ITS. Additional analysis of the 
T-screen revealed a positive correlation between the THR-mediated effects of the tested 
compounds in vitro and their effects on relative heart weight in vivo, suggesting that the 
T-screen may directly predict this THR-mediated in vivo adverse effect.
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1 Introduction
Endocrine disruption has been the source of considerable debate since 1991 when Ana 
Soto reported that man-made compounds could act as estrogen mimics (Soto et al., 
1991), an observation that was popularized with the publication of Our Stolen Future 
by Theo Colborne in 1996. Although some environmental chemicals have been shown 
to affect endocrine activity in in vitro and in vivo test systems, there is still debate as 
to whether this activity can truly result in adverse effects to humans at realistic levels 
of exposure (Boas et al., 2006; Brucker-Davis, 1998; Leghait et al., 2010; Brouwer et 
al., 1998). So far, attention on the endocrine activity of chemicals has largely focused 
on estrogen disruption. An analysis of literature search results in Scopus™ reveals that, 
in the last decade, the majority of the papers published on endocrine disruption have 
focused on estrogen rather than on androgen or thyroid hormone disruption. This is in 
contrast to the number of chemicals listed on the Toxnet hazardous substance data bank 
(HSDB) as of 25 January 2013 which lists 159 chemicals for androgen, 352 chemicals 
for estrogen, and 924 chemicals for thyroid activity. This is a cause for concern as altered 
thyroid hormone (TH) levels can cause adverse effects such as decreased fertility and 
retarded development, especially of the bones and the brain (Poppe and Velkeniers, 
2004; Wajner et al., 2009; Göthe et al., 1999; Aronson et al., 1990; Zoeller and Crofton, 
2000). 
Changes in thyroid hormone levels are also directly related to changes in cardiac 
output, heart rate, and systemic vascular resistance (Zamoner et al., 2011). The clinical 
outcomes of such disturbances include arrhythmias, reduced exercise performance, and 
an increased risk of cardiovascular mortality (Klein and Ojamaa, 2001; Fazio et al., 2004).
Considering that thyroid hormones play a crucial role in the development of the 
human brain, bones, and gonads, in pregnancy as well as in cardiac pathogenesis, the 
possibility of alterations to the normal function of the thyroid system by xenobiotics could 
have substantial societal implications (Oppenheimer and Schwartz, 1997; Zoeller et 
al., 2002; Göthe et al., 1999; Aronson et al., 1990; Wagner et al., 2008; Gardiner-Hill, 
1929; Mestman et al., 1974; Sugrue and Drury, 1980; Fazio et al., 2004; Char, 1996). 
For this reason, the Organization of Economic Cooperation and Development (OECD) has 
amended and validated its test guideline number 407 (TG 407) for repeated-dose 28-
day oral toxicity studies in rodents to include endpoints relevant to the thyroid system, 
including histopathology of the pituitary and thyroid weight. Thyroid hormone levels in 
plasma or serum are included as an optional endpoint for the confirmation of toxicants 
with a mode of action related to the thyroid system (OECD, 2007). However, testing on 
animals raises issues related to ethics, high costs, long duration, and difficulties in the 
interpretation of inter-species data. This has prompted research into suitable in vitro 
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assays that, once validated, could serve as alternatives.
Wang et al. (2012) recently published an in-depth comparison of the proliferative 
response of different estrogen-responsive human cell lines with data on the in vivo 
change in uterine weight in the rat uterotrophic assay upon exposure to a series of model 
compounds. Proliferation of the MCF-7 human breast cancer cell line subclone MCF-7/
BOS upon exposure to the test compounds appeared to be predictive for the in vivo effect 
on rat uterine weight resulting in a squared sample correlation coefficient of 0.85 (Wang 
et al., 2012). Hence, as in the case of the estrogen-responsive MCF-7 cell proliferation 
assay, called “E-screen” (Soto et al., 1992), in vitro proliferation correlates well with the in 
vivo increase in uterine wet weight. For thyroid hormone activity, the so-called “T-screen” 
has been developed, detecting proliferation of rat pituitary adenoma cells upon exposure 
to thyroid hormone receptor (THR)-active compounds, whereas in vivo pituitary weight is 
an endpoint for the disruption of thyroid activity (Gutleb et al., 2005; Umano et al., 2009; 
Sellers and Schänbaum, 1965). Given the correlation of the E-screen with uterine weight, 
the objective of the present study was to investigate the correlation between the effects 
of a series of model thyroid-active compounds on cell proliferation in the T-screen and 
in vivo data for their effects on pituitary weight. Compounds that tested positive in the 
T-screen were further tested in the GH3-TRE-Luc reporter gene assay using the same cell 
line in order to find out if the observed proliferation was directly caused by activation of 
the thyroid hormone receptor (Freitas et al., 2011). GH3 cells express all thyroid nuclear 
receptor isoforms, with THRβ2 and THRα1 being, in order, the most abundant, which is 
in line with pituitary expression patterns (Hahn et al., 1999; Freitas, 2012; Yen et al., 
1992). Since these receptors shuttle between the nucleus and the cytoplasm, THR-active 
compounds must be able to cross the cell membrane to have an effect (Mavinakere et 
al., 2012). The cellular uptake of TH-like compounds is mediated by specific plasma 
membrane transporters showing preferential transport of T4 or T3 or their metabolites 
(Hennemann et al., 2001). Very lipophilic compounds also can cross the cell membranes 
by passive diffusion. Moreover, as thyroid weight is another endpoint in in vivo studies for 
thyroid hormone activity, an additional objective was to develop an in vitro counterpart 
(OECD, 2007). To this end, a physiologically-relevant assay based on thyroid stimulating 
hormone (TSH)-induced proliferation of cells from the FRTL-5 rat thyroid cell line was 
developed (denoted TSH-screen). This screen was subsequently used to explore parallels 
between the effects of the selected model thyroid-active compounds on in vitro FRTL-5 rat 
thyroid cell proliferation and their effects on in vivo rat thyroid weight. Changes in thyroid 
weight are associated mainly with hyperplasia and hypervascularization and, to a lesser 
extent, hypertrophy, thereby suggesting that proliferation assays may be able to reflect 
the in vivo effects (Martin et al., 1973; Kero et al., 2007). Given the complexity of the in 
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vivo hypothalamic-pituitarythyroid (HPT) axis, it may be expected that the T-screen and the 
newly developed TSH-screen may prove less predictive for effects on pituitary and thyroid 
weight in vivo than the E-screen is for effects on uterine weight in the uterotrophic assay. 
Thus, the ultimate aim of this study was to provide insight into the predictive potential 
and relative value of the two in vitro cell proliferation screens within an integrated testing 
strategy (ITS) for thyroid activity. 
Compound Abbreviation CAS No. Description Mode of Action Concentration 
Range (nM)
Thyrotropin-
Releasing Hormone
TRH 24305-27-9 Endogenous 
ligand
Binds 
thyrotropin-
releasing 
hormone 
receptor
0.001 - 
160,000
bovine Thyroid 
Stimulating 
Hormone 
bTSH 9002-71-5 Endogenous 
ligand
Binds thyroid 
stimulating 
hormone 
receptor
0.001 x 10-3 
- 143
Triiodothyronine T3 6893-02-3 Endogenous 
ligand
Binds thyroid 
hormone 
receptor
0.001 - 
1,000
Thyroxine T4 51-48-9 Endogenous 
ligand
Binds thyroid 
hormone 
receptor
0.001 - 
1,000
Propylthiouracil PTU 51-52-5 Antithyroid 
drug
Inhibits 
enzyme thyroid 
peroxidase
1 - 100,000
Methimazole MMI 60-56-0 Antithyroid 
drug
Inhibits 
enzyme thyroid 
peroxidase
1 - 100,000
Ethylene thiourea ETU 96-45-7 Environmental 
contaminant
Inhibits 
enzyme thyroid 
peroxidase
0.01 - 
100,000
Aminotriazole 3-AT 61-82-5 Environmental 
contaminant
Inhibits 
enzyme thyroid 
peroxidase
0.01 - 
100,000
Sodium perchlorate 
monohydrate
NaClO4•H2O 7791-07-3 Environmental 
contaminant
Inhibition of 
iodide uptake
0.01 - 
200,000
Bisphenol F BPF 620-92-8 Environmental 
contaminant
Binds to 
estrogen 
receptor
0.01 - 1,000
4,4’-Butylidenebis BBBC 85-60-9 Environmental 
contaminant
Unknown 0.001 - 100
Tab. 1: List of compounds used in this study with their main mode of action on the thyroid hormone 
system and concentration ranges used in the in vitro experiments.
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TRH Iglesias et al., 1985 34-day repeated 
oral dose with SD 
rats (F, n=6)
D’Angelo et al., 
1975
14-day repeated 
oral dose with CR 
rats (F, n=4)
- - Connors et al., 1988 6-day chronic IV 
dose with SD rats 
(M, n=4)
bTSH NA NA Connors et al., 1988 6-day chronic IV 
dose with SD rats 
(M, n=4)
T3 Nedvidkova et al., 
1996
20-day repeated 
oral dose with WSTR 
rats (M, n=6)
Soukup et al., 2001 6-month repeated IP 
dose with LEW rats 
(F, n=10)
T4 OECD, 2006b OECD TG 407
(M, F, n=10)
OECD, 2006b OECD TG 407
(M, F, n=10)
Seller and 
Schonbaum, 1965
64-week repeated 
oral dose with WSTR 
rats (M, n=6)
- -
PTU OECD, 2006b OECD TG 407
(M, F, n=10)
OECD, 2006b OECD TG 407
(M, F, n=10)
MMI Moreira et al., 2005 21-day repeated 
oral dose with DM 
rats (M, F, n=10)
Hood et al., 1999 21-day repeated 
oral dose with SD 
rats (M, n=4)
ETU Lu and Staples, 
1978
9-day repeated oral 
dose with CR rats
(F, n=6-12)
Graham et al., 1972 30-day repeated 
oral dose with OM 
rats (M, n=10)
3-AT Umano et al., 2009 OECD TG 407
(M, F, n=10)
Umano et al., 2009 OECD TG 407
(M, F, n=10)
NaClO4 Stoker et al., 2006 31-day repeated oral 
dose with CR rats 
(M, n=25)
Siglin et al., 2000 90-day repeated 
oral dose with SD 
rats (M, F, n=10)
BPF Higashihara et al., 
2007
OECD TG 407
(M, F, n=10)
Higashihara et al., 
2007
OECD TG 407
(M, F, n=10)
BBBC Yamasaki et al., 
2008
OECD TG 407
(M, F, n=10)
Yamasaki et al., 
2008
OECD TG 407
(M, F, n=10)
Tab. 2: List of compounds used in this study and overview of the in vivo data. Selection was based 
on significant in vivo change in either thyroid weight (∆ thyroid wt) or pituitary weight (∆ pituitary 
wt) in rats. The direction of the changes and their magnitude are presented in Tables 3 and 4. Two 
studies are included for the effect of TRH on thyroid weight so that both sexes are represented and 
two studies using different exposure periods are included for the effect of T4 on pituitary weight. 
M, male; F, female; OM, Osborne-Mendel; SD, Sprague-Dawley; DM, Dutch-Miranda; CR, Charles 
River; LEW, Lewis; WSTR, Wistar; IV, intravenous; IP, intraperitoneal; NA, not available.
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2 Materials and methods
Compound selection
Table 1 presents the list of compounds selected and the concentration range used 
in the in vitro experiments. BBBC was obtained from Wako Pure Chemical Industries 
(Tokyo, Japan), while all other compounds were obtained from Sigma-Aldrich Chemie 
(Zwijndrecht, The Netherlands). All chemicals were of high purity (≥95%). With the 
exception of bTSH, which was diluted in phosphate buffered saline (pH 7.2) (PBS), all test 
chemicals were added from 500-fold concentrated stock solutions in dimethylsulfoxide 
(DMSO, Acros Organics, Geel, Belgium), resulting in a final concentration of DMSO of 
0.2%.
Compound selection was based on whether in vivo data for effects of the compounds 
on pituitary and/or thyroid weight were available (Tab. 2). The mode of action underlying 
the increase in organ weights was not used as a selection criterion, since the objective 
was to test whether the proliferation assays could replace in vivo assays detecting organ 
weight changes, as was shown feasible for the E-screen and in vivo effects on uterus 
weight (Wang et al., 2012). Changes in pituitary weight induced by the selected model 
compounds are presented in Table 3, and changes in thyroid weight induced by these 
compounds are presented in Table 4.
Cell culture
GH3-TRE-Luc cells were cultured at 37°C in a humid atmosphere containing 5% (v/v) 
CO2 and passaged twice a week in Dulbecco’s Modified Eagle’s medium: Ham’s F12 
(1:1) with 15 mM HEPES (DMEM:F12, Gibco, Paisley, Scotland) supplemented with 10% 
fetal calf serum (FCS, Gibco, Paisley, Scotland). The construction and validation of the 
GH3-TRELuc cells was previously described (Freitas et al., 2011).
FRTL-5, a rat thyroid cell line (obtained from CLS, Germany), was cultured as 
a monolayer in tissue-culture flasks (obtained from Corning, Badhoevedorp, The 
Netherlands) at 37°C in a humid atmosphere containing 5% (v/v) CO2 and passaged 
once a week with an interim refresh of the medium, which consisted of Coon’s Modified 
F-12 medium (obtained from Biochrom, Berlin, Germany), supplemented with 5% 
FCS, and a mixture of six hormones (referred to as 6H5, reflecting the presence of 6 
hormones and 5% FCS). The six hormones included bTSH (1 mIU/ml), insulin (10 µg/
ml), hydrocortisone (10 nM), apo-transferrin (5 µg/ml), glycyl-L-histidyl-L-lysine acetate 
(10 ng/ml), and somatostatin (10 ng/ml). All these hormones were obtained from 
Sigma-Aldrich Chemie (Zwijndrecht, The Netherlands). This 6H5 cell culture medium 
was supplemented with 1 mM non-essential amino acids, 2 mM L-glutamine, 100 
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U/ml penicillin and 100 µg/ml streptomycin (Difco, Amsterdam, The Netherlands). 
Enzymatic passaging was performed using a cell detachment and disaggregation 
solution containing 20 units/ml collagenase, 0.075% trypsin, and 2% chicken serum 
(CTC) in PBS. Collagenase and chicken serum were obtained from Sigma-Aldrich Chemie 
(Zwijndrecht, The Netherlands) while trypsin was obtained from Difco (Amsterdam, The 
Netherlands).
Pituitary organ weight (literature) Pituitary cell proliferation (T-screen)
Male Female
Compound Fold 
change
BMDL10 
(mg/kg 
bw/day)
Fold 
change
BMDL10 
(mg/kg 
bw/day)
HTD (mg/
kg bw/
day)
Fold 
change
EC50 
(nM)
HTC (µM) IVIVC
TRH NA NA ↔ X 50 1.4x 
↑**
0.90 160 0
bTSH NA NA NA NA NA ↔ NA 0.143 NA
T3 1.1x ↑ X NA NA 0.0005 5x ↑** 0.09 1 0
T4 ↔ X ↔ X 1 4.3x 
↑**
1.73 1 0
1.3x 
↑**
NA NA NA 0.012 4.3x 
↑**
1.73 1 +ve
PTU 1.4x 
↑**
NA 1.4x 
↑**
NA 10 ↔ NA 100 0
MMI ↔ X ↔ X 75 ↔ NA 100 X
ETU NA NA 1x ↔ X 40 ↔ NA 100 0
3-AT 1.3x 
↑**
38.97 1.2x ↑* 51.31 125 ↔ NA 100 0
NaClO4 1x ↔ X NA NA 500 ↔ NA 200 X
BPF 1.1x ↑ X 1.1x ↑ X 500 ↔ NA 1 X
BBBC 1x ↔ X 1x ↔ X 125 ↔ X 0.1 X
Tab. 3: Effects of the selected model compounds on relative pituitary organ weight (mg/100g body 
weight) in male rats compared to in vitro pituitary cell proliferation (T-screen). Arrows indicate an 
increase (↑), decrease (↓), or (↔) no change in relative thyroid weight. If available the fold-change 
in mean response to the highest tested dose (HTD) compared to the unexposed controls also was 
presented. * indicates significance (p < 0.05) and ** indicates high significance (p < 0.01) for fold 
change calculations. Benchmark doses associated with a 10% change in organ weight (BMD10) 
were calculated and presented as the lower 95% confidence limit (BMDL10). For the effect on 
cell proliferation in vitro, besides fold change and when applicable, EC50 values are shown. The 
highest tested concentrations (HTCs) also are represented and were chosen in such a way that 
they were not cytotoxic based on results from the resazurin assay. NA, not applicable. In vitro-in 
vivo correlation (IVIVC) was evaluated qualitatively and represented by +ve when the direction 
of change was similar in both situations, by 0 when there was no correlation, by -ve when the 
direction of change was opposite and by X when there was no significant change in both situations 
leading to an invalid correlation.
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T-screen
The T-screen was performed as previously described (Schriks et al., 2006) and using 
the rat GH3-TRE-Luc cell line. Compared to wild type GH3 cells, this cell line is stably 
transfected with a thyroid-hormone response element (TRE) driven luciferase expression 
construct, allowing for the comparison between cell proliferation and TRE-driven gene 
expression with the same cell line (Freitas et al., 2011). Briefly, GH3-TRE-Luc cells at 
80% confluence were incubated for 48 h in serum-free PCM-0 medium, as originally 
described by Sirbasku (1991). PCM-0 consists of phenol red-free DMEM:F12 with 15 
mM HEPES, 10 µg/ml bovine insulin, 10 µM ethanolamine, 10 ng/ml sodium selenite, 
10 µg/ml apo-transferrin, and 500 µg/ml bovine serum albumin (BSA, obtained from 
SigmaAldrich Chemie, Zwijndrecht, The Netherlands). The cells were then harvested and 
plated at a density of 2,500 cells/ well on a 96-well plate. Following an attachment period 
of 2 to 3 h, the cells were exposed in triplicate and for 96 h to a concentration range 
of the chemicals to be tested alone or in combination with 0.25 nM T3. Subsequently, 
and following a 4-h incubation period with 10 µl/well of 0.1 mg/ml resazurin (obtained 
from Sigma-Aldrich Chemie, Zwijndrecht, The Netherlands) in PBS, cell proliferation was 
measured as relative fluorescence units (RFUs) resulting from the reduction of non-
fluorescent resazurin to the fluorescent product resorufin. Fluorescence was measured 
at λex = 530 nm and λem = 590 nm on a SpectraMax M2 microplate reader (Molecular 
Devices, Menlo Park, CA, USA).
TSH-screen
FRTL-5 cells at 70% confluence and below passage 30 were incubated in serum-free, 
phenol red-free DMEM containing 0.2% BSA for a period of 96 h. The cells were then 
harvested and plated at a density of 5,000 cells/well on a 96-well plate in phenol red-free 
DMEM with insulin (10 µg/ml) and, following an attachment period of 2 to 3 h, exposed to 
a concentration range of the chemicals to be tested alone or in combination with 1 mIU/
ml bTSH, in triplicate, for 72 h. Following this incubation, cell proliferation was measured 
4 h after the addition of 10 µl/well of 0.1 mg/ml resazurin as described above.
GH3-TRE-Luc Reporter Gene Assay
GH3-TRE-Luc cells at 80% confluence were incubated in serum-free PCM-0 medium for 
24 h. The cells were then harvested and plated at a density of 30,000 cells/well on a 
96-well plate and, following an attachment period of 2 to 3 h, exposed in triplicate for 
24 h to a concentration range of the chemicals to be tested alone or in combination 
with 0.25 nM T3. To measure luciferase activity, cell culture medium was thoroughly 
aspirated, and the cells were lysed by addition of low salt buffer, which consisted 
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of 10 mM Tris (Invitrogen, Carlsbad, CA), 2 mM dithiothreitol (DTT) and 2 mM trans- 
1,2-diaminocyclohexane-N,N,N′,N′-tetra-acetic acid monohydrate (obtained from Sigma-
Aldrich Chemie, Zwijndrecht, The Netherlands) (pH 7.8). Cell lysis was completed by one 
subsequent freeze-thaw cycle. Luciferase reagent, which consisted of 20 mM tricine, 
Thyroid organ weight (literature) Thyroid cell proliferation (TSH-screen)
Male Female
Compound Fold 
change
BMDL10 
(mg/kg 
bw/day)
Fold 
change
BMDL10 
(mg/kg 
bw/day)
HTD (mg/
kg bw/
day)
Fold 
change
EC50 
(nM)
HTC (µM) IVIVC
TRH NA NA 1.1x↑ X 12.5 ↔ NA 160 X
1.7x↑* NA NA NA *** ↔ NA 160 0
bTSH 1.8x↑* NA NA NA *** 1.6x 
↑**
4.6 0.143 +ve
T3 NA NA 1.9x↓* NA 0.15 ↔ NA 1 0
T4 ↔ X 1.3x ↓* 0.26 1 1.3x ↓* 0.11 1 +ve
PTU 7.2x 
↑**
0.02 7.7x 
↑**
0.14 10 ↔ NA 100 0
MMI 3.3x 
↑**
0.11 NA NA 50 ↔ NA 100 0
ETU 2.7x 
↑**
1.52 NA NA 37.5 ↔ NA 100 0
3-AT 3x ↑** 3.86 3.7x 
↑**
2.10 125 ↔ NA 100 0
NaClO4 1.3x 
↑**
0.36 1.2x ↑* 6.44 10 ↔ NA 200 0
BPF 1.3x 
↑**
30.28 1.2x ↑ X 500 ↔ NA 1 0
BBBC 1.2x ↑ X 1.3x 
↑**
5.02 125 ↔ NA 0.1 0
Tab. 4: Effects of the selected model compounds on relative thyroid organ weight (mg/100g body 
weight) in male rats compared to in vitro thyroid cell proliferation (TSH-screen). Arrows indicate 
an increase (↑), decrease (↓), or (↔) no change in relative thyroid weight. If available the fold-
change in mean response to the highest tested dose (HTD) compared to the unexposed controls 
also was presented. * indicates significance (p < 0.05) and ** indicates high significance (p < 
0.01) for fold change calculations. † TRH and bTSH were chronically administered intravenously to 
male rats at 240 µg/day and 800 mIU/day, respectively. Benchmark doses associated with a 10% 
change in organ weight (BMD10) were calculated and presented as the lower 95% confidence limit 
(BMDL10). For the effect on cell proliferation in vitro, besides fold change and when applicable, 
EC50 values are shown. The highest tested concentrations (HTCs) are also represented and were 
chosen in such a way that they were not cytotoxic based on results from the resazurin assay. NA, 
not applicable. In vitro-in vivo correlation (IVIVC) was evaluated qualitatively and represented by +ve 
when the direction of change was similar in both situations, by 0 when there was no correlation, 
by -ve when the direction of change was opposite and by X when there was no significant change 
in both situations leading to an invalid correlation.
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1.07 mM (MgCO3)4•Mg(OH)2•5H2O, 2.67 mM MgSO4 (all obtained from Sigma-Aldrich 
Chemie, Zwijndrecht, The Netherlands), 0.1 mM EDTA, 2 mM dithiothreitol (obtained from 
Merck, Darmstadt, Germany), 470 µM D-luciferin and 5 mM ATP (both obtained from 
Duchefa Biochemie, Haarlem, The Netherlands) (pH 7.8), was adde d to the wells, and 
luciferase flash-kinetics activity was measured as relative luminescence units (RLUs) 
using a Luminoskan Ascent luminometer from Labsystems (Helsinki, Finland).
Data analysis
In the T-screen, GH3-TRE-Luc reporter gene assay and TSHscreen, data points are 
representative of at least two independent experiments and three replicate wells per 
data point in each experiment. Raw data from triplicate wells were averaged, converted 
to fold change over solvent control and represented graphically as the means of 
independent experiments with bars representing the standard error of that mean (SEM). 
The luminescent signal in the GH3-TRE-Luc reporter gene assay was normalized to cell 
viability as determined by a resazurin cell viability test with an incubation period of 2 h. 
Non-linear curve fitting was done using the Hill equation with the help of GraphPad Prism 
software version 5.04 (GraphPad Software, San Diego, CA, USA). In vitro, EC50 values 
were calculated from the fitted models as the concentration of the tested compound that 
gave 50% of the maximal response.
For the in vivo data collected from literature, with included standard deviations and 
more than one dose level used, the benchmark dose (BMD) approach was used and BMDL 
(95% lower confidence limit of the BMD) values with a relative deviation from the controls 
of 10% (BMDL10) were calculated using Benchmark Dose Software (BMDS) version 2.1.2 
(US EPA, Washington, DC, USA). For organ weight changes that were significant (p<0.05) 
among dose levels, the curve fitting models used for in vivo BMDL calculations were 
based on either polynomial, power, or Hill equations, and the choice of the best model 
to fit the data was based on the highest p-value for three tests, namely, homogenous 
variance, adequate modeling of the variance and model fit and when these p-values were 
similar across models, then a lower Akaike Information Criterion (AIC) value was used for 
selection. Models with a goodness of fit for the means with a p-value<1 were rejected. 
BMDL10 calculations were based on data from male rats (except for TRH for which data 
from virgin females were used and ETU for which data from gestating females were used).
Doses of 0, 50, 100, 500, and 750 ppm ETU in feed were converted to 0, 2.5, 5, 
25, and 37.5 mg/kg bw/day, a T3 dose of 0.01 mg/kg was converted to 0.0005 mg/kg 
bw/day and a T4 dose of 0.25 mg/kg diet was converted to 0.012 mg/kg bw/day, based 
on the assumption that rats consume 5% of their body weight of food each day. 0.03% 
(0.3 mg/ml) MMI, 0.2 mg/ml, and 0.05 mg/ml TRH in drinking water were converted to 
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75 mg/kg bw, 50 mg/kg bw and 12.5 mg/kg bw, respectively, based on a previous study 
reporting an average water intake of similarly aged rats of 250 ml/kg bw (McGivern et al., 
1996). To calculate the molar concentrations of bTSH, it was considered that TSH has a 
molar mass of 28,000 g/mol and conversion to mIU/ml was based on the manufacturer’s 
stated activity of 2 IU/mg (Pierce et al., 1971). 
a)
c)
e)
d)
b)
Fig. 1: Concentration-dependent GH3 cell proliferation (T-screen) upon exposure to a) T3 (n=5) and 
T4 (n=3), c) triac (n=1) and tetrac (n=1) or e) TRH (n=2) and luciferase response in the GH3-TRE-
Luc thyroid hormone receptor reporter gene assay for b) T3 (n=3) and T4 (n=2) or d)  triac (n=2) 
and tetrac (n=2). The response is expressed as fold change over control, error bars represent the 
standard error of the mean (SEM) of the indicated number of independent experiments.
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3 Results
3.1 Activity of selected compounds in the T-screen
Figures 1A and 1C show that the endogenous agonists T3 and T4, along with their 
respective acetic acid analogues triac and tetrac resulted in a concentration-dependent 
increase in cell proliferation in the T-screen. Figures 1B and 1D show that a concentration-
dependent response also was obtained in the GH3- TRE-Luc reporter gene assay, which 
is an indication that the observed cell proliferation is likely to be THR-mediated. The other 
model compounds tested with known in vivo effects on pituitary weight, propylthiouracil 
(PTU) and 3-amino-1,2,4-triazole (3-AT) did not induce a proliferative response in the 
assay for in vitro GH3 pituitary cell proliferation. On the other hand, TRH, which does not 
lead to an increase in pituitary weight in vivo, was found to be an agonist in the T-screen 
with an EC50 of 0.9 nM (95% confidence interval 0.3-2.4 nM, Fig. 1E).
3.2 Correlation of in vitro pituitary cell proliferation with in vivo pituitary weight
Table 3 presents an overview of the effects of the selected model compounds on 
pituitary weight in in vivo studies derived from literature, as well as the results obtained 
in the present study on the effects of the compounds in the T-screen assay. A correlation 
between the in vitro T-screen and effects on pituitary weight reported in the in vivo 
studies was observed only for T4. 
3.3 Development of the TSH-screen based on FRTL-5 cell proliferation
FRTL-5 cells are a differentiated, continuously growing, nontransformed subclone of FRTL 
rat thyroid cells derived from primary cultures of Fischer rat thyroid glands. Differentiated 
features such as the cellular uptake of iodide and the secretion of thyroglobulin in FRTL 
cells are dependent on a low concentration of FCS (0.5-1%) which results in slow growth 
(AmbesiImpiombato et al., 1980). FRTL-5 is a fast growing subclone of the FRTL cell line 
that grows in 5% FCS while maintaining iodide uptake and thyroglobulin secretion. In 
addition, FRTL-5 cells exhibit enhanced TSH sensitivity, especially after TSH starvation 
(Ambesi-Impiombato, 1986).
To optimize the proliferation of FRTL-5 cells, a series of compounds was tested for 
its ability to improve TSH-induced cell proliferation, subsequently defining cell culture 
conditions in the TSH-screen. As can be seen in Figure 2, FRTL-5 cells exhibited little 
response to bTSH (1 mIU/ml) alone and a limited response to insulin (10 µg/ml), while 
the combination of both TSH and insulin resulted in a synergistic effect. Forskolin, a 
compound that directly activates cAMP, the downstream target of TSH’s proliferative 
action, also was tested alone or in combination with TSH (Kimura et al., 2001). The 
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forskolin response closely mimicked 
that of TSH, and the combination of 
forskolin with insulin had an effect 
similar to that of TSH in combination 
with insulin, showing that the 
membrane receptor-mediated TSH-
response was near optimal and reflects 
the differentiated characteristics of 
this cell line. As little as 0.2% FCS had a 
proliferative effect that was larger than 
bTSH. The addition of apo-transferrin 
and hydrocortisone, which are needed 
in the culture of FRTL-5 cells, had little 
effect in terms of TSH-responsiveness 
of the cells (Ambesi-Impiombato, 
1986). The addition of a somatostatin 
antibody, to block any inhibitory action 
of residual somatostatin, also had little 
effect (Medina et al., 1999). Based 
on these results, further testing using 
the TSH-screen was performed in 
serum-free medium containing insulin 
(10 µg/ml). Figure 3 shows the TSH 
concentration-dependent proliferation 
of FRTL-5 cells in the newly developed TSH-screen. This response was achieved in cell 
culture medium completely devoid of serum but supplemented with 10 µg/ml insulin and 
0.2% BSA. BSA is commonly added to serum-free media as it is thought to protect cells 
from agitation and aeration damage by biological and fluid-mechanical mechanisms 
(Papoutsakis, 1991; Michaels et al., 1995). The EC50 for TSH-dependent induction of 
cell proliferation was found to be 4.6 nM (95% confidence interval 1.7-12.6 nM).
3.4 Activity of selected compounds in the TSH-screen
In a next step, the series of model compounds was tested in the TSH-screen for either 
agonistic or antagonistic activity, the latter by testing cell proliferation in the presence 
of 1 mU bTSH (14.3 nM). The TSH-screen only gave a significant response with the 
endogenous agonist TSH while T4 showed antagonism with an IC50 of 0.11 nM (95% 
confidence interval 0-0.4 nM, Fig. 4).
Fig. 2: FRTL-5 cell proliferation expressed as 
fold change over control upon exposure to 0.2% 
DMSO as solvent control (SC), 0.1 µM forskolin 
(FSK), 1 mIU/ml bovine thyrotopin (bTSH), 10 
µg/ml insulin (INS), bTSH with INS, FSK and INS, 
0.2% fetal calf serum (FCS), bTSH with 0.2% 
FCS, bTSH with 0.2% FCS in addition to 5 µg/ml 
apo-transferrin (ATF) and 10 nM hydrocortisone 
(HCT), bTSH with 0.2% FCS and 4 µg/ml anti-
somatostatin antibody (Anti SS), and lastly bTSH, 
0.2% FCS, FSK and Anti SS (n=1). Proliferation 
was measured as fluorescence resulting from 
the mitochondrial metabolism of resazurin to the 
fluorescent resorufin.
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3.5 Correlation of in vitro thyroid 
cell proliferation with in vivo thyroid 
weight
Table 4 presents an overview of 
the effects of the selected model 
compounds on thyroid weight in in vivo 
studies, derived from literature, as well 
as the results obtained in the present 
study on the effects of the compounds 
in the TSH-screen. As can be observed 
from Table 4, the effects of the series 
of model compounds on in vitro FRTL-
5 thyroid cell proliferation correlates 
in only a very limited number of cases 
with the effects of the compounds on thyroid weight in vivo. The endogenous agonist 
TSH was one of the two compounds that had a similar proliferative effect both in vitro 
and in vivo. The other compound, T4, acted in a potentially physiological manner since 
it reduced thyroid weight in vivo in female rats and showed an antagonistic activity in 
the TSH-screen, both with and without 
TSH (Fig. 5).
3.6 Correlation of T-screen with 
cardiac hypertrophy
Given that the effect of some of the 
thyroid-active model compounds on 
GH3 cell proliferation (T-screen) and 
THR activity (GH3-TRE-Luc reporter 
gene assay) could not be correlated 
to effects on pituitary weight in 
vivo, investigations into potential 
correlations with effects on other 
organs was carried out based on data 
retrieved from the literature. It was 
found that the proliferative response to thyroid-active compounds in the T-screen may 
correlate with the in vivo effects of these compounds on cardiac hyperthrophy. Figure 5 
presents the plasma concentration-dependent effect of T4 and tetrac (Fig. 5A) and of T3 
and triac (Fig. 5B) on relative heart weight as reported in literature (Liang et al., 1997; 
Fig. 3: TSH-induced FRTL-5 cell proliferation in 
the TSH screen. Proliferation is expressed as 
fold change over control, error bars represent 
the standard error mean (SEM) of two different 
experiments.
Fig. 4: Effect of T4 (n=3) on basal proliferation 
(closed circles) and TSH-induced proliferation 
(open circles) of FRTL-5 cells.
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Lameloise et al., 2001). Comparison of these results with the results for T3, triac, T4 
and tetrac mediated effects in the T-screen (Fig. 1A,C) indicates that the THR-mediated 
cell hyperplasia in the T-screen correlates well with the receptor-mediated cardiac 
hypertrophy (Fig. 6). This is corroborated by the results presented in Figure 6 in which 
the in vivo BMDL10 for 10% increase in relative heart weight in the in vivo studies was 
plotted against the EC50 for cell proliferation in the T-screen obtained in the present 
study, showing a correlation with a squared coefficient of correlation (r2) of 0.89. Thus, 
whereas activity of these thyroid-active compounds on pituitary cell proliferation in vitro 
in the T-screen did not correlate with their effects on pituitary weight in vivo, their activity 
in the T-screen did correlate with their effects on relative heart weight in vivo.
4 Discussion
The objective of the present study was to investigate a potential correlation between the 
effects of a series of model thyroidactive compounds on GH3 pituitary cell proliferation 
in the T-screen assay and their effects on pituitary weight in in vivo studies. Given that 
thyroid weight is one of the endpoints used in in vivo studies for thyroid hormone activity, 
an additional objective was to develop an in vitro thyroid cell proliferation assay and 
explore correlations between the in vitro data obtained and in vivo data for compounds 
known to affect thyroid weight (OECD, 2007). This was done in order to gain further 
insight into the relative value of these proliferative in vitro tests for an integrated testing 
strategy (ITS) for thyroid activity.
The newly developed TSH-screen was based on the proliferation of cells from the 
FRTL-5 cell line. The preservation of TSH-induced cell proliferation in the FRTL-5 cell 
line is a property exhibited by only three cell lines that originate from normal rat thyroid 
follicular epithelium. The other two cell lines, PC Cl3 and Wistar rat (WRT), have been 
a) b)
Fig. 5: Increase in relative heart weight (expressed as % of total body weight) with increasing serum 
levels of a) T4 and tetrac (data from Lameloise et al., 2001) and b) T3 and triac (data from Liang 
et al., 1997).
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reported to have a suitable TSH-mediated proliferative response but are not as widely 
used and are not commercially available (Fusco et al., 1987; Brandi et al., 1987; Kimura 
et al., 2001). The reference compound used in this screen, TSH, has been shown to 
result in cell hyperplasia and hypertrophy, both in FRTL-5 cells in vitro and in the thyroid 
gland in vivo (Ossendorp et al., 1989; Ambesi-Impiombato et al., 1980; Brewer et al., 
2007). Figure 2 shows that insulin is needed for the mitogenic action of TSH and was 
included in both culture and exposure media used in the TSH-screen. While TSH is the 
main hormone that regulates the growth of the thyroid gland, the requirement for insulin 
has been well documented in both rodents and humans (Felice et al., 2004).
In a previous study, it was demonstrated that an in vitro-in vivo correlation (IVIVC) 
for endocrine-active compounds exists between estrogen-mediated cell proliferation in 
the so-called E-screen and in vivo effects on uterine weight (Wang et al., 2012). The 
relative potency of a series of estrogens for estrogen-induced MCF-7 cell proliferation in 
the E-screen correlated with the relative potency of the same compounds in the in vivo 
uterotrophic assay (Wang et al., 2012). In a detailed review paper on thyroid hormone 
disruption assays, the OECD mirrors a widely-held notion among toxicologists that the 
T-screen is an in vitro bioassay that can detect compounds that interfere with THR 
signaling much the way the MCF-7 cells are used in the E-screen to detect compounds 
that interfere with estrogen receptor (ER) signaling (OECD, 2006a). However, results 
obtained in this study show that this comparison between the T-screen and the E-screen 
is inaccurate when it comes to in vitro-in vivo correlation (IVIVC), since the activity of the 
selected model compounds in the T-screen did not correlate well with their in vivo effect 
on pituitary weight. Likewise, the in vivo effects of thyroid-active compounds on thyroid 
weight did not exhibit a consistent correlation with thyroid cell proliferation in a newly 
developed TSH-screen. The discrepancy between the two endocrine systems in terms 
of the applicability of the in vitro-in vivo extrapolation may be due to the fact that the 
uterotrophic assay for estrogen activity is based on ER-mediated increases in uterine 
weight, while increases in pituitary or thyroid weight may reflect much more complex 
mechanisms. These mechanisms include, among others, acute xenobioticinduced 
dyshormogenesis, displacement of thyroid hormones from transport proteins, changes in 
metabolism and clearance, alterations in feedback mechanisms, onset of autoimmune 
thyroiditis, effects on cofactors and inhibitors, as well as crosstalk with other pathways 
(Roy and Mugesh, 2006b; Cao et al., 2010; Gayrard et al., 2011; Zabka et al., 2011; 
Kosuda et al., 1997; Grover et al., 2007; Liu and Brent, 2010). Thus, with the exception 
of T4 and TSH, the effects of the selected thyroid-active compounds on pituitary and 
thyroid organ weights in vivo are not likely to be due to a direct effect on cell proliferation. 
The T-screen and TSH-screen are therefore less predictive for the effects of thyroid-active 
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compounds on pituitary and thyroid weight in vivo than the E-screen is for the effects of 
estrogenic compounds on uterine weight in the uterotrophic assay. Altogether, the results 
obtained indicate that while the Tscreen and the TSH-screen accurately reflect TH and 
TSH receptor-mediated cell proliferation, respectively, an integrated testing strategy for 
replacement of these in vivo endpoints by a battery of in vitro tests will need additional 
assays to cover mechanisms of action that are neither THR nor TSHR mediated. The 
known modes of action underlying the effects of these compounds are presented in the 
following text, thereby highlighting some of the critical issues that have to be accounted 
for with additional in vitro assays. Recently, a mechanism-based testing strategy has 
been proposed using a battery of in vitro assays for the identification of thyroid hormone 
disrupting chemicals (Murk et al., in press). The TSH-screen presented in this study is 
already included in the proposed battery as well, in addition to tests for NIS and cAMP 
production that play an important role in TH biosynthesis in thyrocytes.
TRH is a hypothalamic hormone whose main role is to stimulate the release of 
TSH and prolactin from the pituitary gland. TRH reaches the pituitary through the 
hypothalamic-hypophyseal portal system, triggering a signaling cascade by binding to the 
TRH receptor that eventually leads to TSH and prolactin secretion (De Léan et al., 1977). 
TRH is rapidly metabolized, resulting in a half-life of 4 minutes, rendering it undetectable 
in the systemic circulation (Redding and Schally, 1972; Bassiri and Utiger, 1973). It was 
previously shown in in vivo experiments performed on rats that TRH alone does not have 
a proliferative effect on pituitary cells, which is not in accordance with the results of 
the present study in which TRH did have an agonistic activity on GH3 cell proliferation 
(Quintanar-Stephano and Valverde, 1997). TRH did not have any proliferative effect on 
FRTL-5 thyroid follicular cells in the TSH-screen even though in vivo thyroid weight is 
increased. The in vivo effect can be simply an indirect effect, whereby TRH leads to an 
increase in TSH secretion which, in turn, is mitogenic to thyroid cells, a sequence of 
events that is not easily mimicked in vitro.
TSH, the pituitary hormone whose main role is to stimulate thyroid growth and 
thyroid hormone production, had no effect on GH3 cell proliferation in the T-screen, 
which is in agreement with previous studies (Felice et al., 2004; Theodoropoulou et 
al., 2000). It did, nonetheless, exhibit a physiologically relevant and concentration-
dependent mitogenic effect on FRTL-5 cells in the TSH-screen.
T3 and T4, the thyroid hormones, resulted in a concentrationdependent increase in 
GH3 pituitary cell proliferation, which is the basis of the T-screen (Gutleb et al., 2005). 
However, only T4 leads to a significant increase in pituitary weight in vivo, and this 
increase was found to be heavily dependent on the duration of exposure (Tab. 3). The 
endogenous THR agonist precursor T4 causes a significant increase in pituitary weight 
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but only after long-term exposure of more than one year, while in the OECD TG 407, 
which is based on subacute exposure (28 days), no significant effect is found (Sellers 
and Schänbaum, 1965; OECD, 2006b). This stands in contrast to the 4-fold increase 
in GH3 pituitary cell proliferation observed upon exposure to T4 for only 4 days (Fig. 
1A). The effect of T3 on FRTL-5 rat thyroid cell proliferation was indistinguishable from 
the controls, and this does compare well with the lack of change in thyroid weight upon 
T3 administration. T4 had an antagonistic effect in the TSH-screen, which correlated 
significantly but only with female rats used in one of the in vivo studies conducted by the 
OECD to validate the updated TG 407 (OECD, 2006b). It is possible that T4, an iodinated 
hormone precursor that is deiodinated intrathyroidally, acts in a similar way to iodide, 
which is known to lead to cell cycle arrest in FRTL-5 cells (Laurberg, 1988; Smerdely 
et al., 1993). Moreover, amiodarone, a T4 analogue, has an inhibitory effect on TSH-
induced cAMP production at concentrations that are lower than iodide, suggesting a 
direct mechanism of action (Pitsiavas et al., 1999). This in vitro effect could indicate a 
physiologically relevant short-feedback regulatory loop.
Antithyroid drugs PTU and MMI, the degradation product of ethylene bis-
dithiocarbamate fungicide ETU, as well as the herbicide 3-AT, decrease serum levels 
of thyroid hormones by inhibiting thyroperoxidase (TPO), a critical enzyme in thyroid 
hormone synthesis (Roy and Mugesh, 2006a; Marinovich et al., 1997; Hurley, 1998). The 
increase in thyroid weight resulting from the in vivo administration of these compounds 
and the increase in pituitary weight resulting from the administration of PTU and 3-AT 
are not related to a direct effect on cell proliferation as was reflected in this study by the 
T-screen and the TSH-screen. It can therefore be concluded that their effect may rather 
be due to a drop in thyroid hormone production, which in turn diminishes the inhibitory 
effect of T4 on pituitary weight and triggers an increase in TSH secretion by the pituitary 
and a subsequent mitogenic effect on the thyroid.
NaClO4, a non-reactive electrolyte under physiological conditions, exerts its effect 
on the thyroid by inhibiting iodide transport through the sodium iodide symporter (NIS), 
resulting in a drop in the iodide-dependent thyroid hormone production (Yoshida et 
al., 1998). In vivo, this drop in thyroid hormone levels results in decreased negative 
feedback on the thyroid and a concomitant increase in TSH secretion, which in turn 
results in an increase in thyroid weight. Pituitary weight is not affected, nor is pituitary or 
thyroid cell proliferation as assessed by the T-screen and the TSH-screen, respectively.
BPF, widely used in the production of polycarbonate and epoxy resins, causes liver 
toxicity and was found to be estrogenic in the uterotrophic assay. Following the OECD 
TG 407 which includes endpoints for thyroid hormone disruption, Higashihara et al. 
found effects on thyroid hormone level in addition to changes in thyroid and pituitary 
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weight (Higashihara et al., 2007). 
While the exact mechanism of action is 
not yet elucidated, BPF did not affect 
cell proliferation in both the T-screen 
and the TSH-screen, suggesting that 
its main mechanism of action is not 
THR or TSHR-mediated. Initial data, 
as suggested by the authors of the in 
vivo study, pointed at a possible effect 
on thyroid hormone metabolism in the 
liver which can lead to compensatory 
TSH production which could ultimately 
lead to goiter and thyroid hyperplasia 
(Curran and DeGroot, 1991).
Altogether, it is concluded that 
unlike the direct in vitro-in vivo correlation that can be made with the E-screen, which 
tests for the estrogenic activity of compounds, proliferation of pituitary and thyroid cells 
is representative of only a small part of an array of mechanisms of actions involved in 
thyroid hormone disruption.
Interestingly, however, additional results of the present study indicated a possible 
correlation between the effects of thyroidactive compounds on cell proliferation in the 
T-screen and relative heart weight in vivo (Fig. 6). This correlation between the T-screen 
and cardiac hypertrophy may align well with studies on both GH3 cells and the heart. 
The adult rodent heart expresses 70% THRα1 and 30% THRβ1. It was found that THRβ 
knockout (KO) mice did not exhibit a T3-mediated increase in left ventricular heart mass 
whereas THRα KO mice did (Swanson et al., 2003; Weiss et al., 2002). This indicates 
that THRβ expression is a requirement in the well-established thyroid hormoneinduced 
cardiac hypertrophy.
There are more factors affecting cardiac hypertrophy such as the renin-angiotensin 
system. However, this system is itself regulated by thyroid hormones (Diniz et al., 2009). 
Makino et al. (2009) reported that cardiac capillary networks are reduced in THRβ 
KO mice but not in THRα KO mice. Taken together, these studies indicate that THRβ-
regulated cardiac hypertrophy acts together with THRβ-mediated angiogenesis to result 
in an overall effect on heart weight that is dominated by thyroid hormone agonism of 
THRβ. In GH3 cells, these effects are likely to be mediated by THRβ2 – the predominant 
isoform in pituitary cells (Lazar, 1990; Ball et al., 1997; Hahn et al., 1999). Regardless 
of the mechanism of action, the thyroid hormone-dependent cell proliferation that is the 
Fig. 6: Correlation between EC50 for in vitro 
thyroid hormone-dependent GH3 pituitary cell 
proliferation (T-Screen) and BMDL10 for in vivo 
change in relative heart weight as induced by the 
compounds T3, T4, triac and tetrac.
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hallmark of the T-screen correlates more closely with in vivo heart weight than with in 
vivo pituitary weight. This correlation between in vivo BMDL10 and in vitro EC50, could 
be expanded to compare absolute effect levels by taking toxicokinetics into account 
whereby the in vivo blood levels are calculated from the in vivo exposure levels, as has 
been done recently for estrogenic effects (Punt et al., 2013).
5 Conclusion
In vitro pituitary and thyroid cell proliferation assays are not viable substitutes for 
assessing pituitary and thyroid organ weight change, respectively. This calls into 
question the use of thyroid hormone-dependent cell proliferation assays and related 
TR-mediated reporter gene assays as alternative in vitro tests for the in vivo effect of 
chemicals on the HPT axis. When these THR-activation tests turn out negative, this 
study indicates that there is a considerable chance of a false negative result with the 
compound still affecting thyroid or pituitary weight in vivo. Nonetheless, the present 
study has found that the T-screen has potential applications in assessing the effects 
of compounds on thyroid hormone-mediated cardiac hypertrophy. In the context of the 
3Rs (refinement, reduction, or replacement of animal studies), it is concluded that it 
is not currently feasible to have simple standalone in vitro replacements for in vivo 
tests for the disruption of the thyroid system. The results of the present study indicate 
that a complex interplay between factors within the HPT axis may underlie the effects 
of thyroid-active compounds on thyroid and pituitary organ weight endpoints in vivo. 
Therefore, it is concluded that the development of future alternative tests, aiming at 
refinement, reduction, or replacement of animal studies should include a broad battery 
of in vitro tests that cover the various modes of action of thyroid-active compounds as 
an initial screen and/or use more complex model systems that more closely reflect an 
intact HPT axis such as the nematode Caenorhabditis elegans or the vertebrate Danio 
rerio. Tests with both organisms can be performed in such a way that they are still 
considered alternatives to animal testing in higher vertebrates such as mouse and rat 
(Van der Ven, 2009). 
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Summary
A simple and rapid luminometric assay for the detection of chemical inhibitors of 
human thyroid peroxidase (hTPO) activity was developed and validated with 10 model 
compounds. hTPO was derived from the human thyroid follicular cell line Nthy-ori 3-1 
and its activity was quantified by measuring the oxidation of luminol in the presence 
of hydrogen peroxide (H2O2), which results in the emission of light at 428 nm. In this 
assay, hTPO activity was shown to be inhibited by 5 known TPO inhibitors and not 
inhibited by 5 non-inhibitors. Similar results were obtained with porcine TPO (pTPO). The 
inhibition of hTPO by the model compounds was also tested with guaiacol and Ampliflu 
Red as alternative indicator substrates. While all substrates allowed the detection 
of pTPO activity and its inhibition, only the Ampliflu Red and luminol-based methods 
were sensitive enough to allow the quantification of hTPO activity from Nthy-ori 3-1 cell 
lysates. Moreover, luminol gave results with a narrower 95% confidence interval and 
therefore more reliable data. Whole extracts of fast-growing Nthy-ori 3-1 cells circumvent 
the need for animal-derived thyroid organs, thereby reducing costs, eliminating potential 
contamination and providing the possibility to study human instead of porcine TPO. 
Overall, the application of luminol and Nthy-ori 3-1 cell lysate for the detection of the 
disruption of hTPO activity was found to represent a valuable in vitro alternative and a 
possible candidate for inclusion within a high throughput integrated testing strategy for 
the detection of compounds that potentially interfere with normal thyroid function in 
vivo.
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1 Introduction
Thyroid hormones are essential for normal development and the regulation of basal 
metabolism. A deficiency in these hormones due to a lack of iodine during the first two 
trimesters of pregnancy is prevalent in landlocked areas and leads to cretinism (Cao et 
al., 1994). The tell-tale signs of cretinism include short stature and mental retardation. 
Later on in life, thyroid hormone deficiency or excess lead to goitre, which is a swelling 
of the neck due to the enlargement of the thyroid gland. In the case of deficiency, the 
symptoms include weight gain, constipation and lethargy while in the case of excess, 
the symptoms include adrenergic stimulation as well as hypermetabolism (Dogra et al., 
2006). The turn of the 21st century witnessed a worldwide drop in iodine deficiency due 
to decades of table salt fortification with iodine and a rise in concern over the ability 
of manmade chemicals to disrupt the thyroid hormone system (Delange et al., 2001; 
Jomaa, 2014). Addressing endocrine disruption, including the disruption of the thyroid 
hormone system, has been mandatory in the US since 1996 and the EU since 2006 
(USEPA, 1996a; b; European Commission, 2006). Testing for thyroid hormone disrupters 
has been challenging due to the long duration, costs and unethical nature of the animal 
experiments involved. This has prompted the Organisation for Economic Co-operation 
and Development (OECD) to search for high-throughput in vitro alternatives (Jacobs et 
al., 2013; OECD, 2014).
The in vivo tests to be replaced include the OECD test guideline number 407 (TG 
407) for a repeated dose 28-day oral toxicity study in rodents that defines serum thyroid 
hormone levels, thyroid histopathology, as well as pituitary and thyroid organ weights 
as endpoints (OECD, 2007 p. 407). While it is currently not possible to replicate thyroid 
histopathology in vitro, in a previous study, we have searched for potential correlation 
between the effects of chemicals on pituitary and thyroid organ weights in vivo and the 
effects of the same set of chemicals on cellular proliferation in vitro using pituitary and 
thyroid model cell lines. To this end, 11 thyroid-active compounds were tested and it was 
concluded that in vitro cellular proliferation alone correlates poorly with pituitary and 
thyroid organ weight change in vivo (Jomaa et al., 2013). This is likely due to the complex 
multi-organ paradigm that the thyroid system represents (Jomaa, 2014). A remaining in 
vivo endpoint that may prove suitable for the development of in vitro alternatives is the 
serum level of thyroid hormones, which is under the control of a feedback mechanism 
that accounts for hormonogenesis, metabolism and excretion.
Maternal thyroid deficiency is associated with subtle deficits in the neuropsychological 
development of the fetus (Haddow et al., 1999). Thyroid dyshormonogenesis can be due 
to either genetic mutations or chemicals present in our food and environment. There is 
a high prevalence of thyroid peroxidase (TPO) mutations in patients with low levels of 
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thyroid hormones at birth, a condition known as congenital hypothyroidism (Avbelj et 
al., 2007). Left untreated, this disease negatively affects growth and leads to mental 
retardation (Rose and Brown, 2006). The environment, through chemical inhibitors, can 
also affect TPO function. These chemical TPO inhibitors include the anti-thyroid drugs 
propylthiouracil (PTU) and methimazole (MMI), the industrial chemicals benzophenone 
2 (BP2) and bisphenol A (BPA), and also foods rich in glucosinolates and flavonoids 
(Alexander and Zenker, 1986; Divi and Doerge, 1996; Schmutzler et al., 2007). Eating 
large quantities of cabbage, a source of glucosinolates, can lead to hypothyroidism and in 
extreme cases even coma (Chu and Seltzer, 2010; Dolan et al., 2010). Moreover, infants 
fed soy formula, which are rich in flavonoids, can develop soybean goiter (Shepard et al., 
1960).
TPO is a heme-dependent enzyme that, in the presence of H2O2, catalyses 
the iodination and coupling of tyrosyl residues on thyroglobulin (TG), which are 
important steps in the biosynthesis of the thyroid hormones triiodothyronine (T3) and 
tetraiodothyronine (T4).
Even though the reduction in thyroid hormone levels due to the inhibition by 
chemicals of human TPO (hTPO) activity is a cause of concern, there is still no effective 
assay suited for hTPO-based high throughput screening (HTS). In a new scoping document 
on in vitro and ex vivo assays for the identification of modulators of thyroid hormone 
signaling, the OECD concluded that it was necessary to develop a screening assay for 
the inhibition of TPO that does not use animal tissue and is suited for HTS (Jacobs et 
al., 2013; OECD, 2014). Moreover, the OECD mentioned a study by Takamaya et al. that 
found rat TPO to be in some cases more than 455 times more sensitive to xenobiotic 
inhibitors than monkey TPO, emphasizing the potential for substantial interspecies 
differences (Takayama et al., 1986). The aim of the present study is to address these 
issues by developing an assay that a) uses hTPO instead of TPO from animal tissue, and 
b) is suited for HTS.
2 Materials and methods
Chemicals
Methimazole (MMI), propylthiouracil (PTU), quercetin (QE), naringenin (NAR), resorcinol 
(RES), triiodothyronine (T3), tetraiodothyronine (T4), ouabain (OUB), benzyl butyl 
phthalate (BBP), and amiodarone hydrochloride (AMI) were of high purity and were 
obtained from Sigma-Aldrich Chemie (Zwijndrecht, The Netherlands). Unless otherwise 
specified, all reagents were also obtained from Sigma-Aldrich Chemie.
simple and rapid in Vitro assay for detectinG human thyroid peroxidase disruption   73
Ch
ap
te
r 
3
Cell culture
Nthy-ori 3-1, a normal thyroid follicular epithelial cell line, was obtained from the 
European Collection of Cell Cultures (EACC, Wiltshire, UK) and grown as a monolayer in 
RPMI-1640 medium (Gibco, Paisley, Scotland) supplemented with 10% Fetal Calf Serum 
(FCS). The cells were cultured at 37°C in a humid atmosphere containing 5% (v/v) CO2 
and passaged enzymatically twice a week.
FRTL-5, a rat thyroid cell line (obtained from CLS, Germany), was cultured as 
a monolayer in tissue-culture flasks (obtained from Corning, Badhoevedorp, The 
Netherlands) at 37°C in a humid atmosphere containing 5% (v/v) CO2 and passaged 
once a week with an interim refresh of the medium, which consisted of Coon’s Modified 
F-12 medium (Biochrom, Berlin, Germany), supplemented with 5% FCS, and a mixture 
of six hormones/growth factors (this medium was referred to as 6H5, reflecting the 
presence of 6 hormones/growth factors and 5% FCS). The six hormones/growth 
factors included bovine thyroid stimulating hormone (1 mIU/ml), insulin (10 µg/ml), 
hydrocortisone (10 nM), apo-transferrin (5 µg/ml), glycyl-L-histidyl-L-lysine acetate (10 
ng/ml), and somatostatin (10 ng/ml). All these hormones/growth facors were obtained 
from Sigma-Aldrich Chemie (Zwijndrecht, The Netherlands). This 6H5 cell culture 
medium was supplemented with 1 mM non-essential amino acids, 2 mM L-glutamine, 
100 U/ml penicillin and 100 µg/ml streptomycin (Difco, Amsterdam, The Netherlands). 
Enzymatic passaging was performed using a cell detachment and disaggregation 
solution containing 20 Units/ml collagenase, 0.075% trypsin, and 2% chicken serum 
(CTC) in PBS. Collagenase and chicken serum were obtained from Sigma-Aldrich Chemie 
(Zwijndrecht, The Netherlands) while trypsin was obtained from Difco (Amsterdam, The 
Netherlands). The FRTL-5 cell line was used as a reference cell line that is positive for 
TPO (Suzuki et al., 1998).
The human hepatocellular carcinoma (HepG2) cell line was used as a reference 
cell line that is negative for TPO activity and cultured in DMEM/F12 medium containing 
10% FCS, passaged twice a week and kept at 37°C in a humid atmosphere containing 
5% (v/v) CO2.
TPO preparation
TPO from Nthy-ori 3-1 cells was prepared as a whole cell extract. Briefly, cells were 
washed with phosphate buffered saline (PBS), scraped, resuspended in a small volume 
of PBS and spun down for 5 minutes at 150 g. The supernatant was discarded and 
the cell pellet lysed by resuspension in 0.1 % sodium deoxycholate (DC, in PBS) and 
incubation on ice for 20 minutes. The lysed cells were centrifuged for 5 minutes at 
11,350 g to separate the soluble protein fraction from unlysed cells and debris. Protein 
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concentration of the supernatant was then measured using the Pierce BCA protein assay 
(Pierce, Etten-Leur, The Netherlands) following the manufacturer’s protocol. Cell lysates 
from one 75 cm2 cell culture flask that is ≥ 80% confluent were resuspended in 2 ml of 
0.1% DC and had a protein content of 0.1 – 0.2 mg/ml. With 100 µl used per 96-well 
plate quadruplicate, one 75 cm2 cell culture flask was therefore sufficient for testing ~ 
20 different concentrations of a test compound or controls. For long-term storage, cell 
lysates were kept at -80°C. Relative TPO gene expression in the Nthy-ori 3-1 cell line 
has been previously quantified by others (Tuncel et al., 2007). In our experiments, TPO 
activity in cell extracts, which is proportional to relative fluorescence (for Ampliflu Red) or 
relative luminescence (for luminol) obtained from cell lysates containing 0.1 – 0.2 mg/
ml total protein, was consistently above the limit of quantitation (LOQ) assessed as the 
mean of the blank + 10 times the standard deviation.
TPO from porcine thyroid glands was prepared essentially as described previously 
(Hosoya et al., 1985), with some modifications. Briefly, porcine thyroid tissue was 
obtained at the slaughterhouse (Visser, Lunteren, The Netherlands) and homogenized 
in sterile buffer (0.25 M sucrose; 20 mM Tris/HCl, pH 7.4; 100 mM KCl; 40 mM NaCl; 
10 mM MgCl2) with 10 strokes at 24,000 rpm using an Ultra-Turrax. The sample was 
homogenized further by 10 strokes in a Potter-Elvehjem tissue grinder (VWR, Amsterdam, 
The Netherlands). The ground tissue was centrifuged for 10 minutes at 375 g. The 
supernatant was then diluted to 50 mg/ml of tissue in sterile buffer.
Guaiacol and Ampliflu Red assays for TPO activity
Reactions were conducted in 96-well plates with a volume of 200 µl per well containing 
a thyroid tissue protein content of 0.6 - 1 mg/ml or a cell lysate protein content of 0.1 
– 0.2 mg/ml, 0.1 M potassium phosphate (pH 7.4), and the desired concentration of 
the test compound added from a 100 times concentrated stock solution in DMSO (1% 
DMSO final concentration). 1% DMSO does not interfere with either the guaiacol or the 
Ampliflu Red assays for peroxidase activity (Vogt et al., 2002; Schmutzler et al., 2007; 
Dabir et al., 2013). The mixture was incubated for 30 minutes with gentle shaking at 
37°C after which the reaction was initiated by addition of 20 µl of either 1 M guaiacol or 
1 mM Ampliflu Red and 5 µl of 80 mM H2O2. Guaiacol absorbance was measured at 470 
nm (ε = 2.66 x 104 M-1 cm-1 (Chance and Maehly, 1955)) and Ampliflu Red fluorescence 
was measured at 544/590 nm excitation/emission wavelengths, with readings every 
30 seconds for 10 minutes on a SpectraMax M2 microplate reader (Molecular Devices, 
Menlo Park, CA, USA). The reaction rate was calculated as the slope of a linear fit of 
the 21 absorbance values using the SoftMax Pro software provided with the microplate 
reader.
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Luminol assay for TPO activity
Reactions were conducted in 96-well plates with a volume of 200 µl per well containing 
a thyroid tissue protein content of 0.6 - 1 mg/ml or a cell lysate protein content of 0.1 
– 0.2 mg/ml, 1M glycine-NaOH (pH 9.0), 1 mM EDTA, and the desired concentration of 
the test compound added from a 100 times concentrated stock solution in DMSO (1% 
DMSO final concentration). 1% DMSO does not affect luminol luminescence (Shertzer et 
al., 2004). The mixture was incubated for 30 minutes with gentle shaking at 37°C after 
which the reaction was initiated by the addition of 20 µl of luminol mix containing 1M 
glycine-NaOH (pH 9.0), 1 mM EDTA and 400 µM luminol. Following a 4 second delay, 5 
µl of 80 mM H2O2 was automatically added. Luminescence was measured as relative 
luminescence units (RLUs) integrated over 10 seconds using a Luminoskan Ascent 
luminometer from Labsystems (Helsinki, Finland).
Data analysis
In the guaiacol, Ampliflu Red and luminol assays for TPO activity, data points are 
representative of three independent experiments (N = 3) and four replicate wells per data 
point in each experiment. Raw data from quadruplicate wells were averaged, converted 
to percent of solvent control and represented graphically as the means of independent 
experiments with bars representing the standard error of that mean (SEM). Nonlinear 
curve-fitting described in the results was done using the Hill equation with the help of 
GraphPad Prism software version 5.04 (GraphPad Software, San Diego, CA, USA). In 
vitro, relative IC50 values were calculated from the fitted models as the concentration 
of the tested compound that gave 50% of the maximal response. A response was 
considered positive when the squared Pearson’s coefficient of correlation (r2), as an 
indication of goodness-of-fit of a logistic dose-response model, had a value of 0.8 or 
higher. The dynamic range, Z′ factor (Zhang et al., 1999) and average assay coefficient 
of variation (CV) were calculated in order to describe the performance of the luminol 
assay for TPO activity. The Z′ factor is defined in terms of the standard deviations (SD) 
and the means of the positive and negative (DMSO) controls with the following formula:
3 Results
3.1 Compound selection
Five model compounds known to inhibit TPO in vitro were selected and these are MMI, 
PTU, QE, NAR and RES. Five thyroid-active compounds that interfere with the thyroid 
hormone system through a non-TPO mode of action were also selected and these are T3, 
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Compound Abbr. CAS No. Description Chemical 
structure
In vitro TPO 
inhibition 
literature 
(Guaiacol 
assay)
In vivo thyroid 
disruption 
literature
Methimazole MMI 60-56-0 Antithyroid 
drug
 (Taurog et 
al., 1996)
(Hood et al., 
1999)
Propylthiouracil PTU 51-52-5 Antithyroid 
drug
 (Hosoya, 
1963)
(OECD, 
2006)
Quercetin QE 117-39-5 Plant 
copigment
 (Divi and 
Doerge, 
1996)
(Giuliani et 
al., 2014)
Naringenin NAR 480-41-1 Plant 
copigment
 (Divi and 
Doerge, 
1996)
(Panda and 
Kar, 2014)
Resorcinol RES 108-46-3 Antiseptic used 
in cosmetics
 (Divi and 
Doerge, 
1994)
(Berthezéne 
et al., 1979)
Triiodothyronine T3 6893-02-3 Endogenous 
hormone
 - (Soukup et 
al., 2001)
Thyroxine T4 51-48-9 Endogenous 
hormone
 - (OECD, 
2006)
Benzyl butyl 
phthalate
BBP 85-86-7 Plasticizer  - (Nagao et 
al., 2000)
Ouabain OUB 630-60-4 Cardiotonic 
and 
antiarrhythmic 
drug
 - (Wardlaw, 
1986)
Amiodarone 
HCl
AMI 19774-82-4 Antiarrhythmic 
drug
 - (Safran et 
al., 1986)
Tab. 1: Test compounds used in this study with a brief description of their use or nature and their 
chemical structure. A dash represents a lack of literature on the compound’s effect on TPO.
CH3
N
HN
S
CH3
ON
H
S
HN
O
O OH
OH
HO
HO
HO
O
O OH
OH
HO
OH
HO
O I
O
HO
NH2
II
HO
I
O
I
HO
I
I
O
OH
H2N
CH3
O
O
O
O
H3C
O
O
OH
HO
H3C
O
O
OH
HO
HO
OH
OH
HO
I
O
N
CH3 CH3
I
CH3
O
O
HCl
simple and rapid in Vitro assay for detectinG human thyroid peroxidase disruption   77
Ch
ap
te
r 
3
T4, BBP, OUB and AMI. Table 1 details the CAS numbers, common use or origin, chemical 
structure and a representative literature reference pertaining to existing guaiacol-based 
in vitro tests of effects of these compounds on TPO activity as well as the in vivo effects 
of these compounds on the thyroid hormone system. All test compounds and reagents 
were of high purity and were obtained from Sigma-Aldrich Chemie (Zwijndrecht, The 
Netherlands).
3.2 Luminol assay for TPO activity
Figure 1 shows that the protein content of the porcine thyroid homogenate and Nthy-
ori 3-1 lysates correlate linearly with the luminescence that is being produced in the 
luminol assay. For thyroid homogenate the squared coefficient of correlation (r2) was 
0.96 and for the Nthy-ori 3-1 lysate the r2 was 0.98. Based on results obtained with MMI 
(N = 3) as a positive control, the luminol assay for TPO activity had a dynamic range of 
25.4 ± 4.3 (mean  ±SEM), a Z’ factor of 0.74 ± 0.021 (mean ±SEM) and an average CV 
(%) of 4.94. In the luminol assay, the reaction was started with H2O2 that was added 
by the automatic dispenser in the luminometer followed by a 2 second delay before 
measurement and integration of the signal over 10 seconds. The luminol signal decays 
more quickly than ampliflu red, however, the integration procedure enables reproducible 
results (%CV = 4.94 for MMI) irrespective of the decay of the luminescence signal. The 
fact that the luminol signal can be measured within a shorter period of time allowed for 
a more rapid assay. In case of the Ampliflu Red assay, the reaction proceeded linearily 
over the measured reaction period of 10 min.
b)
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Nthy-ori 3-1 thyroid cell lysate (mg/ml)
R
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r  = 0.982
a)
1 2 3
0
20
40
60
80
100
Thyroid gland homogenate (mg/ml)
R
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r  = 0.962
Fig. 1: TPO-mediated light emission upon oxidation of luminol. a) Porcine thyroid gland homogenate 
and b) human Nthy-ori 3-1 thyroid cell lysate dependent enzymatic activity in terms of RLU emitted 
upon oxidation of luminol in the presence of H2O2.
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3.3 TPO inhibition
In figure 2 dose response curves for the 5 tested TPO inhibitors are presented based 
on three separate experiments with four replicate wells per concentration. It can be 
seen that the luminol assay detects the disruption of TPO activity by the 5 selected TPO 
inhibitors in a dose-dependent manner. Moreover, while the Ampliflu Red (Paul et al., 
2014), guaiacol and luminol (Table 1) methods are all able to detect pTPO activity that 
is present in porcine thyroid tissue samples, the guaiacol assay was negative with hTPO 
from the Nthy-ori 3-1 human thyroid cell line (data not shown), and only the Ampliflu 
Red and luminol methods were able to detect hTPO activity in lysates from Nthy-ori 
3-1 human thyroid cells cultured in vitro (Table 1). The selected non-inhibitors of TPO, 
namely, T3, T4, BBP, OUB, and AMI were also all correctly identified as non-inhibitors by 
both the Ampliflu Red method and the luminol method (figure 3).
A comparison of the concentrations resulting in 50% inhibition (IC50s) presented in 
table 2 reveals that the luminol method detects the effects of the tested compounds with 
a narrower 95% confidence interval (CI). The overall potency ranking for pTPO inhibition 
was MMI > RES > QE > PTU > NAR. The potency ranking for hTPO inhibition was MMI > 
QE > RES > PTU > NAR.
Compound IC50 µM (95% CI or 
reference) guaiacol assay
IC50 µM (95% CI)
Ampliflu Red assay
IC50 µM (95% CI)
luminol assay
pTPO r2 hTPO r2 pTPO r2 hTPO r2
MMI  4.0 
(Taurog, 
1970)
- 2.7 (0.4 
- 19.9)
0.95 5.7 (3.0 
- 10.7)
0.95 4.0 (1.6 - 
10.1)
0.91
RES  6.5 
(Taurog, 
1970)
- 18.7 
(6.8 – 
51.9)
0.84 5.8 (4.0 
- 8.3)
0.99 5.0 (3.6 
to 6.9)
0.98
QE 8.4 (1.2 
– 60.1)
0.78 7.7 (3.9 - 
15.4)
0.96 10.0 
(6.7 - 
14.9)
0.99 4.1 (3.2 
to 5.3)
0.99
PTU 10.7 (5.1 
– 22.2)
0.92 35.2 
(10.4 - 
119.1)
0.86 41.6 
(24.9 - 
69.5)
0.94 16.4 
(10.0 - 
27.0)
0.91
NAR 10 - 150 
(Divi and 
Doerge, 
1996)
- 59.0 
(30.4 - 
114.6)
0.94 67.5 
(29.24 - 
155.6)
0.95 55.5 
(43.2 to 
71.3)
0.98
Tab. 2: IC50 values of the compounds as TPO inhibitors in the guaiacol assay, Ampliflu Red assay 
and luminol assay. CI stands for confidence interval (n=3). r2 is indicated for the goodness-of-fit of 
a logistic dose-response model.
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33.4 Confounders of peroxidase activity measurements in samples from in vivo or 
in vitro origin
In order to find out whether contamination of thyroid tissue with blood or muscle tissue 
could be a confounder when analysing thyroid peroxidase activity in samples from 
animal origin, hemoglobin-rich muscle tissue homogenates were tested for peroxidase 
activity and compared to results obtained for thyroid homogenates. Figure 4a shows that 
hemoglobin-rich muscle tissue has peroxidase activity as well.
Confounding of measurement of TPO activity when using samples from in vitro 
cell lines could come from non-TPO based activity in cells from non-thyroid origin. The 
cell lines used in this experiment were grown under controlled conditions to ensure 
uniformity and kept at below passage 30 in order to retain as much of the characteristics 
of their organ of origin as possible. Figure 4b shows that in the luminol assay using cell 
lysates from follicular rat thyroid cells grown using 5% serum (FRTL-5), from human Nthy-
ori 3-1 cells or from human hepatocellular carcinoma (HepG2) cells, only cell lysates 
from cells of thyroidal origin have peroxidase activity.
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Fig. 2: Effect of MMI, PTU, quercetin, naringenin and resorcinol on a) hTPO activity in the Ampliflu 
Red assay, and on b) pTPO, and c) hTPO activity in the luminol assay.
Fig. 3: Effect of T3, T4, ouabain, BBP and amiodarone on a) hTPO activity in the Ampliflu Red 
assay, and on b) pTPO, and c) hTPO activity in the luminol assay.
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4 Discussion
The aim of the present study was to address the pitfalls of animal tissue-based assays 
using guaiacol as a substrate by developing an assay that a) uses human TPO (hTPO) 
instead of TPO from animal tissue, and b) uses a substrate that is suited for HTS.
The results obtained reveal that lysates of the Nthy-ori 3-1 human thyroid cell line retain 
peroxidase activity that can be detected in the Ampliflu Red assay and luminol assay 
but not in the guaiacol assay. The greater sensitivity of luminol in comparison with 
guaiacol supports previous findings where luminol was found to be 3-fold more sensitive 
than guaiacol in detecting TPO activity (Kaczur et al., 1997). While already used for the 
detection of TPO inhibition by anti-TPO antibodies and in the detection of the inhibition 
of HRP by chemical inhibitors (Kaczur et al., 1997; Navas Díaz et al., 1998), the present 
study reports the application of luminol as a highly sensitive and reliable substrate that 
can be applied to detect the effect of chemical inhibitors on TPO activity. Figure 2 shows 
that all compounds that tested positive for inhibition in the guaiacol assay also tested 
positive for inhibition in the luminol assay. These results are in accordance with the 
known in vitro effect of these compounds on TPO activity (table 1). Moreover, while the 
Ampliflu Red assay was also able to detect compounds known to inhibit TPO activity, 
the 95% CI of the IC50s of the compounds tested was wider and therefore the Ampliflu 
Red-based assay is regarded to be less reliable than the luminol-based assay (table 2).
Even though the guaiacol oxidation assay is widely used to detect peroxidase activity, 
the apparent lack of sensitivity is one of several drawbacks since guaiacol is also readily 
oxidized upon exposure to air and light, which means that necessary precautions have 
to be put in place to avoid premature color change. Moreover, the measurement time 
needed is 2 - 10 minutes, compared to 10 seconds for the luminol assay. Compound 
purity could be yet another drawback as it has been previously reported that guaiacol 
from Aldrich Chemical Co. contained contaminants that lead to low values for peroxidase 
activity (Taurog et al., 1992).
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Fig. 4: In vivo and in vitro TPO activity. a) Peroxidase activity can be detected from both thyroid 
homogenates and muscle tissue. b) In vitro peroxidase activity is present in thyroid cell lines only. 
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The successful use of TPO derived from the human follicular thyroid cell line 
Nthy-ori 3-1 avoids the use of animal tissue and eliminates interspecies differences 
when evaluating risks for the human population. Such interspecies differences exist 
and have been previously reported (Takayama et al., 1986; Paul et al., 2013) and are 
also illustrated in the present study by the difference in potency ranking observed 
between pTPO and hTPO in the luminol assay. Moreover, animal sources of TPO are 
often contaminated with blood hemoglobin that can also act as a peroxidase, a fact 
that can be attributed to the catalytic heme moiety present in both hemoglobin and TPO 
(Harauchi and Yoshizaki, 1982). In this study, it was demonstrated that hTPO from Nthy-
ori 3-1 cells can be easily used in combination with a luminol assay method to detect 
thyroid-active compounds whose mechanism of action involves TPO inhibition. While 
other studies have reported increased in vitro TPO protein levels and activity in cells 
transfected with a TPO expression construct (Marinovich et al., 1995), the present study 
shows that the luminol assay is sensitive enough to detect the activity of endogenously 
expressed TPO from cells of the commercially-available human Nthy-ori 3-1 cell line. 
This overcomes the inability to measure TPO activity in samples derived from this cell 
line when using guaiacol as a substrate. It can therefore be concluded that there is no 
apparent need for using porcine TPO instead of human TPO. The relative high speed, 
stability and sensitivity of the luminol-based assay relative to the guaiacol-based assay 
fulfilled our objective to have an assay suited for HTS.
The results obtained with hTPO also mirror the effect of the TPO inhibitors tested 
in humans (Divi and Doerge, 1994; Nakamura et al., 2007). hTPO inhibition profiles 
derived from both the luminol and Ampliflu Red assay showed that MMI followed by 
quercetin and resorcinol were the most potent of the inhibitors tested. PTU was less 
potent than MMI, a finding that is supported in clinical studies (Nakamura et al., 2007), 
whereas naringenin was the least potent TPO inhibitor tested, showing no reported 
effects in humans. The association between the topical application of resorcinol 
in ointments and thyroid dysfunction in humans has a long history but even though 
rodent studies support causality, the higher sensitivity of rodents to thyroid disruption 
means that causality in humans is still considered inconclusive (Lynch et al., 2002). The 
resorcinol derivative quercetin, which is present in plant components of the human diet, 
is thought to be offsetting the benefit of iodized salt in parts of India that are affected 
by endemic goitre and while further human studies are necessary to confirm causality, 
recent rodent studies support the notion that quercetin inhibits thyroid function (Divi 
and Doerge, 1994; Giuliani et al., 2014). Overall, these antioxidants inhibit TPO in vitro 
and are associated with thyroid dysfunction in vivo and this is accurately reflected in 
the luminol assay. In conclusion, the combination of luminol as a chemiluminescent 
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indicator of TPO activity and the Nthy-ori 3-1 cell line as a source of hTPO results in an 
alternative assay for the detection of TPO inhibitors that holds promise for inclusion 
within a high throughput integrated testing strategy.
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Summary
Nuclear receptor coregulators play a central role in mediating the effect of endocrine-
active compounds. Here we report the application of a microarray assay for real-
time coregulator-nuclear receptor Interaction (MARCoNI) for the characterisation 
of coregulator recruitment by thyroid hormone receptor alpha (TRα) and beta (TRβ) 
induced upon binding of the thyroid hormones T3 and T4 acting as receptor agonists, 
and of the thyroid hormone antagonists amiodarone and compound 1-850. The 
modulation, by the test compounds, of TRα and TRβ binding to 154 nuclear receptor 
interaction motifs of 66 coregulators was measured relative to the solvent control, and 
analysed by hierarchical clustering. The agonists T3 and T4 clustered separately from 
the antagonists amiodarone and compound 1-850 for both receptor isoforms tested. 
The results of the current study also reveal new TR-interacting coregulators including 
candidate coactivators BL1S1 and WIPI1 as well as candidate corepressors RBL2, 
DHX30 and LCOR. The results were further supported by full dose-response curves 
for the compounds tested and underlined the potential of the MARCoNI assay as an 
alternative screening test for thyroid-active compounds.
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1 Introduction
Thyroid hormones are essential for normal physical growth and mental development 
(Rastogi and LaFranchi, 2010). They exert their action by binding to the thyroid hormone 
receptor alpha and beta subtypes (TRα and TRβ) that are situated inside the nucleus of 
most of the body’s cells (Abu et al., 1997; Shahrara et al., 1999). As nuclear receptors, TRs 
are transcription factors that can be activated by ligands – in this case thyroid hormones. 
However, unlike type I nuclear receptors such as the estrogen receptor (ER) and androgen 
receptor (AR), type II nuclear receptors, which include TRs and the retinoic acid receptor 
(RAR), form heterodimers with the retinoid x receptor (RXR). In the unliganded state, 
type II receptor-RXR heterodimers bind to DNA within a corepressor complex of proteins 
that condenses chromatin and actively suppresses gene transcription. Whereas type I 
nuclear receptors bind their ligand in the cytoplasm and are translocated to the nucleus to 
activate gene transcription, type II nuclear receptors bind their ligand within the nucleus 
which causes a structural change that dissociates corepressors and recruits coactivator 
proteins that decondense chromatin and mediate gene transcription (Gronemeyer et 
al., 2004; Germain et al., 2006). Coactivators and corepressor proteins, are therefore 
integral and essential coregulators of TR-mediated gene transcription.
The 1990s witnessed the public scrutiny of marketed products after the discovery 
of endocrine-disrupting chemicals in household items (Feldman and Krishnan, 1995). 
This has led to the establishment of regulations that require the testing of chemicals for 
endocrine activity. With increased testing came increased concern for the high cost, long 
duration, and large number of animals needed for safety testing and this increased the 
need for alternative in vitro testing methods (van der Jagt et al., 2004). In the case of 
estrogenic activity, alternative in vitro testing strategies have proven promising. In vitro 
proliferation of uterine cells after exposure to estrogenic compounds was found to correctly 
predict changes in uterine weight after exposure to estrogenic compounds in vivo (Wang 
et al., 2012). On the other hand, we have shown in a previous study that the cellular 
proliferation of pituitary and thyroid cells after exposure to thyroid-active compounds in 
vitro correlates poorly to the weight change of their respective organ in an in vivo test 
(Jomaa et al., 2013). This lack of correlation is likely due to the complex multi-organ 
interaction that controls the thyroid hormone system. Therefore, an elaborate in vitro test 
battery representing the various in vivo endpoints would be required to screen for thyroid-
active compounds (Jomaa, 2014). One type of assay that would contribute to such an 
integrated testing strategy is an in vitro assay for detecting the effects of compounds on 
TR-mediated gene transcription. To this end, a TR-based reporter gene assay has been 
developed by stably transfecting the rat pituitary tumour cell line GH3, that consitutively 
expresses both TRα and TRβ, with a thyroid hormone response element-driven luciferase 
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gene (Freitas et al., 2011). Among the disadvantages of such reporter gene assays are 
the use of luciferase as the reporter gene as it may generate false positives (Sotoca et 
al., 2010), the lack of distinction between receptor isoforms and the interference that 
is exhibited in some cases due to other receptors (Bhattacharjee and Khurana, 2014). 
Recently a novel approach to detect nuclear receptor binding was introduced, being the so-
called microarray assay for real-time coregulator-nuclear receptor interaction (MARCoNI). 
The MARCoNI holds promise as a candidate for inclusion within a high-throughput testing 
strategy (HTS) for endocrine-active compounds. However, studies on nuclear receptor 
ligand interactions using MARCoNI have so far focused mainly on the estrogen receptor 
(ER), the glucocorticoid receptor (GR) and the Pregnane X receptor (Wang et al., 2013; 
Desmet et al., 2014; Evers et al., 2014; Murayama et al., 2014).
As the name suggests, the principle of MARCoNI is based on measuring the 
interaction of a nuclear receptor with its coregulators and studying how a ligand, either 
an agonist or antagonist, affects this interaction. To do this, an array of coregulator 
peptides, each representing a specific coregulator-nuclear receptor interaction motif is 
first printed with a piezoelectric print head on a chip composed of 60 μm-wide aluminum 
oxide capillaries (van Beuningen et al., 2001). Then, capillary flow-through exposure to 
a nuclear receptor with or without ligands is performed and the interaction between the 
LBD of the nuclear receptor of interest and each of the coregulator peptides is quantitated 
based on fluorescence-based immunochemistry.
Previous studies with the ER receptors revealed that MARCoNI is able to measure 
the potency of different agonists and to distinguish known transcriptional agonists from 
antagonists based on coregulator modulation profiles even without the addition of an 
endogenous ligand (Wang et al., 2013).
The aim of the present study is to investigate whether MARCoNI is able to correctly 
identify TR-agonists and TR-antagonists and to investigate possible differences in ligand-
induced coregulator activation by TRα and TRβ. The results obtained will provide an 
insight into the usefulness of this assay within an integrated testing strategy for thyroid-
active compounds.
2 Materials and methods
Compounds
Dimethyl sulfoxide (DMSO), T3, T4 and amiodarone were obtained from Sigma-Aldrich 
Chemie B.V. (Zwijndrecht, The Netherlands). TR antagonist compound 1-850 (CAS 
251310-57-3) was obtained from Merck Millipore (Amsterdam, The Netherlands). 
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MARCoNI
Human GST-tagged TRα LBD (Invitrogen, Breda, The Netherlands) and human GST-tagged 
TRβ LBD (AB Vector (San Diego, CA, USA) were diluted in reaction buffer (20 mM Tris, 
pH 7.5, 500 mM NaCl, 0.2% BSA, 0.05% Tween-20) containing 50 mM D-dithiothreitol 
(DTT) to a final assay concentration of 5 nM. 25 µl of this thyroid receptor LBD solution 
with 25 nM Alexa 488-conjugated GST antibody (Invitrogen, Breda, The Netherlands), 
either with or without ligand (agonist or antagonist) in 2% DMSO, were added to a 
MARCoNI PamChip® containing 154 NR coregulator peptides (Pamgene International 
BV ’s-Hertogenbosch, The Netherlands). All steps were performed on ice. Measurements 
were performed automatically using a PamStation®-12 (PamGene International B.V.) at 
a constant temperature of 20°C according to the provided protocol. Briefly, 80 cycles 
of capillary flow-through and charge-coupled device (CCD) camera-based fluorescence 
measurement were performed at a rate of 2 cycles / min. To minimize non-specific 
binding of the antibody, each chip was first incubated for 20 cycles at a rate of 2 cycles 
/ min in blocking buffer which consisted of TBS with 1% BSA and 0.01% Tween-20. 
Final exposure concentrations were equal to 0.1 µM, 1 µM, 10 µM, 50 µM and 100 µM 
for amiodarone and compound 1-850; 0.001 µM, 0.01 µM, 0.1 µM, and 10 µM for T3; 
0.001 µM, 0.01 µM, 0.1 µM, 1 µM and 10 µM for T4.
Data analysis
Uncompressed tagged image file format (TIFF) images obtained from the PamStation®-12 
were analyzed using BioNavigator software (PamGene International B.V.). Automated 
array grid detection and median signal-minus-background calculation was performed 
with a cut-off value of 5 arbitrary units (AU) for each fluorescent peptide spot and the 
resulting value was used for deriving the modulation index (MI). The MI was calculated as 
the log10 change in binding (relative fluorescence) of the receptor LBD to the coregulator 
in the presence of a ligand over the binding of the receptor LBD to the coregulator in 
solvent only. For each compound-receptor pair, a Student’s t-test was used to determine 
whether the fluorescence measured at the 2 highest concentrations (ligand-saturated 
concentrations) is significantly different from the fluorescence measured from 4 
separate solvent controls.
3 Results
The modulation of TRα-LBD and TRβ-LBD binding to the 154 motifs of 66 coregulators with 
respect to the solvent control (DMSO) was tested for T3, T4, amiodarone and compound 
1-850. An overview based on literature of all 66 coregulators present on the peptide array 
and their function or known interaction with hormone receptors is presented in Tab. 1. 
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Dose response curves for the modulation of the coregulator interactions induced by the 
different model compounds for both TRα and TRβ are presented as supplementary Fig. 
1 - 8. This evaluation involved fitting of a logistic dose-response model and a goodness 
of fit of 0.9 or higher was used as a cut-off for coregulators to be considered to be 
modulated in a dose-dependent manner by the test compounds.
The antagonist compound 1-850 dose-dependently modulates 11 out of 154 
TRα-LBD-coregulator interactions and 10 out of 154 TRβ-LBD-coregulator interactions, 
4 of which are modulated for both TRs, namely the interactions with ANDR, EP300, 
NCOR1 and NELFB (Supplementary Fig. 1 and 5). Amiodarone on the other hand dose-
dependently modulates 21 out of 154 TRα-LBD-coregulator interactions and 22 of the 
154 TRβ-LBD-coregulator interactions with 5 coregulator interactions being modulated 
for both TRs, namely ANDR, MAPE and NRIP (motif # 173_195 and 173_195_C177S) 
(Supplementary Fig. 2 and 6). T3 dose-dependently modulates 49 of the 154 TRα-LBD-
coregulator interactions and 28 out of 154 TRβ-LBD-coregulator interactions, with 11 
coregulator interactions being modulated for both TRs (Supplementary Fig. 3 and 7), 
while T4 dose-dependently modulates 43 of the 154 TRα-LBD-coregulator interactions 
and 81 of the 154 TRβ-LBD-coregulator interactions, 32 of which are modulated by both 
TRs (Supplementary Fig. 4 and 8).
The dose response results revealed that for certain TR-coregulator interations, 
dose response curves did not fit the goodness of fit criteria that were set since T3 and T4 
produced a saturated signal within the greater part of the concentration range tested. 
Therefore, modulation index (MI) values were calculated as complementary analysis 
to the dose response analysis. MI values were calculated as the ratio of the binding 
(fluorescence) of the receptor LBD to the coregulator in the presence of the test compound 
to the binding observed for the solvent control. DMSO solvent controls and the highest 
two (ligand-saturated) concentrations of the test compounds were used to calculate the 
MI patterns displaying the effect on all coregulators tested in alphanumerical order as 
shown in Fig. 1-3. From the MI results presented it can be derived that the MI patterns 
for T3 and T4 partly overlap (Fig. 1). For TRα, T4 recruits most coregulators to a lower 
extent than T3 but both thyroid hormones inhibit the binding of this receptor isoform to 
corepressors NCOR1 and NCOR2 to the same extent (Fig. 1a).The opposite is true for 
TRβ since the only marked difference between T3- and T4-mediated effects on TRβ-
LBD-coregulator interactions is in their inhibition of NCOR1 and NCOR2 binding to the 
receptor, with reduced binding in the case of T3 but a strikingly lower level of modulation 
by T4 (Fig. 1b). Fig. 2 presents a comparison of the binding of T3 (Fig. 2a) and T4 (Fig. 
2b) for both receptors. This comparison reveals that the TR-LBD-coregulator interactions 
affected follow patterns that are comparable for both receptor isoforms tested. T4 is 
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more active in recruiting coregulators to TRβ than to TRα and inhibits the binding of 
corepressors NCOR1 and NCOR2 to TRβ less than it does with TRα. The differences 
between TRα and TRβ with respect to T3-mediated coregulator recruitment are less 
pronounced (Fig. 2a).
The antagonists amiodarone and compound 1-850 modulated LBD-coregulator 
interactions in both a compound-specific and receptor-specific manner (Fig. 1a and 
Fig.1b) with a level of modulation that was much lower than for the agonists T3 and 
T4. Compound 1-850 only inhibited the interaction with the tested coregulators for 
both receptor isoforms, whereas amiodarone showed both stimulatory and inhibitory 
modulation, including stimulation for TRα and inhibition for TRβ of NCOR1 and NCOR2 
corepressor binding, pointing to a different mode of action of the two antagonists tested.
In order to find out whether agonists and antagonists could be clustered separately, 
a heat map visualising hierarchical clustering of the coregulator binding profile versus 
the test compound was created for both TRα-LBD (Fig. 3a) and TRβ-LBD (Fig. 3b). 
Hierarchical clustering of the observed binding profiles showed not only that receptor 
agonists and antagonists clustered separately but also that both TR isoforms have 
different patterns of modulation.
A closer look at the coregulators that showed the most significantly increased 
recruitment by both T3 and T4 in both TR isoforms underscores the physiological relevance 
of the results obtained. CREB-binding protein (CBP), mediator of RNA polymerase II 
Fig. 1: T3, T4, amiodarone and compound 1-850 modulation of coregulator binding to TRα (upper 
panel) and TRβ (lower panel) relative to the solvent control (DMSO), expressed as MI values. 
The 154 coregulator motifs present on the pamchip are represented on the horizontal axis in 
alphanumeric order from left to right. Detailed background information on the coregulators and 
their function can be found in Tab. 1.
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transcription subunit 1 (MED1) and nuclear receptor coactivators (NCoAs) 1, 2 and 3, 
which are the principal thyroid hormone coactivators (Ito and Roeder, 2001) were among 
the coactivators whose binding to both receptor isoforms is significantly modulated by 
T3 and T4 (Fig. 3). The other coregulators whose binding to both receptor isoforms was 
significantly modulated by T3 and T4 were histone acetyltransferase HTATIP (TIP60), 
protein hairless (HAIR), ligand-dependent corepressor (LCOR), peroxisome proliferator-
activated receptor gamma coactivator 1-beta (PRGC-2), nuclear receptor-interacting 
protein 1 (NRIP1), proline-rich nuclear receptor coactivator 1 (PNRC1), nuclear receptor 
subfamily 0 group B member 1 (NR0B1), bromodomain-containing protein 8 (BRD8), 
mediator of RNA polymerase II transcription subunit 1 (MED1), proline-, glutamic acid- 
and leucine-rich protein 1 (PELP1) and protein inhibitor of activated STAT (PIAS2). Binding 
of NRIP1 and LCOR was found to be modulated by T3 and T4 in a dose-dependent 
manner (Fig. 4). Some coregulators appeared to be recruited by one of the two TRs 
upon binding to either T3 or T4, for example biogenesis of lysosome-related organelles 
complex-1 subunit 1 (BL1S1) binding to TRα is significantly modulated by T4 and WD 
repeat domain phosphoinositide-interacting protein 1 (WIPI1) binding to TRβ and TRα is 
significantly modulated by T3 and T4, respectively.
Among the coregulators that showed decreased recruitment by both T3 and T4 in 
both TR isoforms were nuclear receptor corepressor 1 (NCOR1) and its paralog nuclear 
receptor corepressor 2 (NCOR2). These are known to be the canonical nuclear receptor 
corepressors associated with the transcriptional silencing of thyroid hormone receptors 
in the absence of a ligand. NCOR2 is also known by the alias silencing mediator for 
retinoid and thyroid hormone receptors (SMRT) (Moore and Guy, 2005). NCOR1 and 
NCOR2 act as scaffold proteins that recruit histone deacetylase complexes (HDACs) (Ito 
Fig. 2: Comparison of TRα and TRβ coregulator MI profiles for a) T3 and b) T4.
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Fig. 3: A heat map for TRα-LBD a) and TRβ-LBD b) MI values and hierarchic clustering of the data 
showing that agonists and antagonists cluster separately. The significance level of the observed MI 
values based on Student’s t-test are indicated (*P≤0.05; **P≤0.01; ***P≤0.001).
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and Roeder, 2001). It can be seen from Fig. 3 that the endogenous ligands T3 and T4 
significantly reduce the binding of TRα and TRβ to the majority of NCOR1 and NCOR2 
binding motifs tested an observation that is in line with activation of TR mediated gene 
expression by T3 and T4. As shown in Fig. 5 this inhibition occurred in a dose-dependent 
fashion. Other coregulators for which the binding of certain motifs to TR was significantly 
inhibited by T3 and T4 included DHX30, retinoblastoma-like protein 2 (RBL2) and CCR4-
NOT transcription complex subunit 1 (CNOT1) (Fig. 3). The inhibition of binding of DHX30 
and RBL2 (the latter inhibited only in the case of TRβ) was found to occur in a dose-
dependent manner (Fig. 6).
The CNOT1 motifs tested displayed divergent results, CNOT1 motifs # 1929_1951, 
140_162 and 2083_2105 showing a significant decrease in TRβ binding upon exposure 
to T3 with the prior 2 motifs exhibiting a similar interaction upon exposure to T4 (Fig. 
3). On the other hand, motif # 1626_1648 showed a significant increase in TRα binding 
with the addition of T3 and a significant increase in TRβ binding with the addition of T3 
and T4.
4 Discussion
Due to the complex nature of the thyroid hormone system, an in vitro alternative for 
current animal tests for the detection of thyroid-active compounds must include a 
mechanism-based battery of tests (Murk et al., 2013; Jomaa, 2014). This battery can 
include both kinetics and dynamics-based tests, the latter of which could be focused on 
the transcriptional effect of thyroid hormones at the cellular level. Uncovering the role of 
specific coregulator-nuclear receptor interactions in mediating transcription has enabled 
the use of MARCoNI peptide microarray-based assays as a substitute for reporter gene 
assays. The advantages conferred by MARCoNI assays include the use of a cell free 
system which eliminates interference caused by other receptors and reporter-related 
artifacts (Sotoca et al., 2010; Bhattacharjee and Khurana, 2014). 
Peptide microarrays are an up and coming technology that has been successfully 
used in detecting protein kinase activity in drug screening, epitope mapping of food 
allergens, defining patient antibody signatures and most recently in MARCoNI assays 
detecting the modulation of nuclear receptor-coregulator binding by endocrine-active 
compounds (Shigaki et al., 2007; Quintana et al., 2008; Lin et al., 2009; Aarts et al., 
2013; Wang et al., 2013; Evers et al., 2014). Here we report the first application of a 
high-throughput peptide microarray to test the interaction of TRα and TRβ with 154 
coregulator motifs as well as the modulation of this interaction by the thyroid hormones 
T3 and T4 in addition to the two known TR antagonists amiodarone and 1-850 (Drvota 
et al., 1995; Schapira et al., 2003).
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In addition to the improved speed and scalability, microarrays generate relatively 
large data sets that can be used to perform meta-analyses and thus reveal toxicity profiles 
that would otherwise not be readily available. This became evident when test compound 
modulation indices (MIs) were compared among the different ligands and hierarchic 
Fig. 4: Concentration response curves for the T3-mediated inhibition of the binding of NRIP1 to 
a) TRα and b) TRβ and of the T4-mediated inhibition of NRIP1 for c) TRα and d) TRβ; T3-mediated 
e) and T4-mediated f) inhibition of binding of LCOR binding to TRα. The decimal number in red 
in each plot indicates the Pearson correlation coefficient for goodness of fit of a logistic dose-
response model.
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clustering of the data revealed that agonists T3 and T4 clustered separately from the 
antagonists amiodarone and compound 1-850. Results presented in this paper indicate 
that thyroid receptor antagonists amiodarone and compound 1-850 display a different 
pattern of modulation of TR-coactivator interactions. In addition both antagonists tested 
showed a trend to inhibit or significantly inhibited the binding of TRβ to the tested motifs 
of corepressors NCOR1 and NCOR2 (Fig. 3). However, in view of their TR antagonist 
properties, this supposedly transactivation-stimulating effect is apparently outweighed 
by the overall inhibitory effects on coactivator binding. 
With two thyroid hormone receptor isoforms and 66 individual coregulators 
represented by a total of 154 motifs, the resolution provided by the MARCoNI assay 
used in this paper has provided a detailed interaction signature that not only helped 
discriminate between agonists and antagonists but also revealed differences between 
individual agonists and antagonists. Importantly, this can help explain the differing 
physiological effects of some thyroid-active compounds in vivo (Stoykov et al., 2007).
The results of the current study have revealed coregulators whose interaction with 
both TRs is significantly modulated by both thyroid hormones T3 and T4. These included 
coregulators known to interact with TRs including TIP60, HAIR, PRGC-2, NRIP, PNRC1, 
Fig. 5: Concentration-response curves for the T3-mediated inhibition of the binding of N-CoR1 
and N-CoR2 to a) TRα and b) TRβ and the T4 mediated inhibition of the binding of N-CoR1 and 
N-CoR2 to c) TRα and d) TRβ. The decimal number in red in each plot indicates the Pearson 
correlation coefficient for goodness of fit of a logistic dose-response model.
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BRD8 and MED1 (see Tab. 1 for references) as well as coregulators that have not yet 
been show to interact with TRs including NROB1, PELP1 and PIAS2 and LCOR.
While NROB2 has been shown to interact with TR, little is known of the interaction 
of NROB1 with TRs (Seol et al., 1996). However, in research conducted by Ito et al. 
(1997), NROB1 was found not to repress but to activate the T3-mediated transcriptional 
activation by TRα and TRβ, but this coactivator effect was just presented and not 
discussed (Ito et al., 1997). PELP1 is involved in DNA and histone modification and 
interacts with several steroid receptors including the estrogen receptor (ER), androgen 
receptor (AR), glucocorticoid receptor (GR), progesterone receptor (PR) as well as the 
vitamin D3 and mineralocorticoid (MR) receptors (Gonugunta et al., 2014). PIAS2 is an 
inhibitor of signal transducer and activator of transcription (STAT) and a coactivator of 
AR (Lin et al., 2004). LCOR is discussed later in the text along with other corepressors 
based on its established role as a corepressor of other nuclear receptors (Tab. 1).
MI values obtained in this study have also indicated that biogenesis of lysosome-
related organelles complex-1 subunit 1 (BL1S1) binding to TRα is significantly modulated 
by T4 and WD repeat domain phosphoinositide-interacting protein 1 (WIPI1) motif # 
313_335 binding to TRβ and TRα is significantly modulated by T3. BL1S1 and WIPI1 are 
known coactivators of other nuclear receptors (Mishra et al., 2003; Proikas-Cezanne et 
al., 2004) but have not yet been reported to interact with TR.
T3 and T4 also modulated the binding of TR corepressors. T3 and T4 inhibited 
the binding of TRα and TRβ, respectively, to RBL2 in a dose dependent manner with a 
goodness of fit of 1.0 (Fig. 6 a and b). In the case of TRβ, this inhibition was found to 
also be of statistical significance (Fig. 3). RBL2, also known as p130, is a transcriptional 
repressor and a key regulator of cell cycle progression that has not yet been associated 
to TR-mediated transcriptional silencing. The decreased interaction between TRs 
and RBL2 upon exposure to thyroid hormones is likely of physiological relevance as 
decreased expression of RBL2 has been associated with anaplastic thyroid cancer (Ito 
Fig. 6: Concentration response curves for the T3 and T4-mediated inhibition of the binding of RBL2 
to a) TRα and b) TRβ and of the T4-mediated inhibition of DHX30 for c) TRβ. The decimal number in 
red in each plot indicates the Pearson correlation coefficient for goodness of fit of a logistic dose-
response model.
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et al., 2003). DHX30, also known as Ret-COR, interacts with the orphan nuclear receptor 
NR2E3 and is speculated to be a corepressor of that receptor (Takezawa et al., 2007; 
Qin et al., 2013). Here we have found DHX30 to interact with TRα and TRβ and this 
interaction shows significant inhibition by the endogenous ligands T3 and T4 in a way 
that is similar to the cognate corepressors (Fig. 3 and 5c).
Ligand-dependent corepressors are a separate class of corepressors that inhibit the 
transcriptional activation in the presence of a ligand. These includes nuclear receptor-
interacting protein 1 (NRIP1) and ligand-dependent corepressor (LCOR) (Leonardsson et 
al., 2004). While NRIP has previously been associated as a TH-dependent corepressor 
of TR (Wei and Hu, 2004), here we confirm this interaction (Fig. 3 and Fig. 4a for T3 TRα, 
4b for T3 TRβ, 4c for T4 TRα and 4d for T4 TRβ) and report for the first time that T3 and 
T4 are capable of significantly stimulating LCOR-TR binding in the MARCoNI assay (Fig. 
3) and in a dose dependent manner for TRα (Fig. 6e for T3 and 6f for T4), indicating that 
LCOR is likely to act as a TH-dependent corepressor.
 Overall, the results have shown that the MARCoNI assay can be used to discriminate 
between thyroid hormone receptor agonists and antagonists and initial results indicate 
that it holds promise for inclusion as a screen within an integrated testing strategy for the 
detection of thyroid-active compounds. Moreover, this study has shed light on new TR-
interacting coregulators, namely, candidate coactivators BL1S1 and WIPI1, candidate 
corepressors RBL2 and DHX30 as well as candidate ligand-mediated corepressor LCOR.
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Supplementary materials
Supplementary Fig. 1: Concentration response curves for compound 1-850-mediated 
modulation of coregulator-TRα binding. The decimal number in red in each plot indicates the 
Pearson correlation coefficient for goodness of fit of a logistic dose-response model.
Supplementary Fig. 2: Concentration response curves for amiodarone-mediated modulation 
of coregulator-TRα binding. The decimal number in red in each plot indicates the Pearson 
correlation coefficient for goodness of fit of a logistic dose-response model.
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Supplementary Fig. 3: Concentration response curves for T3-mediated modulation of 
coregulator-TRα binding. The decimal number in red in each plot indicates the Pearson 
correlation coefficient for goodness of fit of a logistic dose-response model.
Supplementary Fig. 4: Concentration response curves for T4-mediated modulation of 
coregulator-TRα binding. The decimal number in red in each plot indicates the Pearson 
correlation coefficient for goodness of fit of a logistic dose-response model.
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Supplementary Fig. 5: Concentration response curves for compound 1850-mediated modulation 
of coregulator-TRβ binding. The decimal number in red in each plot indicates the Pearson 
correlation coefficient for goodness of fit of a logistic dose-response model.
Supplementary Fig. 6: Concentration response curves for compound amiodarone-mediated 
modulation of coregulator-TRβ binding. The decimal number in red in each plot indicates the 
Pearson correlation coefficient for goodness of fit of a logistic dose-response model.
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Supplementary Fig. 7: Concentration response curves for compound T3-mediated modulation 
of coregulator-TRβ binding. The decimal number in red in each plot indicates the Pearson 
correlation coefficient for goodness of fit of a logistic dose-response model.
Supplementary Fig. 8: Concentration response curves for compound T4-mediated modulation 
of coregulator-TRβ binding. The decimal number in red in each plot indicates the Pearson 
correlation coefficient for goodness of fit of a logistic dose-response model.
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Summary
Zebrafish embryos were exposed to concentration ranges of selected thyroid-active 
model compounds in order to assess the applicability of zebrafish-based developmental 
scoring systems within an alternative testing strategy to detect the developmental toxicity 
of thyroid-active compounds. Model compounds tested included triiodothyronine (T3), 
propylthiouracil (PTU), methimazole (MMI), sodium perchlorate (NaClO4) and amiodarone 
hydrochloride (AMI), selected to represent different modes of action affecting thyroid 
activity. Tested time windows included 48-120 hours post fertilization (hpf), 0-72 hpf and 
0-120 hpf. All tested compounds resulted in developmental changes, with T3 being the 
most potent. The developmental parameters affected included reflective iridophores, 
beat and glide swimming, inflated swim bladders, as well as resorbed yolk sacs. These 
effects are only evident by 120 hpf and therefore an existing General Morphology Score 
(GMS) system was extended to create a General Developmental Score (GDS) that 
extends beyond the 72 hpf scoring limit of GMS and includes additional parameters 
that are affected by exposure to model thyroid-active compounds. Moreover, the GDS 
is cumulative as it includes not only the scoring of developmental morphologies but 
also integrates developmental dysmorphologies. Exposures from 48-120 hpf did not 
provide additional information to exposures from 0-120 hpf. The results indicate that 
the zebrafish GDS can detect the developmental toxicity of thyroid toxicants and may be 
of use in an integrated testing strategy to reduce, refine and, in certain cases, replace 
animal testing.
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1 Introduction
The EU Regulation on the Registration, Evaluation, Authorisation and Restriction of 
Chemicals (REACH) requires all substances marketed or manufactured in quantities 
above 10 tons per annum to be tested for developmental toxicity (OECD 421 or OECD 
422). Substances that are marketed or manufactured in quantities above 100 tons 
per annum are required to be tested for pre-natal developmental toxicity (OECD 414) 
(REACH, 2006). Based on data on chemical production from 1991 to 1994, the EU 
estimates that 2.6 million animals will be needed for all REACH testing or a total of 9 
million when offspring produced during reproductive and developmental toxicity testing 
are taken into account. While some studies have suggested much higher numbers, the 
EU is sticking to its initial predictions (ECHA, 2009; Hartung and Rovida, 2009; van der 
Jagt et al., 2004; Pedersen et al., 2003). The issues associated with these tests include 
ethical acceptability considerations, high costs and long duration. This has prompted 
research into the development of suitable high-throughput alternative tests that, once 
validated, could reduce animal testing within an integrated testing strategy (ITS).
In a previous study we investigated to what extent thyroid (TSH-screen) and 
pituitary (T-screen) cell proliferation assays could be used as in vitro screens for 
detecting the effects of thyroid hormone-disrupting compounds on thyroid and pituitary 
weights used as endpoints in in vivo assays (Jomaa et al., 2013). While the effect of 
estrogen-mimicking compounds on cell proliferation in the in vitro E-screen was found 
to correlate with their effects on in vivo uterine weight (r2=0.85) (Wang et al., 2012), the 
effects of thyroid-active compounds on thyroid (TSHscreen) and pituitary (T-screen) cell 
proliferation was found to have poor correlation with their effects on the weight of these 
respective organs in vivo. The results of the study indicated that a complex interplay 
between factors within the hypothalamuspituitary-thyroid (HPT) axis may underlie the 
effects of thyroidactive compounds on thyroid and pituitary organ weight endpoints 
in vivo. Therefore, it was proposed that the development of future alternative tests, 
aiming at the refinement, reduction, or replacement of animal studies, should include 
as an initial screen a broad battery of in vitro tests that cover the various modes of 
action of thyroid-active compounds and should in addition be based on more complex 
model systems that better integrate the various processes involved in the HPT axis. 
The vertebrate Danio rerio (zebrafish) may represent such a complex model system 
that includes an intact HPT axis. Given that alterations in the thyroid system can have 
severe effects on development (Boyages and Halpern, 1993; Haddow et al., 1999; 
Utiger, 1999), the aim of the present study was to investigate whether a zebrafish-
based developmental toxicity assay would be able to detect thyroid hormone-active 
compounds.
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Hermsen et al. (2011) developed a zebrafish-based quantitative scoring system 
for developmental and teratogenic endpoints, with the former called the general 
morphology score (GMS). The developmental endpoints include abnormalities related 
to the completion of gastrulation, formation of somites, development of the eyes, 
spontaneous movement, blood circulation, pigmentation, edemata, malformations 
of the chorda structure, spinal cord (scoliosis, rachitis), head, sacculi/otoliths, tail, 
heart, yolk sac, growth retardation, and tail length (Nagel, 2002). The GMS is meant 
to be semi-quantitative and hence more efficient than more complex scoring systems 
while maintaining the same relevance in terms of output (Hermsen et al., 2011). 
The GMS scoring system uses the 0-72 hpf time window and was validated using 
eight glycol ethers and six 1,2,4-triazole antifungals (Hermsen et al., 2011). While 
alternative methods for developmental toxicity testing are unlikely to replace testing 
on rodents, they can potentially be used in pre-screening in order to reduce the need 
for consecutive in vivo testing (Piersma, 2006).
In order to investigate whether a zebrafish-based developmental toxicity assay 
would be able to detect thyroid hormoneactive compounds, the effects in the 
zebrafish-based bioassay of a series of model thyroid-active compounds representing 
different modes of thyroid action in vivo (Tab. 1) was investigated. The selected 
compounds were triiodothyronine (T3), sodium perchlorate (NaClO4), propylthiouracil 
(PTU), methimazole (MMI) and amiodarone (AMI). All selected compounds are known 
to affect thyroid hormone levels in vivo albeit by different modes of action (Grover et 
al., 2007; Hood et al., 1999; de Sandro et al., 1991; Stoker et al., 2006; Yamasaki et 
al., 2002).
2 Materials and methods
Compounds
All compounds were obtained from Sigma-Aldrich Chemie (Zwijndrecht, The 
Netherlands) and were of high purity (≥95%). All test chemicals were added from 500-
fold concentrated stock solutions in dimethylsulfoxide (DMSO, Acros Organics, Geel, 
Belgium) to Dutch Standard Water (DSW; demineralised water supplemented with 
NaHCO3 (100 mg/l), CaCl2•H2O (200 mg/l), KHCO3 (20 mg/l), and MgSO4•7H2O (180 
mg/l)). The exposure medium was then aerated for 24 h at 27°C, the pH was adjusted 
to 7.4-8.4 and O2 concentration was above 6.5 mg/l. The concentration range that was 
selected for the model compounds was based on reported effective concentrations for 
inducing reduction in T4 levels in zebrafish (Raldúa and Babin, 2009).
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Zebrafish embryos
Zebrafish, obtained commercially (Ruinemans Aquarium BV, Montfoort, The 
Netherlands), were maintained and bred at RIVM (Bilthoven, The Netherlands) for 
more than five years. Their daily diet consisted of two servings of dry flakes (Special 
Diet Services, Tecnilab-BMI BV, The Netherlands) and one serving of Artemia 
(Landman BV, The Netherlands). Constant filtering and permanent water flow-through 
kept contaminants to a minimum. Male and female adult zebrafish free from externally 
visible diseases were housed together in 7.5 l ZebTEC aquaria at 27°C ±1°C with a 
light/dark (LD) cycle of 14-hour light/10-hour dark. Three days prior to mating, males 
and females were placed in spawning chambers within separate tanks. Mating involved 
placing two males with two females in the spawning chambers with reduced water 
flow and keeping them in the dark overnight after which turning on the lights induced 
mating, spawning and fertilization within 30 minutes. The spawning chambers have 
a perforated bottom surface that allows the eggs to fall through, thus preventing the 
predation of eggs by adult zebrafish.
Exposure
Spawned eggs were rinsed in DSW and unfertilized eggs, less than 10% of total, were 
removed. Embryos were selected at the 4 to 32-cell stage and one embryo was added 
per well of a 24-well plate containing 2 ml of test medium per well. Alternatively, the 
transfer to the 24-well plates containing 2 ml of the test medium was performed at 
Compound Abbreviation CAS No. Description logP Mode of Action Concentration 
Range (µM)
Triiodothyronine T3 6893-02-3 Endogenous 
ligand
2.80 Thyroid hormone 
receptor agonist
0.00005 – 
0.5
Propylthiouracil PTU 51-52-5 Antithyroid 
drug
1.2 Inhibits thyroid 
peroxidase and 
deiodinase 
type 1
25 - 400
Methimazole MMI 60-56-0 Antithyroid 
drug
0.75 Inhibits thyroid 
peroxidase
125 - 
2,000
Sodium 
perchlorate 
monohydrate
NaClO4 
•H2O
7791-07-3 Environmental 
contaminant
-0.10 Inhibits iodide 
uptake
25 - 400
Amiodarone 
hydrochloride
AMI 19774-
82-4
Antiarrhythmic 
drug
7.64 Increases iodine 
load
0.001 - 10
Tab. 1: List of compounds used in this study with their main mode of action on the thyroid 
hormone system based on rodent studies, and concentration ranges used in the experiments. 
logP was predicted based on structure using chemaxon software.
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48 hpf. The 24-well plates were kept in an incubator at 26.5°C ±1°C with a light/dark 
(LD) cycle of 14-hour light/10-hour dark. Exposure was performed at the start of the 
light cycle.
TSH-screen
FRTL-5 cells at 70% confluence and below passage 30 were incubated in serum-free, 
phenol red-free DMEM containing 0.2% BSA for a period of 96 h. The cells were then 
harvested and plated at a density of 5,000 cells/well on a 96-well plate in phenol red-
free DMEM with insulin (10 µg/ml) and, following an attachment period of 2 to 3 h, 
exposed to a concentration range of the chemicals to be tested alone or in combination 
with 1 mIU/ml bTSH, in triplicate, for 72 h. Following this incubation, cell proliferation 
was measured 4 h after the addition of 10 µl/well of 0.1 mg/ml resazurin as described 
above.
General morphology score (GMS)
Scoring of the developmental morphology was performed using a Leica Labovert FS 
microscope as outlined by Hermsen et al. (2011). Briefly, an incremental binary scoring 
system was used to assign a 0 to a non-event and a 1 to each normal morphologic 
developmental event that is easy to visualize under a regular stereo microscope. Sets of 
developmental events included detachment of tail, somite formation, eye development, 
movement, heartbeat, blood circulation, pigmentation of the head and body, pigmentation 
of the tail, pectoral fin development, protruding mouth, and hatching. The subtotals of all 
sets of developmental events were added towards a general morphology score (GMS), 
which in normal non-exposed embryos amounts to 15 at the 72 hour time point. In a 
separate binary scoring system, teratogenicity was scored, whereby normal embryos 
were assigned a 1 and malformed embryos were given a 0 for every malformation 
studied. These malformations included pericardial edema, yolk sac edema, eye edema, 
malformation of the head, absence/malformation of sacculi/otoliths, malformation of 
tail, malformation of heart, modified chorda structure, scoliosis, rachischisis and yolk 
deformation. Testing was considered valid when no more than 10% of control embryos 
were coagulated, underdeveloped or malformed. 
Immunohistochemistry
Whole-mount immunohistochemistry of T4 was performed as previously described 
by Raldúa and Babin (2009), with slight modifications. Briefly, zebrafish embryos at 
5 dpf were sacrificed by incubation on ice for 5 min and then fixed overnight in 4% 
paraformaldehyde at 4°C. They were then washed repeatedly with PBS, dehydrated 
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with a methanol row (30%, 60%, 100%) and stored overnight or longer at -20°C. The 
embryos were then rehydrated with a methanol row (60%, 30%) and washed several 
times with PBS containing 1% Triton X-100. Permeabilization was achieved by 15 minute 
incubation at room temperature with 0.1% collagenase in PBS. Immediately after the 
incubation, the embryos were washed several times with PBS containing 1% Triton 
X-100 and blocked in blocking buffer containing 4% goat serum, 1% BSA, 1% DMSO, 
0.8% Triton X-100 and 0.1% Tween-20 in PBS for 2 h. This was followed by two washes 
in 1% BSA in PBS and an overnight incubation in a solution consisting of a polyclonal 
antibody against T4 (MP Biochemicals, Amsterdam, The Netherlands) diluted 1:4,000 
in blocking buffer containing 0.02% sodium azide. The following day, the embryos were 
washed several times in 1% BSA in PBS and incubated on a gentle rotation device for 2 
h in a solution containing a 1:300 dilution of the secondary antibody conjugated to the 
fluorescent label Alexa Fluor 488 (Life Technologies, Breda, The Netherlands). Right after 
the incubation, the embryos were either stored in glycerol or embedded in 1% gelatine 
for imaging on an a Zeiss Axiovert 100 M confocal microscope (Zeiss Netherlands bv, 
Weesp, The Netherlands).
Data analysis
Non-linear curve fitting was done using the Hill equation with the help of GraphPad 
Prism software version 5.04 (GraphPad Software, San Diego, CA, USA). For the in vivo 
data that were collected from literature, a dose of 10 ppm MMI, equivalent to 10 mg/kg, 
was converted to 0.5 mg/kg bw/day based on the assumption that rats consume 5% of 
their body weight of food each day.
3 Results
3.1 Zebrafish thyroid development within selected exposure period
A limit of exposure was set at 120 hpf (the end of the embryonic phase), which is the 
regulatory limit to in vitro experimentation as defined by Directive 86/609/EEC (European 
Council, 1986). To place the exposure regimen into perspective, an analysis of zebrafish, 
rat and human developmental staging was performed (Fig. 1a). This comparison was 
based on O’Rahilly and Müller’s developmental stages of human embryos, Witschi’s 
development of the rat, and Kimmel’s stages of embryonic development of the zebrafish 
(Kimmel et al., 1995; O’Rahilly and Müller, 1987; Witschi, 1962). Carnegie stage 24 
is the last stage of embryonic development and occurs at 33 days for humans, the 
equivalent of 16 days for rat and 72 h for zebrafish. Additional stages are added as 
indicated in the figure. The results obtained reveal many parallels between the different 
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species. Thyroid hormone production starts after 71 days in man, 20 days in rat and 2.5 
days (~ 60 hpf) in zebrafish (Bohnsack et al., 2011; Contempré et al., 1993; Strum et 
al., 1971). 
Figure 1b provides a schematic overview of landmarks associated with the 
development of the thyroid and the production of T4 in zebrafish from 0 until 120 hpf. 
Briefly, the zebrafish thyroid gland develops from endodermal cells through a process 
that is in large part evolutionarily conserved (Wendl et al., 2002). The two critical 
transcription factors nkx2.1 and pax2.1 (functionally similar to human pax 8) are already 
expressed at 24 hpf (Antonica et al., 2012; Wendl et al., 2002). A fate mapping study 
showed that the thyroid precursor cells are located near cardiac lateral plate mesoderm 
(Wendl et al., 2007). Thyroglobulin gene expression starts around 32 hpf and the 
expression of the sodium iodide symporter (slc5a5) at 40 hpf. A first follicle is positive 
for the thyroglobulin protein by 55 hpf and for T4 by 60 hpf and expands anteriorly away 
from the heart, leaving a trail of thyroid follicles along the pharyngeal midline (Alt et al., 
2006; Wendl et al., 2007). By 120 hpf, 6-10 thyroid follicles span along this axis from the 
gill region until they reach an axis that intersects the middle of the eyes. This is a time of 
peak T4 production, with the rise starting at around the time of hatching (72 hpf) (Chang 
et al., 2012). Live imaging using a transgenic zebrafish line expressing fluorescent 
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Fig.1: a) Human, rat and zebrafish developmental stages (Carnagie equivalent) plotted against 
time in postovulatory days. Carnagie stage 24 is the last stage of embryonic development and 
occurs at 33 days for humans, the equivalent of 16 days for rat and only 72 hours for zebrafish. 
b) Developmental landmarks of the thyroid hormone system in zebrafish from 0 to 120 hpf., 
including the expression of the differentiation markers nkx2.1 and pax2.1, expression of 
thyroglobulin (tg), the sodium iodide symporter (slc5a5), the first follicle that can be detected by 
T4 IHC, as well as the rise and peak of T4 levels. c) Schematic representation of thyroid follicle 
development. PF stands for primary follicle (additional follicles are circled in red); H for heart; PM 
for pharyngeal midline (represented by a dotted line); E for eyes; G for gills; h for head region. The 
green arrow indicates the direction of PF development from 0 to 120 hpf. In the background, T4 
IHC of a 120 hpf zebrafish provides a visual reference.
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thyroglobulin has recently provided further insight into the development of the thyroid, 
suggesting a role for the hypobranchial artery in guiding late thyroid expansion (Opitz et 
al., 2012). Figure 1c provides a schematic overview of thyroid tissue development with 
T4 immunohistochemistry (IHC) at 120 hpf providing a visual reference. The first follicle 
to be formed (primary follicle) is formed near the heart during early development and 
expands anteriorly along the pharyngeal midline until it reaches the mid-region of the 
eyes, leaving behind a trail of follicular cells that later form additional follicles.
Based on this analysis, two time windows of exposure, namely 48 hpf to 120 hpf 
and 0 to 120 hpf were chosen, with the prior avoiding the potential effect of compounds 
on morphogenesis of the first thyroid follicle and the second one including such effects. 
These thyroid-specific time windows were further compared with the exposure time 
window of 0-72 hpf, which was used by Hermsen et al. (2011) in order to assess the GMS 
of developmental toxicants. Exposures were conducted with 12 replicates per compound 
concentration for all time windows in one experiment. In addition, for the 0-120 hpf time 
window, an additional experiment with 8 replicates was performed resulting in a total of 
20 replicates per compound concentration for the 0-120 hpf time window.
3.2 Morphological effects of thyroid-active model compounds
Figure 2 shows an overview of the altered morphologies of the zebrafish exposed from 
0 to 120 hpf to the highest tested concentrations of the test substances. The highest 
Fig. 2: a) Zebrafish morphology upon exposure to solvent control (0.2% DMSO), 500 nM T3, 
2,000 µM MMI, 400 µM PTU, 10 µM AMI and 400 µM ClO4. b) Sagittal section of zebrafish 
exposed to 500 nM T3 stained with hematoxylin and eosin (H&E) reveals a high degree of 
intestinal convolution that is absent in the solvent control. c) Alcian blue staining of the cartilage 
revealing the anterior-dorsal protrusion of the lower jaw following exposure to 500 nM T3 from 
0 – 120 hpf.
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tested concentration of T3 (500 µM) affected zebrafish embryos 
dramatically with an observed reduction in melanophore 
density and size, abnormal iridophores, deflated swim bladder, 
accumulation of biliverdin around the liver, and an indication 
of an adrenergic response – mainly tachycardia, which is a 
well documented effect of T3 – as well as dyskinesia observed 
as a lack of swimming behavior. In terms of teratogenicity, an 
observation was made for kyphosis (hunchback), however since 
the teratogenicity parameters used only included scoliosis 
(oblique bending), it was scored as such. Most effects on 
morphology could already be seen at 50 nM T3. The effects were 
similar in the 48-120 hpf exposure window while for the 0-72 hpf 
time window only abnormal pigmentation, kyphosis and a mean 
percentage failed or delayed hatching of 41.7 ±1.2% (mean 
±SEM) could be observed. Intestinal convolution could be clearly 
observed with histological slices (Fig. 2b) but could not be clearly 
viewed under a stereo microscope and hence was not included 
as a parameter in the scoring system. Lower jaw protrusion was 
also clearly visible, especially with Alcian blue staining (Fig. 2c).
At doses of 250 µM MMI and higher, failure to hatch was 
observed for the exposure periods 0-72 hpf and 0-120 hpf. For 
the exposure period from 48-120 hpf, only the highest tested 
concentration of 2 mM led to the failed hatching of 16.7 ±0.9% 
of the zebrafish embryos, compared to 100.0 ±0.0% failed 
hatching at the highest tested concentration for 0-72 hpf and 
84.2 ±0.4% for 0-120 hpf. Unhatched embryos had deflated 
swim bladders, unresorbed yolk sacs and, as can be expected 
from unhatched embryos, a lack of swimming behavior. PTU also 
led to failed hatching at the highest tested concentration of 400 
µM at a rate of 27.3 ±1.2% for exposures from 0-72 hpf, 11.1 
±0.5% from 0-120 hpf while no failed hatching was observed for 
the exposure period from 48-120 hpf.
Upon exposure to NaClO4 from 0-120 hpf, deflated swim 
bladders were observed starting at 25 µM up to the highest 
tested concentration of 400 µM in an average of 12.0 ±0.4% of embryos, while exposure 
to AMI at the highest tested concentration of 10 µM led to deflated swim bladders in 35.3 
±0.7% of embryos exposed during the same time period. No significant effects could be 
0.2% DMSO
0.05 nM T3
0.5 nM T3
5 nM T3
50 nM T3
500 nM T3
Fig. 3: Lateral view 
of 120 hpf zebrafish 
showing iridophore 
pigmentation (reflective 
pigments) increasing 
dose-dependently upon 
exposure to T3.
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observed during exposures to either compound using the other time windows tested (0-72 
hpf or 48-120 hpf) suggesting exposure duration to influence the sensitivity of the assay 
and 0-120 hpf to be the preferred time window for exposure.
3.3 Adjusted morphological scoring: general development score
The GMS scoring system was developed to look at the effect of chemicals on zebrafish 
development at 72 hpf (Hermsen et al., 2011). Based on the results obtained here with the 
selected thyroid modulating compounds, four main adjustments were made to the GMS 
scoring system. First, 120 hpf-specific developmental endpoints affected by thyroid-active 
compounds were added to the GMS. These endpoints included reflective iridophores (Fig. 
3), beat and glide swimming, inflation of swim bladder and resorption of yolk sac (Fig. 2). 
Since these endpoints are not included in the GMS for 0-72 hpf, they were incorporated in 
a new scoring system denoted general development score (GDS). Secondly, a refinement 
was made in the newly defined GDS by combining both morphology and teratogenicity 
endpoints in a similar way to the total morphological score (TMS) applied in the method 
of Piersma et al. (2004) for the rat whole embryo culture (WEC) which combines 
teratogenicity and developmental toxicity (Fig. 4). Thirdly, a refined scoring approach was 
also implemented similar to that used by Teixidó et al. (2013) whereby developmental 
abnormalities for an endpoint are treated as a lack of development and therefore result in 
a score of 0 for that developmental endpoint compared to a score of 1 per event for normal 
development. Fourthly, the terms used for developmental abnormalities are compliant with 
major databases with the use of the Entity Quality Ontology (EQO) convention suggested 
by the Open Biomedical Ontologies (OBO) Consortium, which involves describing an entity 
(e.g. tail vasculature) and a quality (e.g., edema) (Balhoff et al., 2011; Dahdul et al., 2010). 
This leaves room for the standardized annotation of additional abnormalities based on 
anatomical location or feature (such as movement). Database compliance also enables 
computable phenotypes as well as the development of iterative models that improve 
the accuracy of future chemoinformatic predictions. Examples of commonly observed 
abnormalities are included in Figure 4 for reference purposes. Minor adjustments to the 
highlighted abnormalities include the addition of visible biliverdin or bilirubin as well as 
the changing of the term scoliosis to spinal curvature in order to encompass all forms of a 
bent spine, which include kyphosis and lordosis in addition to scoliosis (Fig. 4).
3.4 GMS compared to GDS
The GMS for the highest concentration of T3 (500 µM) decreased to 12.9 ±0.7 (n=12) 
for the exposure period from 0-72 hpf, 11.3 ±0.5 (n=12) from 48-120 hpf and 11.1 ±2.6 
from 0-120 hpf (n=20), as compared to a value of 15.0 ±0.0 for the unexposed control. 
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Abnormality
General Development Score - Part 1 of 3
12 hpf 24 hpf 48 hpf 72 hpf 120 hpf 
Detachment of tail All tail 
malformations 
including  :
 
□  tail,  
malformation  
□  tail 
vasculature,
edema 
□  vertebral 
column,  
curvature 
(scoliosis, 
kyphosis, 
lordosis)  
□  neural tube,  
malformation 
(rachischisis, 
anencephaly)
□  notochord,
malformation  
 
 
0 
 
18hpf
0 1 2 3 3 3 
Somite formation All somite 
malformations 
including:  
 
□  somite 
border,  
incomplete
0 No = 0 Yes = 1 Yes = 1 Yes = 1 Yes = 1 
Eye development All eye 
malformations 
including:
 
□  eye, single 
(cyclopia)  
□
□
 eye, absent  
eye, edema 
 
 
0 1 2 2 + 1 for 
pigment 
2 + 1 for 
pigment 
3 + 1 for 
reflective 
iridophores
Movement All movement 
abnormalities 
including:
 
□  organismal 
movement,  
abnormal 
(spasms)  
 
0 No = 0 Yes = 1 Yes = 1 Yes = 1 Yes = 1 + 1 for 
beat and glide 
swimming
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Heartbeat  All heart 
malformations 
including:
 
□  heart , 
malformation  
□  pericardial 
sac, edema  
 
    
 0 No = 0 Yes = 1 Yes = 1 Yes = 1 Yes = 1 
Blood circulation  All circulation 
abnormalities 
including:
 
□  blood 
coagulation,
present 
□  bilirubin 
oxidase 
activity, 
increased in 
magnitude  
 
    
 0 No = 0 No = 0 Yes = 1 Yes = 1 Yes = 1 
Pigmentation head -
body  
All 
pigmentation 
abnormalities in 
head body 
region (except 
eyes) including:
 
□  pigmentation,
irregular 
spacial 
pattern  
□  pigmentation,
decreased 
□  pigmentation,  
increased  
 
 
 
 
  
 0 0 0 1 1 1
0 0 0 1 1 1
 
Pigmentation tail  All 
pigmentation 
abnormalities in 
tail including:
 
□  pigmentation,
irregular 
spacial 
pattern  
□  pigmentation,
decreased 
□  pigmentation,
increased  
 
 
 
  
 
Abnormality
General Development Score - Part 2 of 3
12 hpf 24 hpf 48 hpf 72 hpf 120 hpf 
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The GDS for the highest concentration of T3 was 12.2 ±3.7 (n=20) from 0-120 hpf as 
compared to18.8 ±0.7 for the control. For better comparison, normal growth was set as 
a common denominator with a baseline value of 1, and the fold change relative to the 
controls was also calculated. The fold change relative to the controls for the two highest 
concentrations of T3 (1-120 hpf, n=20) went from 0.9 and 0.7 in the GMS to 0.8 and 0.6 
in the GDS, respectively, thereby increasing the statistical significance from p≤0.01 to 
p≤0.0001.
The GMS at the highest tested concentration of MMI (2,000 µM) was 13.1 ±0.3 
as an average of all exposure periods, which represents a fold change of 0.9 relative to 
Pectoral fin   
 
 
 
 0 0 0 0 1 1 
Head:  
Protruding mouth  
All head 
malformations 
(except for eyes) 
including:  
 
□  head, 
malformation  
□  head, edema 
□  saccule / 
otolith,  
malformation  
□  brain, small 
volume  
 
 
 
 
 0 0 0 0 1 1
Hatching   
0 
 
No = 0 No = 0 
 
No = 0 Yes = 1 
 
Yes = 1 
Inflated swim 
bladder  
All swim 
bladder 
malformations
 
 
 0 No = 0 No = 0 No = 0 No = 0 Yes = 1
Yolk sac resorbed All yolk 
malformations 
including:
 
□  yolk, 
malformation  
□  yolk 
extension, 
malformation  
 
  
 
 
 0 No = 0 No = 0 No = 0 No = 0 Yes = 1 
GDS 7 12 15 19
 
Abnormality
General Development Score - Part 3 of 3
12 hpf 24 hpf 48 hpf 72 hpf 120 hpf 
10
Fig. 4: GDS system for the assessment of general developmental toxicity at 120 hpf. The system 
takes into account morphology, dysmorphology as well as non-morphological parameters such as 
swimming. Additions made to the GMS scoring system (Hermsen et al., 2011) in order to better 
accommodate effects of thyroid-active compounds are highlighted with a bold outline.
deVelopmental toxicity of thyroid-actiVe compounds in a zebrafish embryotoxicity test   135
Ch
ap
te
r 
5
the control (GMS = 15.0 ±0.3). The GDS at the highest tested concentration of MMI was 
12.8 ±2.7 (0-120 hpf), which represents a fold change of 0.7 relative to the control (GDS 
= 18.4 ±1.6; p≤0.0001). Moreover, statistical significance could be reached at the lower 
concentration of 1,000 µM (p≤0.05) with the GDS but not the GMS.
Figure 5 gives an overview of the effects of T3, MMI, PTU, and ClO4 on zebrafish 
development, in both GMS and GDS, represented as fold change relative to the 
controls. These tested compounds led to developmental abnormalities at the highest 
tested concentration and the GDS was better able to reflect these abnormalities than 
the GMS.
A comparison of the exposure time windows of 0-72 hpf and 0-120 hpf, reveals 
that the most significant results were achieved with exposures from 0-120 hpf (Fig. 5). 
The time window of 48-120 hpf did not add any additional information or significance 
compared to the other time windows. In the GDS, T3 and MMI exposure resulted in a no 
observed adverse effect level (NOAEL) of 5 nM and 500 µM, respectively. The GDS for 
PTU, amiodarone and ClO4 did not change significantly and therefore a NOAEL could not 
be established for these compounds.
3.5 T4 immunohistochemistry
The model compounds tested were selected based on their known ability to alter thyroid 
homeostasis and only those that significantly affected the GDS score, namely T3 and 
MMI, were further tested for thyroid status by T4 immunohistochemistry (IHC) in order 
to confirm that the developmental toxicity detected by the GDS for these compounds 
was accompanied by an effect on the thyroid system (Fig. 6). Under control conditions, 
the thyroid follicles are well spaced out anteriorly by 120 hpf. In zebrafish exposed to 
T3 both number of follicles and their spread were affected compared to the control (Fig. 
6a), indicating potential thyroid dysmorphogenesis, while MMI exposure led to a clear 
drop in signal intensity and in the number of follicles compared to the control (Fig. 6b,c), 
confirming a drop in follicular T4 levels.
4. Discussion
Critical to the proper development of the vertebrate embryo, thyroid homeostasis is 
prone to disruption by man-made chemicals with an ability to act through very diverse 
modes of action and within multiple organs (Hartoft-Nielsen et al., 2011; Jomaa, 2014; 
Tan et al., 2007). Given that alterations in the thyroid system can have severe effects 
on development (Boyages and Halpern, 1993; Haddow et al., 1999; Utiger, 1999), the 
aim of the present study was to investigate whether a zebrafish-based developmental 
toxicity assay would be able to detect thyroid hormone-active compounds.
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Fig. 5: Effect of T3 exposure on a) GMS b) GDS; PTU exposure on c) GMS d) GDS; MMI exposure 
on e) GMS f) GDS ClO4 exposure on g) GMS h) GDS. Results are based on 12 replicates per 
concentration (n = 12) and since the total scores are different, these are expressed as fold 
decrease relative to the full score (normal development). A top down approach was used to 
minimize the number of embryos used and the 0 – 120 hpf exposure window, which was 
found to be the most appropriate time window for the thyroid-related parameters studied, was 
selected for an additional independent experiment at a separate laboratory with 8 replicates per 
concentration (n = 8; a total of n = 20 for 0-120 hpf experiments). The error bars are shown for 
only this time window as the standard error of the mean of these two experiments (N = 2). The 
calculation of statistical significance was done by pooling all replicates from each experiment for 
each concentration and comparing it to the 0.2% DMSO solvent controls in a two tailed student’s 
t-test. * P ≤ 0.05; ** P ≤ 0.01; *** P ≤ 0.001; **** P ≤ 0.0001.
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The pathways involved in human thyroid development are conserved in the 
zebrafish and so are its tissue architecture, function and feedback regulation by the HPT 
axis, making it a promising model for the study of thyroid-active compounds (Bourque 
and Houvras, 2011; Jomaa et al., 2013; Raldúa and Babin, 2009).
T3, acting through its nuclear receptor, is a morphogenic agent in certain animal 
species, controlling the metamorphosis of tadpoles and frogs (Shi et al., 1996). In the 
present study, T3 exposed zebrafish clearly showed significant developmental toxicity 
evident as scoliosis, abnormal iridophores, reduced melanophore density and size as 
well as a lack of an inflated swim bladder (Fig. 4). Moreover, T3 exposed zebrafish showed 
signs of acute toxicity such as excess biliverdin that is visible under a stereo microscope, 
tachycardia and dyskinesia. The latter two are symptomatic of an adrenergic response 
and are likely a result of T3 increasing beta-adrenergic receptor density (Mooradian 
and Scarpace, 1993). A high rate of 42% failed hatching occurred only at the 0-72 hpf 
exposure window. Increased sensitivity for hatching failure is expected at 72 hpf since 
that is around the time hatching occurs. However, as can be seen in Figure 5, overall 
sensitivity to thyroid-active compounds is higher in the GDS at 0-120 hpf as it includes 
additional parameters that are specific to that time window.
PTU and MMI have a direct effect on thyroglobulin iodination by thyroid peroxidase, 
thereby inhibiting thyroid hormone synthesis (Taurog, 1976). These compounds are used 
medically to treat hyperthyroidism. A decrease in the circulating T3 levels can affect 
various developmental endpoints including intestines, brain and reproductive capacity. 
Raldúa and Babin (2009) reported a complete lack of T4 immunoreactivity beyond 
0.75 mM and 0.18 mM in zebrafish for MMI and PTU, respectively. This reduction in 
thyroid hormone levels was accompanied by a reduction in the GDS (Fig. 5). Moreover, 
the hatching rate was strikingly low in the MMI-treated group and this was deemed 
significant, not only statistically, but also physiologically. This result is in line with the 
observation that chicken embryos have been reported to have delayed hatching upon 
exposure to MMI (Haba et al., 2011). Interestingly, another compound shown to affect 
zebrafish hatching rate is perfluorooctanoic acid (PFOA), an established thyroid-active 
compound (Lopez-Espinosa et al., 2012; Melzer et al., 2010; Zheng et al., 2011). Hence, 
the change in zebrafish hatching rate that was induced by thyroid active compounds 
was accurately reflected in the GDS developmental toxicity assay (Fig. 5). Moreover, 
MMI exposure resulted in a NOAEL of 500 µM in the GDS, which is several orders of 
magnitude higher than the T3 NOAEL of 5 nM, and this relative potency compares well 
with the NOAEL based on changes in thyroid stimulating hormone (TSH) levels derived 
from rodent studies (a NOAEL of 0.5 mg/kg bw/day for MMI and a NOAEL of less than 
10 µg/kg bw/day for T3) (Grover et al., 2007; Hood et al., 1999).
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NaClO4 inhibits sodium iodide symporter (NIS) transport of iodide into the thyroid 
follicular cells, thereby resulting in a decline in thyroid hormones and a rise in thyrotropin 
(Stoker et al., 2006). The morphological changes observed in the developing zebrafish 
embryo included uninflated swim bladder and incomplete resorption of the yolk sac. 
While these were consistent observations that could only be made by including 120 
hpf-specific parameters, they did not have enough weight within either the GMS or GDS 
system to significantly change the overall score. This corroborates in vivo data on altered 
thyroid hormone levels in rodent studies showing that NaClO4 is less potent than either 
PTU or MMI (Hood et al., 1999; Stoker et al., 2006; Yamasaki et al., 2002). Moreover, 
a human epidemiological study failed to find an association between perchlorate levels 
in drinking water and congenital defects of the thyroid (Crump et al., 2000). In another 
study with volunteers given perchlorate in drinking water the administered dose was 
negatively correlated with thyroidal iodide uptake but even a 70% decrease in iodide 
transport did not result in altered T4 levels (Greer et al., 2002; Strawson et al., 2004). 
The relatively low developmental toxicity of perchlorate is supported by animal studies 
showing that pregnant rats and rabbits exposed to a perchlorate dose as high as 30 mg/
kg bw/ day do not give birth to offspring with signs of developmental toxicity and changes 
in thyroid hormone levels were seen as adaptive and reversible (York et al., 2003, 2005).
Amiodarone is an anti-arrhythmic agent (heart), beta blocker and calcium blocker. 
Its chemical structure resembles that of T4 and the compound alters thyroid hormone 
0.2% DMSO
0 - 120 hpf
a) b) c) d) e)500 nM T3
48 - 120 hpf
2,000 µM MMI
48 - 120 hpf
2,000 µM MMI
0 - 120 hpf
500 nM T3
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Relative uorescence
intensity (RFU): 
Number of follicles:
1.48
4
1.41
5
4.42
4
3.95
4
Fig. 6: T4 whole mount immunohistochemistry upon exposure of zebrafish to a) 0.2% DMSO as 
the solvent control from 0 – 120 hpf; 500 nM T3 from b) 48 – 120 hpf and c) 0 – 120 hpf; and 
2,000 µM MMI from d) 48 – 120 hpf and e) 0 – 120 hpf. Thyroid follicles were tested for the 
signal intensity of T4 immunofluorescence and expressed as relative fluorescence units (RFU). 
The number of follicles was counted based on the images taken with the confocal laser scanning 
microscope (the region of interest is enlarged and presented at the right side of each panel). T3 
exposure at the highest tested concentration and both time points resulted in a decrease in the 
number of follicles. MMI exposure at the highest concentration resulted in both lower T4 signal 
intensity and lower number of follicles.
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levels in vivo (de Sandro et al., 1991), likely due to its high iodide content (Pitsiavas, 
1999). In zebrafish, amiodarone was reported to lead to a significant reduction in T4 
immunoreactivity at 1 µM (Raldúa and Babin, 2009). However, while morphological 
changes were observed in the present study upon exposure to amiodarone, such as the 
lack of an inflated swim bladder in some animals, which is included in the GDS, statistical 
significance could not be reached in both the GMS and GDS (data not shown). Indeed, 
human studies on amiodarone treated mothers indicate that transient hypothyroidism 
in the newborn may occur but there is no adverse effect on development (Matsumura et 
al., 1992; Valensise et al., 1992).
The thyroid-active compound associated phenotypes observed in 120 hpf zebrafish 
include 1) hatching (discussed in the previous section), 2) yolk sac resorption, 3) 
iridiophore pigmentation, 4) melanophore pigmentation, 5) swim bladder inflation, 
6) bent spines, 7) beat and glide swimming, 8) lower jaw cartilage protrusion and 9) 
maturation of the gastrointestinal system, with the last two being better suited for 
staining techniques or high resolution microscopy for accurate assessment. These 
developments occur concurrently with a surge in thyroid hormone levels, which reach 
a peak at 120 hpf (Chang et al., 2012). The overall results have indicated that the time 
window of 0-120 hpf is better able to reflect the effect of thyroid-active compounds on 
zebrafish development than the other time windows studied (Fig. 5) and support the 
suggestion by Liu and Chan that there is a distinct thyroid hormone-mediated embryonic 
to larval transition in zebrafish that is analogous to the thyroid hormone-mediated larval 
to juvenile transition originally proposed by Brown (Brown, 1997; Liu and Chan, 2002).
The period from the time the zebrafish embryo has hatched (72 hpf) until the time 
it is free swimming (120 hpf) is termed the yolk-sac larva (Balon, 1990). The resorption 
of the yolk sac and hence the maternal food supply is only evident at around 120 hpf, 
with total resorption evident by around 168 hpf (Jardine and Litvak, 2003; Kimmel et al., 
1995). The role of thyroid hormones in this developmental process has been previously 
documented whereby MMI co-administered with AMI resulted in the retardation of yolk 
sac resorption and this was rescued with T4 (Liu and Chan, 2002).
Overall, the results obtained in this paper show the importance of the 0-120 hpf 
time window of zebrafish exposure in the assessment of the developmental toxicity of 
thyroid-active compounds. The newly developed GDS scoring system takes into account 
parameters that occur after 72 hpf. The defined GDS can successfully detect zebrafish 
developmental toxicity induced by thyroid-active compounds and can benefit from the 
model organism’s potential for high-throughput, which, for screening purposes, is a 
key advantage over rodent assays. The parameters affected, which include reflective 
iridophores, beat and glide swimming, inflated swim bladders, and resorbed yolk sacs, 
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are shown to be sensitive towards toxicity induced by TH disrupting compounds. One 
could envisage that other compounds causing developmental toxicity by different modes 
of action may also affect these parameters. Since this opens the way to false positives 
if the assay were to be used in isolation to detect TH activity, we envision that the GDS 
could be part of an ITS that includes specific biomarkers of thyroid hormone disruptor 
activity. Although the GDS will detect developmental toxicity resulting from various 
modes of action, it is shown in the present study that the GDS can be used to flag 
compounds as potential thyroid disruptors. Due to the presence of an intact thyroid 
hormone feedback loop, the zebrafish represents an experimental in vitro platform that 
is vastly more comprehensive than individual cell lines. Moreover, the zebrafish embryo 
up to 120 hpf is more socially-acceptable as a test organism than higher vertebrates. 
When applied in combination with other in vitro tests within an ITS, the zebrafish GDS 
holds promise to reduce, refine and, in certain cases, replace animal testing.
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The aim of this thesis was to find in vitro and toxicogenomics-based alternatives to 
in vivo thyroid hormone disruption tests. Thyroid hormone receptor (TR) and thyroid 
stimulating hormone (TSH)-mediated cellular proliferation, thyroid peroxidase (TPO) 
inhibition, nuclear receptor-coregulator binding, and developmental toxicity were 
chosen as endpoints for this research based on their relevance for the thyroid hormone 
system. In vitro alternatives can help reduce the amount of animal testing required 
under the European Union regulation for the registration, evaluation, authorization and 
restriction of chemicals (REACH). Moreover, with the use of human cell lines and human-
identical synthetic proteins, interspecies differences can be reduced and in some cases 
eliminated.
In Chapter 1, a mode-of-action-based alternative strategy focused on the in 
vitro testing for thyroid activity was introduced and set the framework upon which 
complementary alternative tests can be developed. This strategy followed a multi-
compartmental approach, as explained below, which divides the thyroid hormone system 
into 6 main compartments, starting with the thyroid itself, and subsequently expanding 
to other organs and tissues that play a role in thyroid hormone signaling:
1) Thyroidal hormonogenesis: TSH receptor (TSHR) activation, iodination, 
 coupling of iodinated tyrosyl residues, transport of iodide, proteolysis of 
 iodinated thyroglobulin, iodide scavenging and thyroid hormone (TH) synthesis
2) Pituitary control: Thyrotropin (TSH)-releasing hormone receptor (TRHR) 
 activation, TSH synthesis
3) Hypothalamic CNS control: Thyrotropin-releasing hormone (TRH) synthesis
4) Thyroid hormone activity at the target tissue: TR activation and coregulator 
 interaction
5) Kinetics: TH blood transport, cellular uptake of TH and TH metabolism
6) Epigenetics, immune response and other mechanisms: ITG αvβ3 activation
The above-listed compartments will be discussed in this chapter and will cover the 
research that has been presented in this thesis as well as new avenues of research that 
are part of a proposed future perspective for testing thyroid-active compounds. Overall, 
the aforementioned compartments will form the foundation upon which an integrated 
testing strategy for the testing of thyroid-active compounds can be built.
1) Thyroidal hormonogenesis
The first compartment that is outlined in this approach focuses on the effects of 
compounds on the thyroid and includes TSHR activation, which was tackled with the 
TSH-screen in Chapter 2; iodination & coupling, which was tackled with the luminol-
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based TPO assay in Chapter 3; and TH synthesis, which was tested in zebrafish in 
Chapter 5 using immunochemistry techniques. Iodide transport, proteolysis of iodinated 
thyroglobulin and iodide scavenging will be discussed at the end of this section as topics 
of future research.
While not many compounds have yet been found to act through TSHR activation, 
it is presently unclear to what extent this is due to lack of knowledge. Therefore, we 
developed a new assay enabling the measurement of chemical interference with 
normal TSH signaling, called the TSH-screen and described in Chapter 2. This assay 
might facilitate the identification of thyroid disruptors acting through this membrane 
receptor (Jomaa et al., 2013). The assay measures TSHR activation-dependent thyroid 
cell proliferation without added TSH (to detect agonist activity) as well as in the presence 
of 1 milli-international unit per milliliter (mIU/ml) TSH (to detect antagonist activity). 
The cell proliferation signal quantified in this simple and inexpensive assay reflects 
the integrated effects of the binding of TSH to TSHR, second messenger activity, and 
downstream signal transduction on gene expression, which is finally determining the 
level of hormone-mediated mitogenesis. One of the objectives of the study reported 
in Chapter 2 was to find out whether the TSH-screen can predict in vivo thyroid organ 
weight change, which is an endpoint used in rodent toxicity assays to detect thyroid-active 
compounds (OECD test guidelines (TG) 407, 416, 443, 452 and 453). To this end, 11 
compounds found to be thyroid-active in rodents were tested in the TSH-screen. Results 
indicated that the in vitro - in vivo correlation was poor and highlighted the shortcoming 
of current in vitro tests such as the lack of an intact hormonal feedback system.
Not all potential effects on the thyroid are related to TSH signaling. In this regard, 
a transcriptomics test using microarray technology might be a promising addition to 
a battery of assays in order to uncover the effects of test chemicals that modulate 
physiologically relevant thyroid endpoints that are not, or not only regulated by TSH. 
Furthermore, nongenetic endpoints may also be affected by thyroid active compounds. 
An example of an important nongenetic parameter is the inhibition of thyroid function-
related enzyme activities. One of the most important enzymes for the thyroid hormone 
system is thyroid peroxidase (TPO), which is a critical factor in the iodination and coupling 
of tyrosyl residues on thyroglobulin in order to produce the thyroid hormones T3 and T4. 
Important for toxicity testing is that, a large number of compounds that have been found 
to be thyroid-active in rodent toxicity assays appear to exert their effect by inhibiting the 
activity of this enzyme (Jomaa et al., 2013; OECD, 2014).
Iodination and coupling of iodinated tyrosyl residues are carried out by TPO and 
in Chapter 3, a TPO inhibition assay was developed as a refinement of existing assays 
(Jomaa et al., 2015). TPO assays are routinely performed using extracts from porcine 
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thyroid glands based on the principle that TPO will oxidize a substrate such as guaiacol 
leading to a color change that can be quantified (Hosoya, 1963). Guaiacol is a small 
volatile organic compound that gives a smoky aroma to tomatoes and roasted coffee 
(Mageroy et al., 2012). During testing, guaiacol is unstable and is readily oxidized upon 
exposure to air leading to a change in color (Sr, 2008), which can either jeopardize the 
reliability of experimental results or necessitate precautions being put in place to avoid 
artifacts due to guaiacol instability. The other downside of traditional TPO tests is the 
use of an enzyme derived from an animal’s thyroid tissue. Beyond ethical concerns, 
this also raises the question of inter-species differences and potential contamination 
with hemoglobin, which itself can act as a peroxidase (Harauchi and Yoshizaki, 1982). 
Recently, there have been efforts to overcome the obstacles posed by guaiacol using 
an alternative substrate, namely Ampliflu Red, but this study was using TPO originating 
from rat thyroids (Paul et al., 2014), compromising the extrapolation to the human 
situation. The assay that we developed addresses the shortcomings of the porcine TPO 
/ guaiacol assay by using luminol, which is a luminescent substrate that oxidizes TPO 
in the presence of hydrogen peroxide, in combination with human TPO derived from a 
commercially available thyroid cell line. Five TPO inhibitors were tested and compared 
with the guaiacol and the Ampliflu Red TPO assays. The results indicated that the 
luminol assay is successful in detecting TPO inhibitors and does so within a smaller 
95% confidence interval than with guaiacol or Amplifu Red TPO assays, which is an 
indication of reliability. Moreover, the luminol assay proved to be simple and rapid. It did 
not require the overexpression of TPO and was suited for high-throughput applications, 
since the experiment was performed in 96-well plates with the reagents being dispensed 
automatically by a Luminoskan Ascent luminometer from Labsystems (Helsinki, Finland). 
The measurement time for guaiacol and Ampliflu Red was 10 minutes whereas the 
measurement time for the luminol assay was only 10 seconds. The luminol assay shows 
potential as a simple, rapid and reliable TPO assay with added value as compared to 
the existing TPO assays for an integrated testing strategy for thyroid-active compounds.
The sodium/iodide symporter (NIS) mediates the transport of iodide into thyroid 
follicles (Dohán et al., 2003) and this can be detected in radioactive iodide (I-131) 
transport studies (Tonacchera et al., 2004). In general, there is a general move away 
from radioisotopes in testing, when possible, in favor of fluorescence and hence the 
development of radioisotope-free alternative assays has high priority (Sundberg, 
2000). This has recently been the direction taken by another group that performed 
NIS inhibition studies by measuring the inhibition of yellow fluorescent protein variant 
YFP–H148Q/I152L expressed in FRTL-5 rat thyroid cells by anions including thiocyanate 
and perchlorate (Di Bernardo et al., 2011). The sodium potassium pump (Na/K-ATPase) 
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provide the sodium gradient that is needed for NIS to function as a symporter and 
compounds affecting the Na/K-ATPase can in turn inhibit NIS-mediated iodide transport 
(Josefsson et al., 2006). Promising high throughput assays for Na, K-ATPase function 
have been developed by another group using nonradioactive rubidium ion uptake (Gill 
et al., 2004). 
Another parameter to be considered within the framework of possible effects on 
thyroidal hormonogenesis is proteolysis by lysosomal proteases, which is a critical factor 
in the release of T3 and T4 following the iodination and coupling of tyrosyl residues on 
thyroglobulin (Selmi and Rousset, 1988). The process is inhibited by excess iodine and 
iodine-rich compounds, including amiodarone (Radvila et al., 1976). Research into the 
inhibition of this process by thyroid-active compounds is scant and based on porcine 
thyroglobulin. While an in vitro protease inhibition assay is feasible, in vitro production 
of thyroid hormones is still a challenge that needs to be overcome. Iodide scavenging by 
iodotyrosine deiodinase (IYD) ensures that waste iodide that is produced as a byproduct 
of proteolysis is reused by the thyroid (Gnidehou et al., 2004 p. 1). While mutations in 
the IYD genes have been associated with hypothyroidism, little is known of its possible 
inhibition by thyroid-active compounds and this would be an interesting topic of future 
research (Moreno et al., 2008).
In Chapter 5, T4 immunochemistry (IHC) was used to obtain an indication of the 
inhibition of TH synthesis in zebrafish by model compounds, which was subsequently 
correlated to symptoms of developmental toxicity scored up to 120 hours post fertilization 
(hpf). The scoring system initially used was developed for the 0 – 72 hpf time window, 
but since results indicated that the morphological parameters affected upon exposure 
to thyroid active compounds develop after 72 hpf, an adjusted scoring system was 
developed and named the General Development Score (GDS). These developmental 
1.2% Alginate bead 0% FCS 1.2% Alginate bead 5% FCS 1.2% Alginate bead 10% FCS
Fig. 1: Morphology of Nthy ori 3-1 cells in alginate bead cultured in depletion medium (phenol 
red free DMEM F12 supplemented with 10 μg/ml insulin, 10 ng/ml sodium selenite, 10 μg/ml 
apotransferrin, 0.2% BSA, 500 nM NaI and 10 nM hydrocortisone) with different concentrations of 
FCS for 10 days as seen under light microscopy, 10x magnification. In the presence of 5% and 10% 
FCS the formation of follicle-like spheroids is observed.
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parameters were shown to be regulated at least in part by thyroid hormones (Jomaa et 
al., 2014) indicating that they can be used in combination with other thyroid-regulated 
phenotypical changes to flag compounds as potentially thyroid-active and used within 
a wider testing strategy. A two step bioassay combining thyroid-related zebrafish 
development parameters, which encompass transcriptional and non-transcriptional 
effects, and T4 IHC, which can detect TPO inhibition, can be more informative than 
either test on its own. Most importantly, when development is affected in a GDS screen, 
T4 IHC can reveal whether this is due to an effect related to T4 levels.
To date there are no in vitro methods to produce thyroid hormones and this is due 
to the three dimensional morphology of thyroid follicles which concentrate thyroglobulin 
into a central lumen that acts as a bioreactor for the production of thyroid hormones 
which are later absorbed by pinocytosis into the cell for cleavage and eventual secretion 
into the blood stream. Within the framework of the present PhD thesis, efforts to mimic 
such morphology using alginate beads imbedded with human Nthy-ori 3-1 cells were 
undertaken and revealed serum-
dependency for the formation of 
spheroids (Fig. 1, part of MSc thesis 
work by Qian Zhang). As serum can 
contain thyroid hormones and growth 
factors, future research should focus 
on the development of serum-free 
methods with a defined medium.
2) Pituitary control
The pituitary regulates the levels of 
TSH synthesis and secretion based on 
circulating levels of thyroid hormones. 
In vitro models for TSH secretion 
include the human T-cell leukemia 
cell line Molt 4, the mouse thyrotropic 
pituitary tumor cell line TtT-97 and the 
immortalized mouse pituitary TαT1 
cell line (Martin et al., 1988; Alarid et 
al., 1996; James et al., 1997). Molt 4 
cells  were grown but did not produce 
levels of TSH that are above the limit 
of quantitation using standard ELISA 
Fig. 2: TSH enzyme-linked immunosorbent assay 
(ELISA) performed to test TSH secretion by the 
Molt 4 cell line after 24 h exposure to 1 nM 
TRH (grey bars, n = 3). TSH concentrations were 
quantified by measuring optical density at 450 nm 
(OD450 nm), which is proportional to the amount 
of TSH in solution. 0 µIU/mL and 0.5 µIU/mL TSH 
(open bars, n = 2), tested from standard solutions, 
represent the negative and positive control, 
respectively. It can be derived from the bar graph 
that no detectable levels of TSH were measured 
in MOLT-4 cells. The analytical sensitivity of the 
human TSH ELISA kit (Calbiotech Inc., CA, USA), 
with which the experiments were performed, is 0.5 
µIU/ml according to the manufacturer.
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tests (Fig. 2, part of MSc thesis work by Katerina Kademoglou). On the other hand, 
TαT1 (kindly provided to us by the Mellon lab at the University of California, San Diego) 
cell culture required matrigel, led to low cell densities and was difficult to maintain – 
casting doubt on its use within a high throughput screen. Further research needs to 
be conducted in order to derive a pituitary cell line that is suitable for high throughput 
screening and is of human origin. Instead of measuring TSH activity levels, an alternative 
approach would be to quantitate levels of mRNA encoding the peptide hormone TSH. 
Microarrays have previously been used by other groups in in vivo experiments to show 
the up-regulation of TSHB mRNA in the pituitary by glutamine and glutamic acid (Aizawa 
et al., 2012). The use of microarrays in unraveling the interference of compounds with 
TSH expression has great potential, especially within a broader battery of tests aimed at 
detecting other endpoints that are relevant to thyroid disruption.
3) Hypothalamic CNS control
It is very difficult to mimic in vitro the potential effect of compounds on the control of TRH 
production in vivo at the level of the hypothalamus due to the complex signaling networks 
that are present in the central nervous system. The secretion of TRH is regulated by thyroid 
hormones by a negative feedback mechanism but is also regulated by neuropeptide Y, 
melanocortin-stimulating hormone, and agouti-related peptide (Nillni, 2010). Perhaps 
the biggest obstacle of a purely in vitro test system is the lack of a hormonal feedback 
system. To this end, we explored the application of zebrafish embryos for the testing of 
developmental anomalies caused by thyroid-active compounds since the disturbance of 
normal embryonic development is a major adverse effect that is caused by thyroid-active 
compounds (Atkins et al., 2000). Moreover, zebrafish have an intact thyroid hormone 
feedback mechanism and experiments using zebrafish embryos are considered in vitro 
up to 120 hpf.
4) Thyroid hormone activity at the target tissue
The inhibition of T3-mediated TR activation and subsequent pituitary cell proliferation 
was assessed in a test denoted T-screen. This simple and inexpensive assay 
encompasses the binding of a test compound with TR agonist or antagonist activity 
to TRs endogenously expressed in GH3 rat pituitary cells, second messenger activity, 
downstream signal transduction, and gene expression, in the end resulting in 
mitogenesis dependent on the level of TR activation. The aim of the study reported 
in Chapter 2 was to find out whether the T-screen in combination with the developed 
TSH-screen (discussed in section 1 above) can predict in vivo thyroid and pituitary 
organ weight changes – the latter being parameters used in rodent toxicity assays to 
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detect thyroid-active compounds. To this end, 11 compounds found to be thyroid-active 
in rodent tests were tested in both screens. Results indicated that the in vitro in vivo 
correlation was poor and highlighted the shortcoming of in vitro tests such as the lack 
of an intact hormonal feedback system. This is in contrast with the E-screen, which 
successfully correlated the compound-mediated inhibition of estrogen-induced uterine 
cell proliferation to in vivo uterine weight change (Wang et al., 2012). Another factor 
that has to be taken into account is the complexity of the thyroid hormone system which 
relies on multi-organ interactions to maintain hormonal homeostasis (Jomaa, 2014). 
Nonetheless, further analysis of the data revealed that the EC50s for T3, T4, triac and 
tetrac-mediated pituitary cell proliferation in the T-screen correlated with the BMDL10 
for in vivo change in relative heart weight as induced by these compounds. Indeed, 
thyroid hormones have previously been reported to be linked with cardiac hypertrophy 
(Ojamaa, 2010). This raises the possibility of using the T-screen to predict the adverse 
effect of thyroid-active compounds on heart weight.
In Chapter 4, we focused our research on coregulator interaction. Coregulators 
are mediators of transcription, and the effect of ligands in modulating TR-coregulator 
interactions was evaluated as a way of detecting thyroid-active compounds. Protein-
protein interactions were previously studied by other groups with the use of the yeast-
two hybrid technique, which is a type of protein fragment complementation assay that 
is carried out in yeast (Brückner et al., 2009). While yeast two-hybrid screening helped 
identify SMRT and NCoR as proteins showing decreased interaction with TR upon 
T3 binding, new high-throughput methods are also available such as peptide arrays 
(Chen and Evans, 1995; Hörlein et al., 1995). These are mostly based on tagged TR 
ligand-binding domains (LBDs) that are added to a library/array of known co-regulator 
peptides that contain the LXXLL binding motif (L for leucine, X for any amino acid) 
(Moore et al., 2004; Johnson et al., 2011). Peptides are easier to handle yet maintain, 
by encompassing complete functional motifs, some of the essential features of protein 
function (Volkmer et al., 2012). In chapter 4, we have used the so-called microarray 
assay for real-time coregulator-nuclear receptor interaction (MARCoNI) (Houtman et 
al., 2012) using the LBDs of TR isoforms alpha and beta in conjunction with 4 thyroid-
active compounds, namely, T3, T4, amiodarone and compound 1-850. The results 
underlined the power of such an experimental platform in delivering insights into the 
mechanism underlying thyroid receptor agonists and antagonists action by unraveling 
the coregulators involved. In addition, hierarchical clustering of the modulation index, 
which is defined as the log ratio of the binding of the receptor to the coregulator in the 
presence of a ligand over that of the solvent control (Koppen et al., 2009), resulted in 
agonists T3 and T4 clustering separately from antagonists amiodarone and 1-850. The 
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MARCoNI assay therefore has the potential to be used in the detection of thyroid-active 
compounds within a wider battery of tests that include other endpoints. The MARCoNI 
assay has several advantages over reporter gene assays since the use of luciferase as 
the reporter gene may generate false positives and the endogenous expression of other 
receptors or receptor isoforms can confound the results generated (Sotoca et al., 2010; 
Bhattacharjee and Khurana, 2014).
5) Kinetics
Other endpoints that have to be included within a comprehensive integrated testing 
strategy for thyroid-active compounds should include TH blood transport by binding to 
the transport proteins transthyretin (TTR) and thyroxine binding globulin (TBG), cellular 
uptake of TH by monocarboxylate transporter 8 (MCT8) and organic anion-transporting 
polypeptide (OATP) and TH metabolism by deiodinases (DIOs) and liver enzymes 
including UDP-glucuronosyltransferases (UGTs) and sulfotransferases (SULTs). The 
following text in this section will list some promising assays that are likely candidates for 
inclusion within an integrated testing strategy for thyroid-active compounds.
The 8-anilino-1-naphthalenesulfonic acid ammonium (ANSA) assay can be used 
to detect compounds that bind to the transport proteins TTR and TBG and hence have 
the potential to compete with thyroid hormones in blood transport. When ANSA binds 
to TTR or TBG, the fluorescence peak of ANSA shifts from 515 to 465 nm and the 
fluorescence intensity is substantially increased. By placing an emission filter near 465 
nm and a defined ratio of ANSA–TTR, the decrease in fluorescence at that wavelength 
due to increasing concentrations of T4 is assessed (Cao et al., 2010). This gives a 
dose–response curve from which a half maximal inhibitory concentration (IC50) can be 
calculated.
IC50 values for the displacement of ANSA from TTR by test compounds are calculated 
in a similar manner. The obtained data can then be used to rank the test compounds in 
terms of T4 equivalency factors (TEQ) by dividing the T4 IC50 by the test compound IC50. 
In other words, the higher the TEQ the more potent the test compound is at displacing 
T4 from its binding proteins. Such a method has been successfully applied to test the 
potential of hydroxylated PCBs (polychlorinated biphenyls) and polybrominated diphenyl 
ethers (PBDEs) for competitive binding to TTR (Montaño et al., 2012).
MCT8- and OATP-mediated cellular uptake of thyroid hormones can be assessed 
by transport studies with the radiolabeled hormones [125I]T4 and [125I]T3 (Kinne 
et al., 2009; Westholm et al., 2009). However, since the target tissues are many and 
the cell types that they contain are diverse, mimicking the physiological setting in an 
exact manner is inefficient while screening for thyroid hormone disrupters. Hence, an 
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artificial system has been created with controlled settings. Cells are selected based on 
low endogenous expression of the transporters being studied and then they are stably 
transfected with an expression vector conferring a constitutive high level of transporter 
expression (Kinne et al., 2009; Westholm et al., 2009). In this way, significant amounts 
of thyroid hormones can be transported across the cell membrane and by comparing 
with the wild-type cell line it can be concluded that the effect is specific to the studied 
transporters. It can be deduced that transport studies measuring the uptake of [125I]
T4 and [125I]T3 by cells stably transfected with thyroid hormone transporters have 
the potential to be used to quantify the interference with thyroid hormone transport 
by thyroid-active compounds.  Radioisotope-free alternative assays still have to be 
developed for the inhibition of MCT8- and OATP-mediated thyroid hormone transport by 
thyroid-active compounds.
Assessing the deiodination of T4 to the more active T3 by deiodinase enzymes 
(DIOs) using in vitro testing is currently being tested by measuring [125I] levels (Kuiper et 
al., 2005). Such tests are not suitable for high throughput testing due to the radioactive 
waste produced. With improvements in techniques and hardware, it is becoming 
increasingly likely that future tests might be based on tandem mass spectrometry as is 
being done for TH measurement in the diagnosis of thyroid disease (van Deventer and 
Soldin, 2013).
The last part to be considered in the kinetics compartment is TH metabolism and 
clearance. In metabolism and clearance studies, liver microsomes are currently the gold 
standard for testing for the inhibition of liver enzymes. The enzyme incubation is usually 
followed by an analytical technique, such as high-performance liquid chromatography 
(HPLC), in order to quantitatively determine the metabolite profile of TH (Shah et al., 
2008). The applicability of such assays for thyroid metabolism in a high throughput 
setting still has to be evaluated and forms yet another necessary avenue for future 
research.
6) Epigenetics, immune response and other mechanisms: ITG αvβ3 activation
Epi is Greek for above and epigenetics literally means above genetics, which is a term used 
to describe heritable changes in gene expression that are not due to an altered sequence 
of DNA. This change in gene expression can be due to a variety of factors including DNA 
methylation, histone modification and non-coding RNA-associated gene silencing. This 
field has unraveled in the past decade and the role of epigenetics in mediating the toxicity 
of environmental chemicals is the subject of a growing amount of research (Baccarelli 
and Bollati, 2009; Li et al., 2014). It has recently been shown that the phenolic herbicide 
ioxynil (IOX) and the brominated flame retardant tetrabromobisphenol A (TBBPA) affect 
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TH-induced histone modifications, leading the authors to conclude that these compounds 
exert an epigenetic effect on TH receptor-mediated gene expression (Otsuka et al., 
2014). The inclusion of epigenetic testing within an integrated testing strategy for thyroid-
active compounds requires high throughput techniques, which can include quantitative 
mass spectrometry (MS)-based proteomics and genomic sequencing (Stunnenberg and 
Vermeulen, 2011). Future research could be conducted on the effect of IOX and TBBPA on 
coregulator modulation in a MARCoNI assay since, in Chapter 4, we have found histone 
modifying coregulators among the coregulators that interact with thyroid hormones. 
Thyroid-active compounds can also affect immune response as was found in a study 
showing a link between iodine and autoimmune thyroditis (Rose et al., 1999). Moreover, 
soy isoflavones have been found to be involved in the formation of TPO neoantigens 
during their covalent binding to and inactivation of the enzyme (Doerge and Sheehan, 
2002). It is still unknown what other compounds that inhibit TPO by covalent binding can 
also lead to the formation of neoantigens and more importantly, it is necessary to study 
the clinical relevance of these findings. Hence more research is necessary on this topic 
before it can be deemed a priority for inclusion within a wider panel of tests for thyroid-
active compounds.
The modulation by T4 of the cell surface receptor integrin alpha v beta 3 (ITG αvβ3) 
is the least understood and perhaps the most intriguing mechanism of action of thyroid 
hormones and it has been found to induce a downstream Mitogen-activated protein 
kinase (MAPK) signaling cascade (Bergh et al., 2005). While this might help explain some 
of the in vivo effects of T4 that cannot be accounted for by other mechanisms, it is not 
yet understood if the disruption of T4-mediated ITG αvβ3 signaling cascades is a main 
target of thyroid-active compounds. By establishing the profile of T4-medated ITG αvβ3 
kinase activation using a kinase array, it is possible for future research to determine the 
modification of this profile by thyroid-active compounds. Kinase array technology is high 
throughput and can enable kinetic monitoring of kinase activity from cell lysates (Hilhorst 
et al., 2009).
Conclusions
In the pursuit of an in vitro ITS for the testing of thyroid-active compounds, the present 
thesis:
1. Assessed the in vivo relevance of a newly developed TSH-screen and other 
 currently available thyroid and pituitary cellular proliferation assays. 
2. Outlined the development of a new assay for the detection of chemical inhibitors 
 of TPO.
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3. Reported the application of MARCoNI for the unraveling of TR-coregulator 
 modulation by ligands. 
4. Set up a new zebrafish general development screen that includes endpoints 
 affected by thyroid active compounds.
5. Proposed a multi-compartment model approach that may be of help in the 
 further development of an in vitro integrated testing strategy for the detection 
 of thyroid-active compounds - based on the in vitro assays studied as well as 
 complementary future assays.
The findings described in this thesis have contributed to the current search for 
alternatives to animal testing and not only adhered to the 3R principles of ethical animal 
testing, but also improved the human relevance of current tests. 
In view of the severity of the adverse effects that can be expected from chemical 
disruption of the thyroid system, there is an urgent need to follow an integrated testing 
strategy for the testing of thyroid-active compounds. The set of in vitro tests that we 
developed and those that still need further development in the future shows that there 
is still a lot of work to be done in order to develop comprehensively predictive in vitro 
models for thyroid disruption. 
The inherent complexity of the thyroid hormone system makes it unlikely that one 
in vitro test alone will encompass the multi-organ interactions that result in thyroid 
hormone homeostasis in man. Moreover, the important role that thyroid hormones play 
during development makes finding a simple in vitro alternative even more challenging. A 
reliable in vitro screening strategy for thyroid-active compounds must therefore include 
a battery of in vitro tests within a comprehensive integrated testing strategy. Thyroid 
activity can be affected at various levels through a wide range of modes of action and 
this thesis illustrates that some of these modes of action can be successfully modeled 
in in vitro systems, while for others this is more difficult. In particular, the zebrafish, from 
0–5 days post-fertilization, may prove to be an invaluable addition within an ITS as an in 
vitro model with intact feedback mechanisms that can be used to screen thyroid-acting 
compounds for developmental toxicity.
Further research into suitable in vitro models and the development of high-
throughput screens might lead to a comprehensive testing program, decreased 
expenditure for government agencies, and a decreased need to test on rodents and 
other mammals. Suggestions include the use of DNA microarrays, further development 
of peptide microarrays and computer modeling of individual assay results in order to 
recreate in vivo feedback mechanisms in silico.
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The aim of this thesis was to find in vitro and toxicogenomics-based alternatives to in 
vivo thyroid hormone disruption tests. In vitro alternatives can help reduce the amount 
of animal testing required under the European Union regulation for the registration, 
evaluation, authorization and restriction of chemicals (REACH). Moreover, with the use 
of human cell lines and human-identical synthetic proteins, interspecies differences can 
be reduced and in some cases eliminated.
Chapter 1 introduces thyroid disruption and sets the scene for the rest of the thesis. 
It starts with a brief overview of the historical events that have shaped our understanding 
of the thyroid hormone system and have culminated in public concern over endocrine-
active chemicals. One such decisive event was the so-called ‘cranberry scare’, in which a 
herbicide, aminotriazole, was shown in a rodent study to increase the incidence of thyroid 
cancer. Today, the fear is focused on compounds that may alter thyroid homeostasis in 
a subtle way at much lower doses than those causing cancer but still have the potential 
to affect the hormone system’s well-documented orchestration of sexual and mental 
development. Regulatory authorities have acknowledged the potential dangers to public 
health and have included endpoints related to endocrine disruption in chemical safety 
testing using experimental animal models. Rodent assays, the golden standard for the 
detection of thyroid-active compounds, are costly, have disputable ethicality and do not 
always represent effects seen in humans. It is for these reasons that in vitro alternatives 
would be desirable. Chapter 1 then presents the current state of the art in thyroid toxicity 
testing, followed by the objective of the studies described in this thesis, which is to 
identify and develop in vitro and toxicogenomics-based alternatives to in vivo thyroid 
hormone disruption tests.
Chapter 2 details the testing of eleven thyroid-active compounds that have been 
documented to result in pituitary and/or thyroid weight change in in vivo studies, in 
in vitro pituitary and thyroid cell-proliferation assays denoted T-screen and TSH-screen, 
respectively. Analysis of the results revealed that in vitro-in vivo correlation is poor, and 
this implies that these assays, on their own, cannot be representative of the thyroid 
system. It was concluded that further research is required in order to model the thyroid 
system, which represents a complex multi-organ paradigm. Two approaches were 
proposed and tested to a further extent in the present thesis, the first involving a wider 
battery of in vitro tests  and the second involving in vitro zebrafish embryo-based tests. 
Nonetheless, a good correlation was observed between TR-mediated pituitary cell 
proliferation in the T-screen and increase in heart weight, suggesting that the T-screen 
might represent TH-mediated increases in heart weight. 
In Chapter 3, an alternative luminescence-based in vitro test for thyroid peroxidase 
(TPO) inhibitors was developed which uses human TPO derived from a cultured cell line. 
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This test was evaluated using 10 model compounds which were correctly identified as 
either inhibitors or non-inhibitors of TPO and was found to provide results with a smaller 
95% confidence interval than two other currently-available tests. Another important 
advantage of the newly developed in vitro test is that it enables the use of human TPO 
as an alternative to porcine TPO. 
In Chapter 4, the microarray assay for real-time coregulator-nuclear receptor 
interaction (MARCoNI) was applied to test the effect of two known thyroid hormone 
receptor (TR) agonists and two known TR antagonists in order to assess the usefulness 
of this in vitro test as part of an integrated testing strategy for thyroid-active compounds. 
In the MARCoNI assay, a peptide microarray with 154 motifs representing 66 different 
nuclear receptor coregulators is exposed to TR isoform α or β with and without ligand. The 
MARCoNI assay indicated that ligand-induced modulation of TR-coregulator interactions 
is a potentially useful parameter to detect TR receptor agonists and antagonists and 
also to distinguish agonists from antagonists. 
However, an integrated testing strategy for thyroid-active compounds must also 
include a more complete test system, preferably with an intact hormonal feedback loop. 
This is explored in Chapter 5 with the use of zebrafish embryos aged from 0 – 120 hours 
post-fertilization (hpf). Zebrafish development was scored using the general morphology 
score (GMS) which was developed for the 0 – 72 hpf time window. The results indicated 
that the morphological parameters affected upon exposure to thyroid active compounds 
develop after 72 hpf, and thus an adjusted scoring system was developed and named 
the general development score (GDS). In addition to the thyroid-related morphological 
parameters, dysmorphologies were also integrated into the same scoring system. The 
results of the study suggested that this new zebrafish-based GDS morphological scoring 
system would indeed present a valuable contribution to an integrated testing strategy for 
thyroid-active compounds, specifically addressing their potential developmental toxicity.
Chapter 6 goes on to discuss the results presented in this thesis in context of the 
initial outline and objectives presented in Chapter 1. A number of in vitro tests were 
successfully developed covering TSH-dependent cellular proliferation, TPO inhibition 
and zebrafish developmental toxicity including thyroid-related endpoints, in addition 
to the application of the MARCoNI assay to measure interference with TR-coregulator 
interaction. However, attention was also given to the challenges ahead, mainly the lack 
of suitable tests for high throughput screens covering many relevant endpoints that 
are important for the thyroid hormone system. The development of a cell-based system 
that produces thyroid hormones and the replication of multi-organ hormonal feedback 
mechanisms are among the most important challenges that need to be overcome. 
Suggestions include the use of DNA microarrays, further development of peptide 
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microarrays and computer modeling of individual assay results in order to recreate in 
vivo feedback mechanisms in silico.
In conclusion, this thesis has shed light on the relevance of current in vitro assays 
for thyroid and pituitary cell proliferation, has led to the development of the TSH screen, 
a luminol-based TPO inhibition assay and the zebrafish-based GDS for the detection of 
developmental toxicants, including those that act through the thyroid hormone system. 
Moreover, the MARCoNI assay was used to reveal the modulating effects of thyroid-
active compounds on TRα and TRβ interactions with a peptide array representing 66 
different coregulators. These developments along with an in-depth analysis of the 
thyroid hormone system and the presentation of the state of the art in thyroid disruption 
testing have highlighted the progress made and at the same time have underlined the 
challenges that lay ahead. 

Chapter 8
Samenvatting
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Het doel van dit proefschrift was om in vitro en op toxicogenomics-gebaseerde 
alternatieven te ontwikkelen voor in vivo proeven met betrekking tot ontregelde 
schildklierhormoonwerking. In vitro alternatieven kunnen leiden tot een vermindering 
van het aantal dierexperimenten die noodzakelijk zijn in het kader van de regelgeving 
van de Europese Unie voor de registratie, evaluatie, autorisatie en beperking van 
chemische stoffen (REACH). Bovendien, door gebruik te maken van humane cellijnen en 
aan de menselijke variant-identieke relevante eiwitten kan interspecies variatie worden 
verminderd en in sommige gevallen zelfs volledig worden geëlimineerd.
In Hoofdstuk 1 wordt het onderwerp verstoorde schildklierhormoonwerking 
geïntroduceerd. Dit hoofdstuk begint met een kort overzicht van de historische 
gebeurtenissen die ons begrip van het schildklierhormoonsysteem hebben gevormd en 
hebben geleid tot publieke bezorgdheid over endocrien-actieve stoffen. Een voorbeeld 
van een dergelijke beslissende historische gebeurtenis was de zogenaamde “cranberry 
scare”, waarbij het gebruik van een herbicide, aminotriazole, in een proefdierstudie 
met knaagdieren geassocieerd bleek te zijn met een verhoogde incidentie van 
schildklierkanker. Tegenwoordig gaat de aandacht vooral uit naar stoffen die de 
schildklierhomeostase op een subtiele manier veranderen, bij veel lagere doseringen 
dan die kanker veroorzaken, maar nog steeds het potentieel hebben om het hormonale 
systeem, dat verantwoordelijk is voor de orkestratie van seksuele en geestelijke 
ontwikkeling, negatief te beïnvloeden.
Regelgevende instanties hebben de potentiële gevaren voor de volksgezondheid 
erkend en hebben eindpunten toegevoegd met betrekking tot de verstoring van de 
hormoonhuishouding aan de proefdiertesten voor chemische veiligheid. Proeven 
met knaagdieren zijn de gouden standaard voor de detectie van schildklier-actieve 
verbindingen maar ze zijn erg duur, roepen ernstige ethische vragen op en geven niet 
altijd een goede voorspelling van de effecten in de mens. Om deze redenen zouden in 
vitro alternatieven dus wenselijk zijn. Hoofdstuk 1 geeft de huidige stand van zaken 
weer met betrekking tot schildklier toxiciteitstesten, gevolgd door de doelstelling van 
de in dit proefschrift beschreven studies; namelijk het identificeren en ontwikkelen van 
in vitro en op toxicogenomics-gebaseerde alternatieven voor in vivo testmethoden met 
betrekking tot ontregelde of verstoorde schildklierhormoonwerking.
Hoofdstuk 2 beschrijft het testen in in vitro hypofyse- en schildkliercelproliferatie 
assays, respectievelijk aangeduid als T-screen en TSH-screen, van 11 schildklier-actieve 
stoffen waarvan bekend is dat zij leiden tot gewichtsveranderingen van de hypofyse 
en/of de schildklier in vivo. Uit analyse van de resultaten bleek dat de in vitro-in vivo 
correlatie slecht was, hetgeen impliceert dat deze testen op zichzelf niet representatief 
zijn voor het schildkliersysteem. We concludeerden dat er verder onderzoek nodig is om 
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de schildklier, een paradigma van een complex multi-orgaansysteem, te “modelleren”. 
In dit proefschrift werden 2 benaderingen voorgesteld en verder getest. De eerste 
benadering bestond uit een bredere reeks van in vitro testen en het tweede behelsde 
in vitro proeven met zebravisembryo’s. Overigens beschrijft hoofdstuk 2 dat wel een 
goede correlatie werd gevonden tussen-TR gemedieerde hypofysecelproliferatie in de 
T-screen en een toename van het hartgewicht, wat suggereert dat de T-screen een TH-
gemedieerde toename in gewicht van het hart zou kunnen detecteren.
In Hoofdstuk 3 wordt een alternatieve op luminescentie gebaseerde in vitro test 
voor schildklierperoxidase(TPO)-remmers ontwikkeld, waarbij gebruik gemaakt werd van 
humaan TPO, verkregen uit gekweekte cellen. Deze test werd vervolgens geëvalueerd met 
een behulp van een panel van 10 modelverbindingen die correct werden geïdentificeerd 
als remmers of niet-remmers van TPO. Een belangrijke bevinding was dat de resultaten 
van deze test een kleiner 95% betrouwbaarheidsinterval opleverden dan twee andere 
momenteel beschikbare testen. Een ander voordeel van deze nieuwe in vitro assay was 
dat er gebruik gemaakt werd van humaan TPO in plaats van TPO verkregen uit varkens.
In Hoofdstuk 4 werd gebruik gemaakt van de microarray assay voor real-time 
coregulator-nucleaire receptor interactie (MARCoNI) om het effect van twee bekende 
schildklierhormoonreceptor (TR)-agonisten en twee bekende TR-antagonisten te testen, 
en zo het nut van deze in vitro test te evalueren als onderdeel van een geïntegreerde 
teststrategie voor schildklier-actieve verbindingen. In de MARCoNI test wordt een peptide 
microarray met 154 motieven die 66 verschillende nucleaire receptor coregulatoren 
representeren, blootgesteld aan TR-isovorm α of β met en zonder ligand. De MARCoNI-
test gaf aan dat ligand-geïnduceerde modulatie van TR-coregulatorinteracties mogelijk 
een nuttige parameter is om TR-agonisten en -antagonisten te detecteren en ook om 
agonisten te onderscheiden van antagonisten.
Een geïntegreerde teststrategie voor schildklieractieve verbindingen dient echter 
ook een compleet testsysteem te bevatten, bij voorkeur met een intacte hormonale 
feedback loop. Dit werd onderzocht in Hoofdstuk 5 door gebruik te maken van 
zebravisembryo’s met een leeftijd van 0 tot 120 uur postfertilisatie (HPF). De ontwikkeling 
van de zebravis werd gescoord met behulp van de algemene morfologiescore (GMS), 
die werd ontwikkeld voor de 0 - 72 HPF periode. De resultaten gaven duidelijk aan 
dat de morfologische parameters pas na 72 HPF beïnvloed werden door blootstelling 
aan schildklieractieve stoffen. Naar aanleiding hiervan werd een aangepast 
scoresysteemontwikkeld, namelijk de algemene ontwikkelingsscore (GDS). Naast de 
aan de schildklier gerelateerde morfologische parameters werden ook dysmorfologieën 
geïntegreerd in hetzelfde scoresysteem. De resultaten van deze studie gaven aan dat 
dit nieuwe GDS scoresysteem inderdaad een waardevolle bijdrage kan leveren aan een 
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geïntegreerde teststrategie voor schildklieractieve verbindingen, in het bijzonder voor 
het identificeren van mogelijke toxische effecten op de ontwikkeling.
In Hoofdstuk 6 worden de in de voorgaande hoofdstukken verkregen resultaten 
verder bediscussieerd in de context van het overzicht en de doelstellingen gepresenteerd 
in Hoofdstuk 1. Er werden met succes een aantal in vitro testen ontwikkeld voor door 
TSH-gereguleerde cellulaire proliferatie, TPO-inhibitie en ontwikkelingstoxiciteit bij de 
zebravis, via schildklier-gerelateerde eindpunten, en bovendien de toepassing van de 
MARCoNI-assay om interferentie met TR-coregulatorinteractie te meten. Er werd ook 
aandacht besteed aan de uitdagingen voor de toekomst, met name het opzetten van 
geschikte testen waarmee het mogelijk is om stoffen high-throughput te screenen op de 
vele eindpunten die belangrijk zijn voor het schildklierhormoonsysteem. Tevens behoren 
het ontwikkelen van een cel-gebaseerd systeem om schildklierhormonen te produceren 
en het in vitro simuleren van multi-orgaan feedbackmechanismen tot de belangrijkste 
uitdagingen. In het licht hiervan worden een aantal suggesties gedaan, zoals de verdere 
ontwikkeling van peptide microarrays en het genereren van computermodellen waarmee 
op basis van individuele assayresultaten, de in vivo feedbackmechanismen in silico 
nagebootst kunnen worden.
Uit de  bevindingen, beschreven in de onderzoekshoofdstukken 2, 3, 4 en 5, kan 
geconcludeerd worden dat dit proefschrift licht geworpen heeft op de relevantie van 
de huidige in vitro testen voor schildklier en hypofyse celproliferatie. Voorts hebben de 
bevindingen uit dit proefschrift geleid tot de ontwikkeling van een TSH screeningmethode, 
een op luminol gebaseerde TPO inhibitie-assay en de op zebravis gebaseerde GDS 
voor de detectie van toxische stoffen die de ontwikkeling verstoren, met inbegrip van 
toxines die werken via het schildklierhormoonsysteem. Bovendien is  de MARCoNI-assay 
geschikt gebleken om de modulerende effecten van schildklieractieve verbindingen op 
interacties van TRα- en TRβ met  transcriptionele coregulatoren aan te tonen. Deze 
nieuwe ontwikkelingen, samen met de diepgaande analyse van het schildklierhormoon 
systeem en het overzicht van de huidige state-of-the-art in het testen van verstoringen 
van de schildklier, geven een beeld van de geboekte vooruitgang en onderstrepen 
tegelijkertijd de uitdagingen voor de toekomst.
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